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„There are only three problems in gene therapy: 
delivery, delivery and delivery“ 
Inder Verma, 1999 
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1 Introduction 
This chapter should give a brief introduction into the research field of bioreducible 
polycationic carriers for therapeutic nucleic acids. It was adapted from:  
Klein PM, Wagner E. Bioreducible Polycations as Shuttles for Therapeutic Nucleic Acid 
and Protein Transfection. Antioxid Redox Signal. 2014 Aug 10;21(5):804-17 
 
1.1 The requirements for nucleic acid formulations to act as 
therapeutics 
The therapy with bio-derived macromolecules like proteins or nucleic acids such as 
plasmid DNA (pDNA) [1], small interfering RNA (siRNA) [2, 3], microRNA [4, 5] is a 
field of major importance and continually growing interest. Live threatening, severe 
diseases including cancer obtain a new chance for treatment by the use of gene 
therapy [6, 7]. In order to be used as therapeutics, these macromolecules have to be 
stabilized against degradation in the bloodstream and clearance, taken up by the target 
cells and reach the intracellular site of action. 
Viral vectors have been the number one carriers for intracellular nucleic acid delivery. 
However only minor changes in their structures can be made, the size and type of 
cargo is limited, and they can trigger immune reactions. As such, viral nanoparticles, 
on the one, hand present excellent natural examples for how to design carriers for 
intracellular delivery. On the other hand, synthetic carriers that mimic these transfer 
processes but are not dependent on naturally available nucleotides and amino acids, 
gain more and more attention. 
These synthetic carriers have to handle a lot of challenging tasks. They should offer 
an optimal extracellular stability and an efficient uptake into the cell. Uptake usually 
results in delivery into endocytic vesicles which often end in degradative lysosomes. 
Therefore the same carriers should facilitate an escape from endosomes after uptake 
and release their nucleic acid cargo to the cytoplasm, optionally followed by transfer to 
the nucleus (as required in the case of pDNA). In this process the carriers should act 
like shuttles: while stably associated with their cargo in a covalent or noncovalent 
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manner in the early extracellular delivery steps, they must not disturb the nucleic acid 
cargo in functionality inside the cell and should dissociate or disintegrate after delivery. 
The demands on delivery differ at the different extracellular and intracellular sites, and 
also the microenvironments provide uniquely different properties. Carriers can be 
designed to sense these environmental differences and utilize them to undergo 
changes beneficial for the delivery process [8]. The molecular programming of such 
dynamic carriers may include sensors that react to changes in enzyme activities, in 
pH, or the redox microenvironment (Fig. 1). Among the different sensors, bioreducible 
elements are important tools to distinguish between extra- and intracellular sites, 
where the redox potential displays big differences. As reviewed in the next sections, 
the use of disulfide bonds as sensors for reductive environments have a growing 
impact on the development of oligocation-based delivery systems [9-11]. 
 
Fig. 1 Dynamic nanocarriers utilizing different cellular microenvironments.  Differences in pH 
(lower in endocytic vesicles and also in special extracellular tumor situations) and redox situation (higher 
intracellular GSH concentration) can be utilized in the delivery process. Polyplexes stabilized by disulfide 
formation get internalized by electrostatic interaction with the cell membrane. Protonation of polymers 
in the acidifying vesicle triggers destabilizing membrane interactions necessary to induce endosomal 
escape into the cytosol. In the reductive environment of the cytosol, disulfide bonds are cleaved and the 
cargo is released. pDNA has to enter the nucleus to get transcribed. 
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1.2 Outside cells stable, inside labile – the delivery paradox 
Polyplexes are nanoscaled, interelectrolyte complexes of cationic polymers and 
negatively charged nucleic acids [12]. The extracellular stability is of the highest 
importance. In the bloodstream, these particles are exposed to nucleases, which can 
degrade the cargo, and other serum proteins, that can destabilize the complex by 
electrostatic exchange actions. Additionally, nucleic acids are compacted to 
convenient polyplex sizes of virus-like dimensions (around 100 nm). In the case of 
larger pDNA, this results in favorable compaction and protection. In the case of small 
nucleic acids such as siRNA or oligonucleotides, this results in increased nanoparticle 
sizes due to packaging as multimers, which prevents the particles from being cleared 
too rapidly by the kidney [13]. High molecular weight (HMW) polymeric carriers, usually 
show better transfection efficiency than low molecular weight (LMW) carriers largely 
because of insufficient polyplex stability of the latter ones [14-18]. LMW carriers, 
however, have significant advantages regarding reduced cytotoxicity [19] and better 
biocompatibility, for example, a reduced complement activation [20] relevant for in vivo 
applications. Moreover, too tight binding by HMW polymers can hinder intracellular 
vector unpacking [21, 22] and therefore reduce transfection efficiency. pDNA has to be 
accessible to the transcriptional machinery in the nucleus. siRNA has to be accessible 
to the RNA-induced silencing complex (RISC) [23] after delivery to the cytosol. Often 
the window between sufficient large polymer size for effectivity and sufficiently small 
for high biocompatibility was small or non-existent [24]. To achieve a better carrier 
profile with stability on demand, strategies using biodegradable polymers have been 
explored. The concept often included bioreversible cross-linkage of nontoxic LMW 
oligomers into HMW carriers via hydrolysable ester, acetal bonds or reducible disulfide 
bonds [25-32]. Thus, extracellular polyplex stability and transfection efficiency are 
partnered with intracellular disassembly and polymer degradation into nontoxic 
fragments. 
Within physiological proteins, the presence of disulfide bonds dominates outside the 
cell, both for secreted proteins, matrix proteins, or proteins at cell surfaces [33]. Inside 
the cell, the combination of high glutathione (GSH) concentrations and enzymes from 
the thioredoxin family [34] form a reductive environment of the cytosol. With a 
concentration of 1 - 11 mM GSH [35], the intracellular concentration of GSH is 
approximately 100 - 1000 times higher than outside the cell. This attribute can also be 
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used by artificial reducible systems to be intracellularly cleaved and change their 
properties. Although extracellular stability is expected to be significantly improved by 
disulfides, the situation is not so clear-cut. Disulfide cleavages may also occur in the 
in vivo situation outside the cell [36]. This was already observed in early in vivo work 
using immunotoxins [37, 38]. The liver as the major organ for GSH production [39, 40] 
has been considered as responsible for this extracellular degradation of disulfide 
bonds. Protein disulfide isomerases (PDI) widely known to be localized in the 
endoplasmatic reticulum (ER) can also occur on the cell surface of hepatocytes and 
may cleave disulfide bonds [41]. Low concentrations of cysteine (~8 µM) and 
glutathione (~2 µM) present in human plasma [42] are not considered to significantly 
contribute to extracellular bioreduction. The extracellular stability of disulfides can be 
tuned by their structural environment [38, 43]; see also Section 1.6. Thus, appropriate 
redox chemistry is considered as an excellent approach to solve the conflicting carrier 
requirements between extracellular stability and intracellular instability. 
For example, in early work Rice and coworkers [44] introduced defined oligolysine 
structures containing one to five cysteine residues (CWK18, II, III, IV, V - Fig. 2). The 
oligomers became very reactive at pH 7.5, e. g. oligomer V oxidized completely within 
25 minutes. For this reason, the mercapto forms of oligomers were stored at low pH in 
the absence of oxygen until use. During the incubation with pDNA at physiological pH, 
the cysteines formed disulfide bonds. Polyplexes of oligolysines with more than three 
cysteines, which were able to crosslink in three dimensions, showed the best stability 
in a shear stress stability test and could outperform polylysine tremendously. Still, the 
structure with two cysteines that has only the possibility to polymerize in a linear way 
revealed the best results in transfection with stability properties comparable to 
polylysine polyplexes. The stability of the resulting particles was higher if the thiols of 
the cysteines were kept in the reduced form until they were incubated with the DNA. It 
seems that these bioreducible oligocations created a cage after complexing with the 
DNA template. This outcome was very promising, especially when considering that 
these oligolysine structures were not expected to have high transfection efficiency. 
Endosomal buffer capacity and endosomal escape activity of polylysines were known 
to be very modest.  
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Fig. 2 Polymers based on natural amino acids with cysteine for linking.  Structures of oligomers 
(sequences from N → C-terminus) that are able to form bioreducible linkages by dimerization (CWK18 
[44]), in a linear (II Cys [44], CK10C [45], His 6 [46]) or crosslinking (III-V Cys [44]) way. C, cysteine; 
W, tryptophane; K, lysine; H, histidine. 
 
Based on analogous pre-oxidized polymers, containing Cys-Lys10-Cys monomers 
(CK10C - Fig. 2), lipopolyplexes were generated [45] by combination with a liposomal 
transfection agent for enhanced endosomal escape. This lipopolyplex system achieved 
187-fold higher gene expression levels for pDNA compared to the analogous non-
reducible lipopolylysine formulation.  The effect of reducing agents to these polymers 
was demonstrated by adding 25 mM dithiothreitol (DTT) for 5 minutes to polyplexes in 
an ethidium bromide pDNA binding assay. In this assay the pDNA polyplexes with non-
reducible polylysine showed no significant changes. The pDNA polyplexes with 
reducible polymers, however, showed a more than two times higher fluorescence 
intensity than before the addition of DTT. The higher fluorescence intensity represents 
better accessibility of the DNA to the intercalator ethidium bromide. Importantly, in 
more general terms the better accessibility based on bioreductive carrier cleavage 
improves pDNA delivery by facilitating the release of the nucleic acid in a form 
accessible for transcription into mRNA. 
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1.3 Bioreducible pDNA carriers with endosomal escape function 
For successful gene transfer, several delivery barriers have to be overcome (see Fig. 
1). Release from endosomes after cellular uptake presents a major bottleneck. 
Polyethylenimine (PEI), a polymer often used for pDNA transfections, combines 
optimized DNA binding ability and endosomal buffer capacity within one structure [47, 
48]. Its diaminoethane motif [49] offers a remarkable pH-reversible protonation and 
buffer capacity over a wide pH range, which turns it into an almost perfect “proton 
sponge” [50-53]. Endosomal protonation of PEI was discovered as an excellent way 
for triggering lipid membrane disruption and release into the cytosol. In sum, PEI has 
been established as being a very effective, but also significantly cytotoxic [54, 55] gene 
carrier. In order to create a less toxic, bioreducible branched PEI, LMW (<4.6 kDa) 
linear PEI (LPEI) was crosslinked with dithiodipropionic acid di(N-succinimidyl ester) 
(DSP) or N,N‘-bis-(tert-butoxycarbonyl)cystine linkages (Fig. 3) [25]. Impressively, this 
bioreducible PEI version did not only display far lower cytotoxicity at higher PEI doses, 
but also significantly outperformed the transfection efficiency of standard branched PEI 
25kDa, LPEI 22kDa and several other commercially available reagents in seven cell 
lines (CHO-K1, COS-7, NIH/3T3, HepG2, HCT116, HeLa, and HEK-293 cells). For the 
maximum efficiency for these bioreducible polymers, N/P ratios (ratio between 
protonatable nitrogens in polymer and phosphates in nucleic acid) between 18 and 30 
were required, which were much higher than for non-bioreducible polymers. 
A related effort to produce a biodegradable PEI was taken by Park and coworkers [56]. 
They synthesized a bioreducible linear PEI with a diaminoethane motif that was 
separated by a disulfide bond after every six protonatable amines (PEIS). An agarose 
gel shift showed a less than 2 hours stability in a 5mM GSH solution. As additional 
development these linear bioreducible PEIS were crosslinked to larger structures with 
different amounts of bisepoxide. This resulted in branched structures (bPEIS - Fig. 3) 
with increased stability of more than 4 hours in GSH containing buffer. The transfection 
for the larger branched PEIS was better than for smaller linear PEIS and could reach 
the same level as branched PEI 25kDa at their own optimal N/P ratio. The addition of 
5 % bisepoxide showed best effects in general (results of five cell lines – C2C12, HEK 
293, HeLa, HUVEC, NIH3T3). By adding 10 % serum the transfection of bioreducible 
PEIS was reduced by approximately one log scale, which was more than for bPEI 
(approximately half a log scale). Due to the bioreducibility and the small, calculable 
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degradation products, the cell viability tested with MTT assay was significantly 
improved. On the other hand, serum stability was an issue that still needed 
improvement. 
 
Fig. 3 Structures of PEI and bioreducible polymers.  Non-degradable linear LPEI and branched bPEI 
(left top). Bioreducible bPEI derivates (LRx-lPEIy and BCx-lPEIy) [25] based on LPEI and crosslinker 
(x denotes the molar ratio cross-linker/LPEI, and y denotes the MW (kDa) of the LPEI. For LRx-lPEIy 
the molar ratio between the linker and LPEI monomers was 0.5 % - 3 %, for BCx-lPEIy the molar ratio 
between the linker and LPEI monomers was 3 % - 8 %). bPEIS [56] contains a bioreducible 
diaminoethane system and a non-degradable crosslinker. SS-PAEI [57-59] consists of poly(amido 
ethylenimine) with bioreducible disulfide bonds and variable residues for functionalization (right bottom). 
 
Disulfide-containing poly(amido ethylenimine)s (SS-PAEIs - Fig. 3) are another class 
of bioreducible polymers [57-59]. Agents containing at least two reactive amines like 
ethylendiamine (EDA), diethylentriamine (DETA) or triethylentetramine (TETA) [57] 
were reacted by a Michael-type polyaddition with disulfide-containing bisacrylamides 
to form branched structures. The resulting polymers show very good transfection 
results. Especially in 10 % serum, they have great advantages compared to branched 
PEI 25kDa. SS-PAEIs only had slightly lower transfection efficiency in serum (1.2 × 
difference for EDA polymers, 1.3 × difference for DETA polymers, 11 × difference for 
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TETA polymers) in BAEC cells, whereas bPEI had a dramatic loss with 500 × 
difference compared to the serum-free group. SS-PAEIs also offer another topology; 
comb-like structures can be achieved by introducing side chains into the bioreducible 
backbone [59]. Additionally, with these side chains, a variety of functional elements 
can be incorporated. These elements can be tertiary amines for nucleic acid binding, 
imidazoles for endosomal buffering or protected secondary amines like diaminoethane 
structures or spermine [58], which can be unprotected after the polyaddition. Beside 
these cationic structures, other functional groups like hydrophobic elements can be 
introduced [59]. Polymers resulting from such reactions do not have a precise 
structure, but due to their bioreducibility the cleavage products are small. These 
bioreducible poly(amido amine)s as well as related polyaspartamide-based disulfide-
containing brushed polyethylenimine derivatives (128) showed lower cytotoxicity and 
often more efficient gene delivery than branched PEI 25kDa. 
A modification that strongly improved the efficacy of polylysine and oligolysine shuttles 
was the introduction of histidines [46, 60-62]. The second imidazole nitrogen exhibits 
ideal basicity (pKa 6.0) for an increase of endosomal buffer capacity (lower protonation 
at physiological than at more acidic endosomal pH) and therefore facilitating 
endosomal release by the “proton sponge effect” previously hypothesized for 
polyethylenimine. Hereby it was possible to mediate efficient delivery not only for pDNA 
but also for mRNA and much smaller siRNA (more information on siRNA delivery in 
section 1.5) with one single vector [46]. A histidine/lysine ratio of 4:1 in a Cys-His6-
Lys3-His6-Cys monomer (His6 RPC - Fig. 2) provided the best results. 
 
1.4 Design of precise oligomers for pDNA transfection 
To combine the beneficial transfection properties of bioreducible PEI and related 
oligoethyleneimine polymers with precise chemical structure, solid phase supported 
polymer synthesis [63-65] was introduced. In particular, artificial amino acids 
containing short, defined repeats of the diaminoethane motif were prepared in 
boc/fmoc-protected form, appropriate for standard automated or manual peptide 
synthesis [66]. These building blocks, optionally in combination with natural amino 
acids like cysteine and other units were incorporated into peptide-like oligomers. The 
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artificial amino acids provide the oligomers with proton sponge capacity. For example, 
Stp (succinoyl tetraethylene pentamine) within a polyamide chain provides three 
protonatable amines, the building block Sph (succinoyl pentaethylene hexamine) 
provides four protonatable amines (Fig. 4). By solid-phase synthesis technologies, 
such defined oligomers can be generated with high precision in libraries of various 
sequences and defined lengths. Initial screenings of such a small library based on the 
Stp building block were performed for pDNA transfer activity [67]. Compared with 
standard polymers, the oligomers present LMW carriers. Consistent with their 
incomplete protonation at physiological pH, oligomers did not display significant 
cytotoxicity and were well biocompatible. Not unexpectedly, their limited size provides 
also limited polyplex stability. Compound 23 (Fig. 4) with 5 Stp units (representing 
15 protonatable nitrogens) provided only very low polyplex stability in agarose gel 
electrophoresis assays and had no transfection efficiency at all. Incorporation of two 
cysteines, which after pDNA complexation form disulfide bonds by air oxidation 
strongly improve polyplex stability and gene transfer activity. Compound 74 with two 
cysteines and only two Stps did not transfect, compound 51 with 3 Stps showed low 
but significant gene transfer for N/Ps > 6, and compounds 78 and 82 with 6 or 8 Stp 
units and the two terminal cysteines revealed much better transfection results for 
N/Ps ≥ 15 [67]. These results indicate that even for oligocations that are able to interact 
with each other by disulfides a certain minimum of cationic binding units in each 
oligomer is required for activity. An additional measure for optimizing these LMW 
carriers was the attachment of hydrophobic fatty acids. These have stabilizing effect 
and mediate pH dependent endosomolytic activity. In optimized form such carriers 
outperformed the gold standard LPEI 22 kDa [67]. 
Standard LPEI 22 kDa contains approximately 500 protonatable nitrogens. Synthesis 
of such large linear structures by solid-phase assisted synthesis is not feasible. An 
approach to circumvent this limitation of length was the design of four-arm structures. 
These structures contain two consecutive lysines as branching points via both alpha- 
and epsilon amine modification followed by simultaneous elongation of each arm with 
two to five units of Stp, Sph or other artificial amino acids. Optionally terminal cysteines 
were integrated [68]. By this procedure in a few coupling steps easily carriers with up 
to more than hundred nitrogens (up to 68 protonatable nitrogens) were generated. 
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Fig. 4 pDNA carrier polymers based on artificial amino acids.  There is no gene transfer activity for 
small structures without cysteines like compound 23 [67]. Structures 51,74,78,82 with two cysteines [67] 
for linear linking profit from the longer cationic binding region. 519 [68] presents crosslinking ability in a 
four-arm structure with the longer diaminoethane motif (Sph). 
 
Screening for pDNA transfection showed the following: the number of nitrogens per 
building block (Sph containing 6N > Stp with 5N > Gtt with 4N) was more important for 
pDNA polyplex condensation and transfection than the total number of nitrogens per 
oligomer. Sph-based four-arm structures with three repeating units per arm (Sph3, 72 
ethylenimine nitrogens in total) displayed comparable transfection activity as LPEI 
already in the absence of cysteines, whereas Gtt-based four arms with four repeating 
units (Gtt4, 64 ethylenimine nitrogens in total) were inactive. In all cases the presence 
of terminal cysteines further enhanced transfection activity [68]. Apparently, this 
bioreversible option for disulfide-based stabilization was beneficial. The transfection 
activity of the most potent cysteine-containing Sph four-arm compound 519 (Fig. 4) 
exceeded the gold standard LPEI by up to 50-fold for the N/P ratio 12. 
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1.5 Cargo matters: reversible disulfide bonds stabilizing siRNA 
polyplexes 
The delivery of siRNA with cationic systems poses different challenges than pDNA [13, 
69, 70]. Although both nucleic acids contain a negatively charged backbone 
(phosphodiester for physiological or phosphorothioate in the case for some stabilized 
nucleic acids), the number of base pairs (bp) per molecule and their topology are 
different. With a 7 nm rod-shaped size, 21 - 23 bp and 42 - 46 anionic charges per 
molecule [71, 72], siRNA is comparatively small and cannot offer thousands of negative 
charges a long cyclic pDNA provides for binding. This results in a lower electrostatic 
stabilization, less gain in entropy by complex formation, and therefore less stable 
siRNA polyplexes. Most of the previously described systems for the transport of pDNA, 
including polylysine [73], and PEI [69] show much less efficiency in siRNA transfection 
unless appropriate modifications are introduced. One of the encouraging options 
presents the incorporation of bioreducible stabilizing disulfide bonds; either by 
crosslinking of siRNA into more ‘DNA-like’ oligomers [74-76], by linking siRNA with the 
cationic carrier [77-79], or by crosslinking the cationic carrier molecules. 
Based on the knowledge of pDNA delivery systems new carriers have been invented 
to accomplish the delivery of siRNA. The approximately 4kDa pseudodendritic 
degradable oligomer HDO, consisting of 800 Da oligoethylenimine (OEI) and 1,6-
hexandiol diacrylate was evaluated for siRNA delivery [80]. This LMW polymer 
previously had been proven as an effective pDNA carrier [81], but it did not mediate 
siRNA delivery. Modification of siRNA/HDO polyplexes with DSP provided 
bioreversible stabilization (Fig. 5, top), as demonstrated by improved siRNA binding 
ability in an agarose gel electrophoresis assay. The change in the structures of 
polyplexes could be monitored by the measurement of size and zeta potential. For 
example, the size of particles formed at N/P 4 increased from 113 ± 3 nm to 
197 ± 3 nm and the zeta potential decreased from 27.6 ± 0.4 mV to 20.1 ± 0.7 mV. 
Only the disulfide-stabilized siRNA/HDO polyplexes were taken up by cells and 
resulted in efficient gene silencing. 
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Fig. 5 Carriers optimized for siRNA delivery.  DSP (dithiodipropionic acid di(N-succinimidyl ester)) 
linked with free amines on the surface of HDO/siRNA polyplex [80]. Active three-arm structure 386 and 
its inactive analog 387 [82, 83]. Lipo-oligomer EHCO (122) with histidine, cysteine and oleic acid (OleA). 
Active t-shape polymer 49 and its inactive analog 216 [82]. 
 
The importance of disulfide-based crosslinking for siRNA can be observed when using 
precise sequence-defined oligomers built by solid phase synthesis as described 
earlier. Three-arm structures like 386 (Fig. 5) [82, 83] that contain Stp units for nucleic 
acid complexation were able to bind and transfect siRNA only when containing 
cysteines for crosslinking at the end of each arm. The structure 386 showed perfect 
binding in electrophoresis gel shifts for low N/P ratios from 3 on, whereas control 
structure 387 was inactive. Analogously, four-arm structures [68], which can transfect 
pDNA even without cysteine incorporations, were inactive for siRNA delivery. Cysteine 
at the end of each arm (519 - Fig. 4) resulted in enhanced transfection efficiency for 
pDNA and was absolutely required for siRNA-based gene silencing.  
T-shaped lipo-oligomers such as 49 (Fig. 5) also were dependent on the two stabilizing 
cysteines. Both the alanine analog (216), as well as compound 49 reacted with N-
ethylmaleimide (NEM) irreversibly blocking the thiol groups against disulfide based 
stabilization, had lost the gene silencing activity [82]. FCS measurements in 90 % 
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serum revealed that the size of 49 polyplexes for N/P 12 increased from 49 nm within 
30 minutes to 68 nm at room temperature. At 37°C the polyplex was stable after 
10 minutes, but some dissociation was observed already after 30 minutes [84]. 
Disulfide stabilization was also required for gene silencing using the lipo-oligomer 
EHCO (Fig. 5) [85]. This solid-phase synthesis derived siRNA carrier contains pH-
sensitive ethylenediamine, and histidine units, stabilizing cysteine and oleic acid units. 
In order to improve polylysine properties, Kataoka and coworkers used a polyethylene 
glycol (PEG) -polylysine block polymer, which was reacted with iminothiolane [86]. 
Thereby a few thiols were incorporated onto lysines without losing cationic charges, 
because the primary amines are converted into positively charged amidines. With 
siRNA so-called polyion complex (PIC) micelles are formed. The presence of the 
iminothiolane modification results in disulfide-based crosslinked polymers stabilizing 
the siRNA containing PIC micelles. These micelles were able to achieve 100-fold 
higher transfection efficiencies than the analogous micelle without crosslinking. 
Stability tests with increasing concentrations of sodium chloride revealed that the 
stability of crosslinked polyplexes was significantly increased and could be abolished 
with reducing agents. Polyplexes with unmodified PEGylated polylysine were not even 
stable at physiological ionic strength. 
Many multifunctional carriers for siRNA-based on the same principle but including 
shielding and targeting domains also rely on disulfide bonds [87]. For example, the 
folate receptor-targeted oligomer 356 (Fig. 6) formed stable nanosized siRNA 
complexes of only 6 nm hydrodynamic diameter. Replacing cysteines by serines 
(compound 420) resulted in dramatic loss of siRNA binding as well as gene silencing 
activity. An additional use of bioreducible disulfides in this polyplex was the reversible 
covalent linkage of the siRNA with an endosomolytic influenza virus-derived peptide 
INF7 (Fig. 6), which was important for an efficient endosomal escape and cytosolic 
delivery. 
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Fig. 6 Multifunctional siRNA polyplexes containing pH-and redox-sensitive components.  Active 
356 forms an efficient carrier with siRNA-INF7, whereas control 420 with serine instead of cysteine 
shows low binding and transfection efficiency [87]. The masked siRNA polyconjugate presents a shuttle 
with pH reversible PEGylation with and without targeting ligand, covalently bound siRNA, imidazole 
residues and fatty acids based on a bioreducible poly(amido amine) backbone [79]. 
 
This reversible linking can also be used for attaching siRNA directly to a carrier. Using 
click chemistry, a PEG-folate was covalently attached to siRNA via a disulfide 
containing linkage [77]. Also polycations were attached in this manner. Disulfides have 
been used to connect siRNA covalently to a pH-responsive masked endosomolytic 
polylysine carrier [78]. Wang and coworkers used it for coupling to a bioreducible 
poly(amido amine) backbone (Fig. 6, bottom) [79]. The side chains of the backbone in 
this carrier were functionalized with hydrophobic modifications, imidazoles, and pH 
reversible targeting ligands. These multifunctional systems with bioreducible properties 
demonstrated efficient, targeted gene silencing in vivo. The best performing polymer 
with a mixture of 40/30/30 molar ratio of 2-(2-aminoethoxy)ethyl/ 2-(1H-imidazol-4-
yl)ethyl/ dodecyl and a molar weight of ~8.64 kDa showed 80 % mRNA knockdown in 
mice. 
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1.6 Tuning the timing and extent of bioreduction of dynamic carriers 
The various approaches for dynamic stabilization of bioconjugates and nanoparticulate 
carriers reviewed in the earlier sections build on the favorable difference between 
extracellular/intracellular redox conditions and GSH concentration. However, the 
frequently claimed notions that a) “disulfide bonds are generally stable outside the cell” 
or b) that “they are easily cleaved in endosomes” should be questioned as already 
stated earlier in literature [88], and might be even, in part, misconceptions, or, at least, 
not generally valid. 
Several disulfide-bonded protein conjugates and immunotoxins have been found to be 
cleaved in vivo after intravenous application [36, 37]. The questions about the exact 
site of bioreduction might be less important for some nanocarrier designs but critical 
for others. The majority of the previously mentioned strategies build on cytosolic 
cleavage of multiple disulfide bonds of oligocationic carriers that had caged their cargo 
during the extracellular delivery. In those cases, it might be less important whether 
bioreduction of some fewer bonds starts at the cell surface, significantly takes place in 
the endosomal vesicle system, or largely happens in the cytosol. When cleavages of 
large numbers (approximately hundreds) of disulfide bonds per nanoparticles are 
required, the majority of cleavage processes can be assumed for the cytosolic location 
because of its larger reduction capacity. 
Bioreducible disulfide linkages, however, have also been considered dynamic 
elements in earlier steps of the delivery process: For example, in the process of 
nanocarrier deshielding, which might be beneficial to occur at the cell surface or within 
endosomes, or for activation of endosomolytic domains within endosomal vesicles. 
The so-called “PEG dilemma” comprises the experiences that surface shielding of 
nanocarriers with PEG is very beneficial for extended blood circulation and (passive or 
active) tissue targeting, however, negatively affects intracellular uptake across 
endosomal membranes. Endosomal pH-sensitive cleavable PEGs are able to 
overcome this dilemma [89-93]. Thus, bioreductive cleavage of disulfide-bound PEG 
at the cell surface would be a very useful process [94-97]. In our own research group, 
productive deshielding of PEGylated pDNA/PEI polyplexes was far more successful in 
utilizing pH-labile bonded hydrazone [93] instead of disulfide-bonded [98] PEG chains. 
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Some approaches such as those reported by Lee and coworkers [99] successfully build 
on reductive liberation of endosomolytic agents within the endosome for subsequent 
cytosolic transport of the cargo. Such strategies are rationally supported by natural 
examples, including toxins and viral translocation that include a disulfide cleavage as 
a part of the translocation process [100-107]. For example, several toxins of the 
AB5 family (A toxic subunit, B receptor-binding carrier units), including cholera toxin, 
shiga toxin, or pertussis toxin, enter cells by endocytosis. This is followed by retrograde 
transport into the ER lumen, where repair chaperone PDIs recognize single disulfide 
bonds as “misfolded protein domains”. Then, a physiological repair process named 
ER-associated degradation (ERAD) retro-translocates the A unit through a pore to the 
cytosol for proteasome-mediated degradation (Fig. 7) [106].  
 
Fig. 7 Retrograde transport followed by reductive translocation to the cytosol. Several protein 
toxins (e.g. Cholera toxin, Shiga toxin, Pertussis toxin, ricin, or Pseudomonas exotoxin A) attach to 
receptors on the surface of the cell and are transported via Golgi to the Endoplasmic Reticulum (ER) by 
retrograde transport. A key disulfide is recognized as a “misfolded ER substrate” and reduced in the 
presence of a protein disulfide isomerase (PDI) followed by translocation of a toxin fragment to the 
cytosol. 
 
AB-type toxins such as ricin or Pseudomonas exotoxin, or some viruses such as SV40 
[104], also contain disulfide linkages, which require cleavage for cytosolic 
translocation, presumably mediated by PDIs. For translocation, diphtheria toxin 
requires an analogous cleavage by PDI in the endosomal compartment [103]. It, 
however, should be kept in mind that bioreductive potential in standard acidifying 
endosomes might be more limited [88] and applicable for special cases only. 
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In sum, many bioreductive approaches are built merely on educated guesses that are 
supported by facts from nature and empirical findings and imagination (hopefully not 
too far from reality). A more quantitative understanding of the bioreductive behavior of 
cellular processes, however, would provide enormous help for improved designs and, 
thus, present important opportunities for the future. 
In this direction, Leroux and coworkers [108] developed a well-characterized, defined 
dendrimeric oligomer probe for analysis of bioreductive disulfide cleavage in cellular 
systems. The probe consists of generation 3 dendrimer PAMAM-G3 with disulfide-
linked dye (BODIPY)2, which provides the ability to distinguish between reduction of 
internal (dendrimer core) and surface disulfide bonds. Applying this system to four cell 
lines with different reductive potency (HeLa, A549>PC3>Caco-2 cells), both interesting 
expected findings and surprising findings were made. For example, data based on 
pulsed thiol depletion and endocytosis inhibitor studies revealed the rather surprising 
finding that probe disulfide cleavage occurred exclusively at the extracellular cell 
surface, possibly triggered by cell surface oxidoreductases such as PDIs or 
chaperones (also belonging to the PDI family), with secreted thiols such as GSH acting 
as cofactors. Incubation with a cell membrane-impermeable oxidant completely 
suppressed bioreduction. 
The same study evaluated bioreduction of the PAMAM probe after pDNA complex 
formation. Incorporation into such DNA polyplexes reduced the cell surface 
bioreduction, which is consistent with sterically restricted access of the probe to cell 
surface oxidoreductases. For the most reducing HeLa cell line, the logical distinction 
between cleavable disulfides in surface and core states became apparent. Moreover, 
the expected subsequent bioreduction after delivery into the acidic endosomal 
environment was incomplete. Intentionally, the authors had selected G3 PAMAM, 
which in contrast to higher-generation PAMAM or PEI does not have “proton sponge” 
based endosomal escape properties. The addition of chloroquine as an endosomolytic 
agent strongly enhanced bioreduction, which was consistent with endosomal escape 
and efficient reduction in the cytosol. As the authors note, “efficient bioreduction in the 
endosomes, while sometimes reported, is not a universal phenomenon and should be 
verified for each new system and its corresponding target cell line” [108]. 
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How may we utilize an increased knowledge about reductive characteristics of different 
biological microenvironments? Not only the biological surrounding influences the fate 
of disulfide bonds, but also the molecular chemical environment of disulfide bonds 
within a dynamic carrier can be tuned. For example, by stabilizing disulfide bonds by 
bulky groups providing sterical hindrance [38, 109], different exposure (core or surface) 
within a nanoparticle system (as illustrated in the PAMAM polymer example discussed 
earlier), the electrostatic environment facilitating or restricting electrostatic interaction 
with a reducing agent [108, 110], or the number and positioning of multiple disulfide 
bonds [43]. 
The influence of bulky groups on disulfide stability was shown in vitro with structures 
with methyl, benzene, and cationic residues localized next to disulfide bonds [38]. 
When treated with 0.03 mM DTT at pH 7.4, the stability was as follows: The most stable 
derivate was the one with methyl and benzene residue at the α-C next to the disulfide 
bond, followed by the same derivate without methyl group, followed by a structure with 
an alkyl chain next to the disulfide group. The presence of a cationic charge in δ-C 
position next to the disulfide resulted in a faster reduction than with all uncharged 
linkers mentioned earlier. Based on this information, the most stable and the most 
labile structure were incorporated in a linker to connect an antibody (OX7) with a Ricin 
A toxin subunit to form immunotoxins. These immunotoxins were tested in mice for 
stability in vivo. From the more stable disulfide-linked immunotoxin with methyl and 
benzene residue, 50 % in active form and 50 % in free antibody form were present in 
blood 48 h after an intravenous injection. In contrast, the bioreducible linkage with the 
cationic element in its environment reached the same cleavage stage (50/50 ratio 
immunotoxin/free antibody) after only 8 h [38]. More recently [109], a systematic study 
of disulfide-linked antibody-maytansinoid immunotoxins was reported while evaluating 
the disulfide-linker stability and antitumoral activity in vivo in mice. Sterical hindrance 
(by methyl group substitutions flanking the disulfide bonds) enhanced stability to 
reductive cleavage by DTT and plasma stability in mice. In in vivo efficacy testing, a 
conjugate with intermediate disulfide bond stability (having two methyl groups on the 
maytansinoid side of the disulfide linkage but no methyl substitution on the antibody 
linker side) displayed the highest antitumoral efficacy. 
Not only the sterical and electrostatic environment of disulfides, but also the reducing 
agents and the pH have a crucial influence on the stability of a disulfide bond. It has 
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been shown that positively charged amino acids next to a cysteine in a peptide 
destabilized the disulfide bond between oxidized dimers in a 10 mM GSH solution at 
pH 4.9 (mimics late endosomal/lysosomal environment) [110]. The influence was 
higher for amino acids with higher pKa values (highest for arginine with pKa 12.1) and 
if more positively charged amino acids were incorporated. The distance (α- or β- amino 
acid next to cysteine) played a minor role. Analogous negatively charged amino acids 
with low pKa values (glutamic acid with pKa 4.3 has the strongest influence) stabilized 
the disulfide bond. Consequently, the half-life of structures with α- and β-arginine was 
only 0.17 h compared with 8.7 h for structures with α- and β-glutamic acid. If GSH, 
which is also present in its deprotonated GS ̄ -form, was exchanged by cysteine as a 
reducing agent, which also can be deprotonated, the same tendency could be 
observed. If cysteamine, which does not have a negatively charged form, was used, 
the half-life for all tested peptides was comparable. For higher pH values, such as pH 
7.4 in the cytosol, the cleavage kinetics in GSH redox buffer accelerated profoundly 
(from 8.7 h for pH 4.9 to 0.1 h in half life for the structure with α- and β-glutamic acid). 
The higher amounts of charged GS ̄ at higher pH seem to be responsible for this faster 
cleavage. Special formations of cysteines embedded in a peptidic environment can 
influence not only the kinetics but also the formation of disulfides in structures. A motif 
consisting of cysteine – any amino acid – cysteine (C-X-C) was evaluated for different 
flanking and central natural amino acids and revealed the best properties for the 
cationic amino acid arginine combined with the flanking amino acids glutamic acid     
(G-C-R-C-G) [43]. The motif not only offered a prolonged resistance against a reducing 
solution with 0.02 mM GSH redox buffer (more than 60 % remaining, compared with 
less than 10 % for single cysteines after 6 h), but also formed orthogonal twin disulfide 
dimers in the presence of single cysteines selectively. The arginine was shown to 
strongly direct the equilibrium toward the twin disulfide dimers. Responsible for this 
effect seems to be the positive charge that promotes the reactivity of thiolates, which 
are intermediately required to form a disulfide bond. The surrounding glutamic acids 
seem to stabilize the disulfide bond by reducing the rates of disulfides exchange in 
GSH redox buffer. 
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1.7 Aim of the thesis 
The bioreducible structure of disulfide bonds offers a very beneficial tool for 
oligocationic gene delivery carriers. Importantly, it provides a straightforward option for 
the design of dynamic carriers and shuttles discriminating between intracellular and 
extracellular cytosolic locations. 
The recent development of a solid-phase synthesis platform for the assembly of 
sequence-defined oligo(ethanamino)amides enables quick and easy synthesis of 
cationic oligomers for complexing nucleic acids. Beside specialized cationic building 
blocks, all natural amino acids, and further units can be incorporated to customize 
those delivery systems. The synthesis of precise gene delivery vehicles is an effective 
way to establish structureactivity relationships and optimize existing carriers. In this 
thesis, two strategies were tested to enrich the library of oligocationic carriers by new 
redox-sensitive structures. 
As a first aim of the thesis, cationic oligomers with different topologies had to be 
modified with twin disulfide-forming cysteine  arginine – cysteine (CRC) motifs. 
Recently Wu et al. introduced this new bioreducible dynamic covalent bond, called the 
twin disulfide, which has orthogonal disulfide pairing characteristics to the standard 
single disulfide [43]. Peptides containing the CRC motifs were found to selectively form 
stable twin disulfide dimers with other CRC peptides, which are more stable against 
reducing agents. The influence of this motif versus single disulfide on the biophysical 
properties and biological performance of polyplexes were to be investigated with pDNA 
and siRNA as nucleic acid cargoes. Properties of the structures like nucleic acid 
binding, serum stability, response to reducing agents, and gene transfer/silencing 
should be analyzed. The main focus was to be put on the effect of the CRC motif on 
polyplex stability. Beside non-targeted structures, shielded and folate-targeted 
structures had to be included in this study. 
The second aim was the evaluation of the bioactivity of redox-sensitive siRNA 
lipopolyplexes. Although high stability of siRNA polyplexes is desirable in the 
extracellular space and for cellular uptake, intracellular disassembly is important for 
the cytosolic release of siRNA and RNA-induced silencing complex formation. To 
improve the release of siRNA, bioreducible lipo-oligomers should be synthesized by 
solid-phase assisted synthesis using the building block Fmoc-succinoyl-cystamine for 
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precise positioning of a disulfide unit between a lipophilic diacyl (bis-myristyl, bis-
stearyl or bis-cholestanyl) domain and an ionizable oligocationic siRNA binding unit. 
Especially the effect on transfection efficiency and toxicity had to be analyzed. 
As a third aim, the most potent lipo-oligomers from the last section were to be extended 
by azide functions to form siRNA polyplexes that could further be modified with DBCO-
bearing shielding and targeting agents. The new peptidic agent poly(sarcosine) should 
be tested for its shielding ability in vitro and in vivo. The folate ligand was to be used 
for targeting specific cells. 
The last aim was the optimization of DBCO click reagents. A solid phase approach 
should be used for synthesizing folate-targeted DBCO poly(ethylene glycol) agents. 
Hereby the surface covering part of the gene delivery system can be designed in a 
precise way. Correlations of PEG length and DBCO moieties with biological activity 
should be analyzed. 
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2 Materials and Methods 
2.1 Materials 
The solvents, reagents and buffers used for the experiments are presented in Table 1, 
Table 2 and Table 3. 
Table 1 Solvents used for experimental procedures 
Solvent CAS-No. Supplier 
Acetonitrile1 75-05-8 VWR Int. (Darmstadt, Germany) 
Chloroform2 67-66-3 VWR Int. (Darmstadt, Germany) 
Chloroform-d3 865-49-6 Euriso-Top (Saint-Aubin Cedex, France) 
Deuterium oxide3 7789-20-0 Euriso-Top (Saint-Aubin Cedex, France) 
Dichloromethane4 75-09-2 Bernd Kraft (Duisburg, Germany) 
N,N-Dimethylformamide5 68-12-2 Iris Biotech (Marktredewitz, Germany) 
Dimethyl sulfoxide6 67-68-5 Sigma-Aldrich (Munich, Germany) 
Ethanol absolute4 64-17-5 VWR Int. (Darmstadt, Germany) 
Ethyl acetate7 141-78-6 Staub & Co. (Nürnberg, Germany) 
n-Heptane8 142-82-5 Grüssing (Filsum, Germany) 
n-Hexane8 110-54-3 Brenntag (Mülheim/Ruhr, Germany) 
Methanol4 67-56-1 Fisher Scientific (Schwerte, Germany) 
Methanol-d43 811-98-3 Euriso-Top (Saint-Aubin Cedex, France) 
Methyl-tert-butyl ether9 1634-04-4 Brenntag (Mülheim/Ruhr, Germany) 
N-Methyl-2-pyrrolidone5 872-50-4 Iris Biotech (Marktredewitz, Germany) 
Tetrahydrofuran4 109-99-9 Fisher Scientific (Schwerte, Germany) 
Water10 7732-18-5 In-house purification 
 
1 HPLC grade; 2 DAB grade, distilled before use; 3 NMR grade (> 99.9 %); 4 analytical grade; 5 peptide grade; 
6 BioReagent grade (> 99.9 %); 7 purum, distilled before use; 8 purissimum; 9 synthesis grade; 10 purified, deionized; 
 
Table 2 Reagents used for experimental procedures 
Reagent CAS-No. Supplier 
1-Hydroxybenzotriazole 
hydrate 
123333-53-9 Sigma-Aldrich (Munich, Germany) 
2-Chlorotritylchloride resin 42074-68-0 Iris Biotech (Marktredewitz, Germany) 
5,5′-Dithiobis(2-nitrobenzoic 
acid) 
69-78-3 Sigma-Aldrich (Munich, Germany) 
5β-Cholanic acid 546-18-9 Sigma-Aldrich (Munich, Germany) 
Acetic acid 64-19-7 Sigma-Aldrich (Munich, Germany) 
Acetic anhydride 108-24-7 Sigma-Aldrich (Munich, Germany) 
Agarose NEEO Ultra 9012-36-6 Carl Roth (Karlsruhe, Germany) 
Ammonia solution 25 % 1336-21-6 Carl Roth (Karlsruhe, Germany) 
Boc-L-Cys(Trt)-OH 21947-98-8 Iris Biotech (Marktredewitz, Germany) 
Bromophenol blue 115-39-9 Sigma-Aldrich (Munich, Germany) 
Chloroquine diphosphate 50-63-5 Sigma-Aldrich (Munich, Germany) 
Cystamine · 2HCl 56-17-7 Sigma-Aldrich (Munich, Germany) 
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D-(+)-Glucose monohydrate 14431-43-7 Merck Millipore (Darmstadt, Germany) 
DBU 6674-22-2 Sigma-Aldrich (Munich, Germany) 
Dde-L-Lys(Fmoc)-OH 156648-40-7 Iris Biotech (Marktredewitz, Germany) 
Dibenzocyclooctyne-acid 1353016-70-2 Sigma-Aldrich (Munich, Germany) 
EDTA disodium salt dihydrate 6381-92-6 Sigma-Aldrich (Munich, Germany) 
Fmoc-L-Arg(Pbf)-OH 154445-77-9 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Cys(Trt)-OH 103213-32-7 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Glu-OtBu 84793-07-7 Merck Millipore (Darmstadt, Germany) 
Fmoc-L-Gly-OH 29022-11-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-His(Trt)-OH 109425-51-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Leu-OH 35661-60-0 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Boc)-OH 71989-26-9 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(Fmoc)-OH 78081-87-5 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(ivDde)-OH 204777-78-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Lys(N3)-OH 159610-89-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Trp(Boc)-OH 43824-78-6 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Tyr(tBu)-OH 71989-38-3 Iris Biotech (Marktredewitz, Germany) 
Fmoc-L-Val-OH 68858-20-8 Iris Biotech (Marktredewitz, Germany) 
Fmoc-N-amido-dPEG24-acid 756526-01-9 Quanta Biodesign (Powell, Ohio, USA) 
Fmoc-OSu 82911-69-1 Iris Biotech (Marktredewitz, Germany) 
Fmoc-Stp(Boc3)-OH - In-house synthesis [66] 
Folic acid 59-30-3 Sigma-Aldrich (Munich, Germany) 
GelRed - Biotium Inc. (Hayward, CA, USA) 
Glutathione reduced 70-18-8 Sigma-Aldrich (Munich, Germany) 
HBTU 94790-37-1 Multisyntech (Witten, Germany) 
Heparin sodium 5000 I.E/mL 9041-08-1 ratiopharm GmbH (Ulm,.Germany) 
HEPES 7365-45-9 Biomol (Hamburg, Germany) 
Hydrazine monohydrate 7803-57-8 Sigma-Aldrich (Munich, Germany) 
Hydrochloric acid solution (1 
M) 
7647-01-0 Sigma-Aldrich (Munich, Germany) 
Iminodiacetic acid 142-73-4 Sigma-Aldrich (Munich, Germany) 
LPEI 9002-98-6 In-house synthesis [111] 
MTT 298-93-1 Sigma-Aldrich (Munich, Germany) 
Myristic acid 544-63-8 Sigma-Aldrich (Munich, Germany) 
N,N-Diisopropylethylamine 7087-68-5 Iris Biotech (Marktredewitz, Germany) 
N10-(Trifluoroacetyl)pteroic 
acid 
37793-53-6 Clauson-Kass A/S (Farum, Denmark) 
Ninhydrin 485-47-2 Sigma-Aldrich (Munich, Germany) 
Oleic acid 112-80-1 Sigma-Aldrich (Munich, Germany) 
PEI-Suc 10 % - In-house synthesis [112] 
Phenol 108-95-2 Sigma-Aldrich (Munich, Germany) 
Piperidine 110-89-4 Iris Biotech (Marktredewitz, Germany) 
Potassium cyanide 151-50-8 Sigma-Aldrich (Munich, Germany) 
Pybop® 128625-52-5 Multisyntech GmbH (Witten, Germany) 
Sephadex® G-10 9050-68-4 GE Healthcare (Freiburg, Germany) 
Sodium hydroxide (anhydrous) 1310-73-2 Sigma-Aldrich (Munich, Germany) 
Sodium hydroxide solution 
(0.05 M) 
1310-73-2 Sigma-Aldrich (Munich, Germany) 
Stearic acid 57-11-4 Sigma-Aldrich (Munich, Germany) 
Succinic anhydride 108-30-5 Sigma-Aldrich (Munich, Germany) 
Tetraethylene pentamine · 
5HCl 
4961-41-5 Sigma-Aldrich (Munich, Germany) 
Triethylamine 121-44-8 Sigma-Aldrich (Munich, Germany) 
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Trifluoroacetic acid 76-05-1 Iris Biotech (Marktredewitz, Germany) 
Triisopropylsilane 6485-79-6 Sigma-Aldrich (Munich, Germany) 
Triton™ X-100 9002-93-1 Sigma-Aldrich (Munich, Germany) 
Trizma® base 77-86-1 Sigma-Aldrich (Munich, Germany) 
Table 3 Buffers used for experimental procedures 
Buffer Composition 
10 mM HCl SEC solvent 693 mL water, 300 mL acetonitrile, 7 mL 1M HCl 
solution 
Electrophoresis loading buffer 6 mL glycerine, 1.2 mL 0.5 M EDTA solution (pH 8.0), 
2.8 mL H2O, 20 mg bromophenol blue 
Ellman buffer 0.1 M sodium phosphate buffer (pH 8.0), 1mM EDTA 
HBG 20 mM HEPES, 5 % glucose, pH 7.4 
TBE buffer 89 mM Trizma® base, 89 mM boric acid, 2 mM EDTA-
Na2 
 
Citrate-buffered human blood for erythrocyte leakage assays was kindly supplied by 
Klinikum der Universität München (Munich, Germany). 
 
2.1.1 Equipment for solid-phase synthesis  
Automated parallel synthesis or synthesis with microwave irradiation was carried out 
using a Biotage Syro Wave (Biotage AB, Uppsala, Sweden) peptide synthesizer. 
Disposable polypropylene (PP) syringe microreactors with the volume sizes 2 mL, 
5 mL, and 10 mL were purchased from Multisyntech (Witten, Germany). It was 
conducted with polytetrafluoroethylene (PTFE) filters. The recommended size of the 
reactors was chosen according to the resin amount. For manual solid-phase synthesis 
microreactors with polyethylene filters were used. Reactors were mixed with an 
overhead shaker during reactions. 
 
2.1.2 Nucleic acids  
2.1.2.1 pDNA 
The plasmid pCMVLuc (encoding for firefly luciferase under control of the CMV 
promoter) was purchased from Plasmid Factory (Bielefeld, Germany) or amplified in 
E. coli DH5α and purified from the bacterial lysate using a Qiagen Plasmid Giga Kit 
(Qiagen, Hilden, Germany). The concentration of nucleic acid solutions was 
determined photometrically using an Eppendorf BioPhotometer (Eppendorf, Hamburg, 
   Materials and Methods 
   34 
Germany). Cy5-labeled nucleic acids were produced with a Cy5-labelling kit obtained 
from Mirus Bio (Madison, WI, USA). 
2.1.2.2 siRNA 
All siRNAs and modified siRNA compounds used are presented in Table 4. They were 
synthesized by Roche Kulmbach GmbH (now Axolabs GmbH, Kulmbach, Germany). 
The INF7 peptide (sequence: H2N-GLFEAIEGFIENGWEGMIDGWYGC-amide) was 
purchased from Biosyntan (Berlin, Germany) and conjugated to HS-C6-siRNA 
according to [87]. 
 
Table 4 siRNA strands  
siRNA Target Sequence 
INF7-siCtrl - 
5’-(INF7)(SSC6)AuGuAuuGGccuGuAuuAGdTsdT-3’ (sense) 
5’-CuAAuAcAGGCcAAuAcAUdTsdT-3’ (antisense) 
INF7-siGFP eGFP-Luc 
5’-(INF7)(SSC6)AuAucAuGGccGAcAAGcAdTsdT-3’ (sense) 
5’-UGCUUGUCGGCcAUGAuAUdTsdT-3’ (antisense) 
Cy5-siAHA1 AHA1 
5’-(Cy5)(NHC6)GGAuGAAGuGGAGAuuAGudTsdT-3’ (sense) 
5’-ACuAAUCUCcACUUcAUCCdTsdT-3’ (antisense) 
Cy7-siAHA1 AHA1 
5’-(Cy7)(NHC6)GGAuGAAGuGGAGAuuAGudTsdT-3’ (sense) 
5’-ACuAAUCUCcACUUcAUCCdTsdT-3’ (antisense) 
siCtrl - 
5’-AuGuAuuGGccuGuAuuAGdTsdT-3’ (sense) 
5’-CuAAuAcAGGCcAAuAcAUdTsdT-3’ (antisense) 
siEG5 EG5 / KSP 
5’-ucGAGAAucuAAAcuAAcudTsdT-3’ (sense) 
5’-AGUuAGUUuAGAUUCUCGAdTsdT-3’ (antisense) 
siGFP eGFP-Luc 
5’-AuAucAuGGccGAcAAGcAdTsdT-3’ (sense) 
5’-UGCUUGUCGGCcAUGAuAUdTsdT-3’ (antisense) 
 
Small letters: 2’-methoxy-RNA, s: phosphorothioate. All nucleic acids were synthesized by the Roche Kulmbach 
GmbH (now Axolabs GmbH, Kulmbach, Germany). INF7 modified siRNAs were synthesized according to [87]. 
 
2.1.3 Cell culture  
Cell culture work was carried out by Dr. Petra Kos, Ana Krhac Levacic, Dr. Daniel 
Edinger, Dr. Katharina Müller, Dr. Dian-Jang Lee and Dr. Wei Zhang (Pharmaceutical 
Biotechnology, LMU). All cell culture media, antibiotics and fetal bovine serum (FBS) 
were purchased from Invitrogen (Karlsruhe, Germany). The individual media used for 
the different cell cultures are summarized in Table 5. All media were supplemented 
with 10 % FBS, 4 mM stable glutamine, 100 U/mL penicillin and 100 μg/mL 
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streptomycin. Exponentially growing cells were detached from the culture flasks using 
trypsin-EDTA solution (Invitrogen, Karlsruhe, Germany) and cell suspensions were 
seeded at the desired density for each experiment. Luciferase cell culture lysis buffer 
and D-luciferin sodium salt were purchased from Promega (Mannheim, Germany). 
 
Table 5 Overview of the used cell lines and culture media 
Cell line Description Medium 
DU145/eGFPLuc 
Human prostate cancer cells expressing 
the eGFP-Luciferase fusion gene 
RPMI-1640 
KB Human cervix carcinoma cells RPMI-1640, folate-free 
KB/eGFPLuc 
Human cervix carcinoma cells expressing 
the eGFP-Luciferase fusion gene 
RPMI-1640, folate-free 
L1210 Mouse lymphocytic leukemia cells RPMI-1640, folate-free 
Neuro2A Mouse neuroblastoma cells DMEM 
Neuro2A/eGFPLuc 
Mouse neuroblastoma cells expressing 
the eGFP-Luciferase fusion gene 
DMEM 
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2.2 Methods 
2.2.1 Synthesis of disulfide-linker building block (ssbb): 
Fmoc-succinoyl-cystamine 
 
15.0 g of cystamine dihydrochloride (66.6 mmol, 1 eq.) were suspended in 150 mL of 
THF with 23.2 ml of DIPEA (133.2 mmol, 2 eq.) and cooled down to -80 °C. 18.0 g 
(53.3 mmol, 0.8 eq.) of Fmoc-OSu were dissolved in 200 mL of THF and added 
dropwise over the course of 3 h. The reaction was stirred for additional 1 h at -80 °C 
and then for 1 h at RT. DIPEA (23.2 mL, 133.2 mmol, 2 eq.) was added and the 
reaction mixture was cooled to 0 °C. Succinic anhydride (12.0 g, 119.9 mmol, 1.8 eq.) 
was dissolved in 150 mL of THF. This solution was added dropwise to the reaction 
mixture at 0 °C and stirred over-night. The reaction mixture was concentrated to 
approximately 200 mL, mixed with 200 mL of DCM and was washed 5 × with 0.1 M 
sodium citrate buffer (pH 5.2). The organic phase was dried over sodium bicarbonate, 
concentrated and purified by dry column vacuum chromatography (DCVC) using a        
n-heptane/EtOAc gradient (starting from 1 : 1) to elute Fmoc-byproducts, followed by 
a EtOAc/MeOH gradient to isolate the product. The solvent was removed under 
reduced pressure to give 6.2 g of a white solid (13.1 mmol, 24.5 %). 
 
2.2.2 Loading of a 2-chlorotrityl chloride resin with an Fmoc protected amino 
acid 
After swelling of 750 mg of a 2-chlorotrityl chloride resin (1.2 mmol chloride, 1 eq) in 
water-free DCM for 10 min, the first Fmoc protected amino acid (T-shape: 0.3 eq. 
Fmoc-Tyr(tBu)-OH, Fmoc-Cys(Trt)-OH or Fmoc-L-Lys(N3)-OH; 3-arm: 0.3 eq. Fmoc-
Cys(Trt)-OH; PEGylated 2-arm: 0.3 eq. Fmoc-Lys(ivDde)-OH; i-shape: 0.3 eq. Fmoc-
Stp(Boc3)-OH; U-shape: 0.3 eq. Fmoc-Lys(fmoc)-OH; DBCO PEG agents: 0.3 eq. 
Fmoc-Lys(Dde)-OH and DIPEA (0.6 eq.) were added to the resin for 1 h. The reaction 
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solvent was drained and a mixture of DCM/MeOH/DIPEA (80/15/5) was added twice 
for 10 min. After the removal of the reaction mixture, the resin was washed 5 times with 
DCM. 
About 30 mg of the resin were removed and dried to determine the loading of the resin. 
Therefore, an exact amount of resin was treated with 1 mL deprotection solution (20 % 
piperidine in DMF) for 1 h. Afterwards, the solution was diluted and absorption was 
measured at 301 nm. The loading was then calculated according to the equation: resin 
load [mmol/g] = (A*1000)/(m [mg]*7800*df) with df as dilution factor. 
The resin was treated twice with 20 % piperidine in DMF and twice with 20 % piperidine 
DMF with 2 % DBU to remove the Fmoc protection group. Reaction progress was 
monitored by Kaiser test. Afterwards, the resin was washed with DMF, DCM and           
n-hexane and dried in vacuo. 
 
2.2.3 Oligomer and DBCO agent synthesis 
Oligomers were synthesized using a 2-chlorotrityl resin preloaded with the first C-
terminal amino acid of the respective topology (see 2.2.2) as solid support. All 
sequences and topologies of oligomers can be found in Table 18, all sequences of 
DBCO agents can be found in Table 19. Unless otherwise stated, coupling steps were 
carried out using 4 eq. Fmoc-amino acid, 4 eq. HOBt, 4 eq. PyBOP or HBTU and 8 eq. 
DIPEA (10 mL g−1 resin) for 90 min. General steps of a manual and automated 
synthesis are shown in Table 6 and Table 7. 
Table 6 General steps of a manual synthesis cycle 
Step Description Solvent Volume Time 
1  Coupling DCM/DMF 50/50 5 mL/g resin 90 min 
2  Wash DMF, DCM 10 mL/g resin 3 × 1 min DMF 
3 × 1 min DCM 
3  Kaiser test - - - 
4  Fmoc deprotection 20 % piperidine/DMF 10 mL/g resin 4 × 10 min 
5  Wash DMF, DCM 10 mL/g resin 3 × 1 min DMF 
3 × 1 min DCM 
6  Kaiser test - - - 
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Table 7 General steps of an automatic synthesis cycle with microwave 
Step Description Solvent Volume Time 
1  Coupling NMP/DMF 5 mL/g resin 12 min at 50°C 
2  Double-coupling NMP/DMF 5 mL/g resin 12 min at 50°C 
2  Wash DMF 8 mL/g resin 5 × 1 min 
3  Fmoc deprotection 20 % piperidine/DMF 7 mL/g resin 5 × 10 min 
4  Wash DMF 8 mL/g resin 5 × 1 min 
 
2.2.3.1 Synthesis of T-shapes 
After swelling the preloaded resin, backbones were synthesized with an automated 
synthesizer with microwave support like described in Table 7. Before deprotection of 
the central Dde or ivDde group with 2 % hydrazine solution, the N-terminal NH2-group 
was protected with 10 eq Boc anhydride and 10 eq DIPEA in DCM/DMF. In case of an 
N-terminal cysteine, Boc-Cys(Trt)-OH was used to prevent that step. (iv)Dde-
deprotection was performed 30 times with a Syro WaveTM synthesizer (Biotage, 
Uppsala, Sweden). Hydrazine–DMF solution 1 : 50 was added and vortexed for 2 min. 
The reaction solvent was drained and fresh solution was added again. Afterwards, the 
resin was washed with 5 × 1 min DMF 5 × 1 min 10 % DIPEA/DMF and 3 × 1 min DCM 
(10 mL g−1 resin). The following coupling steps were carried out using the manual 
protocol in Table 6. In case of a positive result of the Kaiser test after coupling, the last 
coupling step was repeated. In case of a negative result after deprotection, the last 
deprotection step was repeated (optionally with 2 % DBU added to the 20 % piperidine 
solution). In case of coupling Fmoc-succinoyl-cystamine, no HOBt was used and only 
DMF was used as solvent (Kaiser tests are not always correct after the deprotection; 
deprotection steps were not performed with additional DBU). All couplings after Fmoc-
succinoyl-cystamine were carried out without HOBt. Symmetrical branching points 
were introduced using Fmoc-Lys(Fmoc)-OH, asymmetric branching in T-shape 
structures was introduced using Fmoc-Lys(Dde)-OH. 
2.2.3.2 Synthesis of 3-arms 
After swelling the preloaded resin, the structures were synthesized manually like 
described in Table 6. Symmetrical branching points were introduced using Fmoc-
Lys(Fmoc)-OH. For the N-terminal cysteine, Boc-Cys(Trt)-OH was used. In case of a 
positive result of the Kaiser test after coupling, the last coupling step was repeated. In 
case of a negative result after deprotection, the last deprotection step was redone with 
2 % DBU added to the 20 % piperidine solution. 
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2.2.3.3 Synthesis of PEGylated 2-arms (736-739) 
After swelling of 0.080 mmol of Fmoc-Lys(ivDde)-chlorotrityl resin in DMF for 30 min, 
the backbone (Stp(Boc)3-Stp(Boc)3-Stp(Boc)3-Stp(Boc)3-Lys(Stp(Boc)3-Stp(Boc)3-
Stp(Boc)3-Stp(Boc)3)-Lys(ivDde) was synthesized with a Syro WaveTM synthesizer 
(Biotage, Uppsala, Sweden). For the automated coupling three equivalents of Fmoc-
Lys(Fmoc)-OH, DIPEA (6 eq) and HBTU/HOBt (3 eq) in DMF were added and 
occasionally vortexed for 60 min. The reaction solvent was drained and the resin was 
washed one time with DMF. Double coupling was performed under the same 
conditions. The reaction solvent was drained and the resin was washed six times with 
DMF. To remove the Fmoc protection group, the resin was treated five times with 20 % 
piperidine in DMF. The resin was washed with DMF (6x). To complete the backbone, 
3 equivalents of Fmoc-Stp(boc)3-OH per free primary amine (6 eq because of 2 free 
amines after branching lysine) were coupled the same way. After the automated 
synthesis of the backbone, the resin was split in 2 equal parts (0.040 mmol each). The 
following couplings were performed manually with 4 eq amino acid, 8 eq DIPEA and 
4 eq PyBOP®/HOBt per free primary amine in DCM/DMF. After 60 min reaction time, 
the reaction solvent was drained and the resin was washed three times with DMF and 
DCM each. Reaction progress was monitored with Kaiser test. After successful 
reaction, the resin was treated twice with 20 % piperidine in DMF (for 10 and 15 min) 
and twice with 20 % piperidine in DMF with 2 % DBU (for 5 min). The reaction solvent 
was drained and the resin was washed three times with DMF and DCM. For structures 
with single cysteines (736, 737) Boc-Cys(Trt)-OH was coupled. For CRC-structures 
(738, 739) Fmoc-Cys(Trt)-OH, Fmoc-Arg(Pbf)-OH and Boc-Cys(Trt)-OH were coupled. 
The ivDde-deprotection was performed with then Syro WaveTM synthesizer (Biotage, 
Uppsala, Sweden). Hydrazine/DMF solution (4/96; vol/vol) was added and vortexed for 
2 min. The reaction solvent was drained and Hydrazine/DMF solution (4/96; vol/vol) 
was added again. After 10 cycles the supernatant's absorption was measured at 
290 nm to monitor the progression of the reaction. After 50 cycles absorption was less 
than 0.1 in all approaches. 
The PEGylation was performed with 4 eq of Fmoc-dPEG24-OH the same way the other 
manual couplings were done. After Fmoc-deprotection the resin of the 2 reactors was 
split again resulting in 4 batches. To get negative control structures (736, 738) 8 eq 
succinic anhydride and 16 eq DIPEA in DCM were added to the resin. To produce 
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structures with folic acid ligand (737, 739) Fmoc-Glu-OtBu followed by N10-
(trifluoroacetyl)pteroic acid were coupled manually like the other amino acids. For the 
deprotection of the trifluoroacetyl-group of pteroic acid, the resin was treated with 25 % 
aqueous ammonia solution/DMF (1 : 1) 4 times for 30 min. After each deprotection 
cycle, the resin was washed with DMF.  
2.2.3.4 Synthesis of i-shapes 
After swelling the preloaded resin, the structures were synthesized manually like 
described in Table 6. Symmetrical branching points were introduced using Fmoc-
Lys(Fmoc)-OH. In case of coupling Fmoc-succinoyl-cystamine, no HOBt was used and 
only DMF was used as the solvent (Kaiser tests are not always correct after the 
deprotection). All couplings after Fmoc-succinoyl-cystamine were carried out without 
HOBt. 
2.2.3.5 Synthesis of U-shapes 
After swelling the preloaded resin, the structures were synthesized manually like 
described in Table 6. Symmetrical branching points were introduced using Fmoc-
Lys(Fmoc)-OH. In case of coupling Fmoc-succinoyl-cystamine, no HOBt was used and 
only DMF was used as solvent (Kaiser tests are not always correct after the 
deprotection). All couplings after Fmoc-succinoyl-cystamine were carried out without 
HOBt. 
2.2.3.6 Synthesis of DBCO PEG shielding agents 
After swelling the preloaded resin, the structures were synthesized manually like 
described in Table 6. In case of folate targeted structures, folic acid was first 
synthesized by coupling of Fmoc-Glu-OtBu at a Lys(Dde)-loaded resin followed by N10-
(trifluoroacetyl)pteroic acid. Dde-deprotection was then performed 20 times with a Syro 
WaveTM synthesizer (Biotage, Uppsala, Sweden). Hydrazine/DMF solution (1 : 50) was 
added and vortexed for 2 min. The reaction solvent was drained and fresh solution was 
added again. Afterwards, the resin was washed with 5 × 1 min DMF 5 × 1 min 10 % 
DIPEA/DMF and 3 × 1 min DCM (10 mL g−1 resin). For the deprotection of the 
trifluoroacetyl-group of pteroic acid the resin was treated with 25 % aqueous ammonia 
solution/DMF (1 : 1) 4 times for 30 min. After each deprotection cycle the resin was 
washed with DMF. Then, Fmoc-dPEG24-OH was coupled. In case of Bis-DBCO 
structures, the branching points was introduced using Fmoc-Lys(Fmoc)-OH. In case of 
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coupling Fmoc-succinoyl-cystamine, no HOBt was used and only DMF was used as 
solvent (Kaiser tests are not always correct after the deprotection). The coupling after 
Fmoc-succinoyl-cystamine was carried out without HOBt. Finally 3 eq DBCO acid were 
coupled using 3 eq DIPEA and 3 eq PyBOP® in DCM/DMF. 
After completion of the reaction, the resin was washed with DMF, DCM and n-hexane 
and dried in vacuo. 
 
2.2.4 Kaiser test 
Free amines of deprotected amino acids on the resin were determined qualitatively by 
the Kaiser test [67]. A small sample of DCM washed resin was transferred into an 
Eppendorf reaction tube. One drop of each 80 % phenol in EtOH (w/v), 5 % ninhydrin 
in EtOH (w/v) and 20 μM potassium cyanide (KCN) in pyridine (mixture of 1 mL 
aqueous 0.001 M KCN solution and 49 mL pyridine) were added. The tube was 
incubated at 99 °C for 4 min under shaking. The presence of free amines was indicated 
by a deep blue color. 
 
2.2.5 Cleavage conditions 
2.2.5.1 General cleavage conditions 
All oligomers were cleaved off the resin by incubation with TFA–TIS–H2O 
(95 : 2.5 : 2.5) (10 mL g−1 resin) for 90 min. The cleavage solution was concentrated 
by flushing nitrogen and oligomers were precipitated in 40 mL of pre-cooled MTBE – 
n-hexane (1 : 1). All oligomers were purified by size exclusion chromatography using 
a Äkta purifier system (GE Healthcare Bio-Sciences AB, Uppsala, Sweden), a 
Sephadex G-10 column and 10 mM hydrochloric acid solution–acetonitrile (7 : 3) as 
solvent. All oligomers were lyophilized. 
2.2.5.2 Cleavage of oligomers containing oleic acid 
The cleavage of the structures off the resin was performed according to an optimized 
protocol (Sören Reinhard, PhD study, LMU Pharmaceutical Biotechnology) by 
incubation with TFA–TIS–H2O 95 : 2.5 : 2.5 (10 mL g−1 resin cooled to 4 °C prior to 
addition) for 30 min followed by immediate precipitation in 40 mL of pre-cooled MTBE 
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– n-hexane (1 : 1). The oleic acid containing oligomers were then purified by size 
exclusion chromatography using a Äkta purifier system (GE Healthcare Bio-Sciences 
AB, Uppsala, Sweden), a Sephadex G-10 column and 10 mM hydrochloric acid 
solution–acetonitrile (7 : 3) as solvent. The oligomers were lyophilized. 
2.2.5.3 Cleavage of DBCO containing reagents 
The cleavage of the structures off the resin was performed by incubating the dried resin 
with DCM–TFA–TIS (92.2 : 5 : 2.5) for 60 min followed by immediate precipitation in 
40 mL of pre-cooled MTBE–n-hexane (1 : 4). The precipitate was then dissolved in 
0.05 M NaOH solution. The pH was adjusted to 7 and the structure was purified by 
dialysis with a 1000 Da cut-off membrane against deionized water. The obtained 
DBCO reagents were lyophilized. 
 
2.2.6 pDNA polyplex formation 
Nucleic acid and oligomers were dissolved at concentrated stock solutions in water, 
and diluted with 20 mM HEPES buffered 5 % glucose pH 7.4 (HBG). pDNA and 
oligomer were prepared in separate tubes. Unless otherwise stated, pDNA at a 
concentration of 20 ng/µL was used. According to the indicated nitrogen/phosphate 
(N/P) ratio, oligomer solutions were prepared and the same volume of pDNA was 
added to the oligomer. Only protonatable nitrogens were considered in the N/P 
calculations (see Table 18). The mixture was rapidly pipetted at least 5 × and 
incubated for 40 min at RT. 
 
2.2.7 siRNA polyplex formation 
Nucleic acid and oligomers were dissolved at concentrated stock solutions in water, 
and diluted with 20 mM HEPES buffered 5 % glucose pH 7.4 (HBG). siRNA and 
oligomer were prepared in separate tubes. For most cases, siRNA at a concentration 
of 50 ng/µL was used. In some experiments higher concentrations of siRNA were 
prepared. Especially for experiments related to in vivo work, siRNA concentrations of 
500 ng/µL. According to the indicated nitrogen/phosphate (N/P) ratio, oligomer 
solutions were prepared and the same volume of siRNA was added to the oligomer. 
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Only protonatable nitrogens were considered in the N/P calculations (see Table 18). 
The mixture was rapidly pipetted at least 5 × and incubated for 40 min at RT. 
2.2.7.1 Modification with DBCO reagents 
For modifying siRNA polyplexes with DBCO click agents, solutions with reagents were 
prepared in ¼ of the volume of polyplex solutions prepared before. The concentration 
of the solution was calculated according to the respective equivalents (eq). Equivalents 
represent the molar ratio of shielding agents to oligomers in the polyplex solution. 
Unless otherwise stated, the reaction time was 4 h. 
 
2.2.8 pDNA binding assays 
A 1 % agarose gel for pDNA analyses was prepared by dissolving agarose in TBE 
buffer (Trizma base 10.8 g, boric acid 5.5 g, disodium EDTA 0.75 g, and 1 L of water) 
and boiling everything up to 100 °C. After cooling down to about 50 °C and addition of 
GelRed™ (Biotum, Hayward, U.S.A.), the agarose gel was casted in the 
electrophoresis unit. Polyplexes with 200 ng pDNA were formed as described and 
placed into the sample pockets after 4 μL of loading buffer (prepared from 6 mL of 
glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of bromophenol blue) was 
added. Electrophoresis was performed at 120 V for 80 min. 
 
2.2.9 siRNA binding assays 
Unless otherwise stated, a 2.5 % agarose gel was prepared by dissolving agarose in 
TBE buffer (10.8 g of trizma base, 5.5 g of boric acid, 0.75 g of disodium EDTA, and 
1 L of water) and subsequent boiling. After cooling down to about 50 °C, GelRedTM 
was added. Polyplexes with 500 ng siRNA were formed using the stated N/P ratios. In 
case of concentrated formulations, polyplexes were diluted with HBG to a final volume 
of 20 µL. Samples were placed into the pockets after 4 µl of loading buffer (prepared 
from 6 mL of glycerine, 1.2 mL of 0.5 M EDTA, 2.8 mL of H2O, 0.02 g of bromophenol 
blue) was added. Unless otherwise stated, electrophoresis was performed at 100 V for 
40 min. 
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2.2.10 pDNA and siRNA polyplexes under reducing conditions 
pDNA polyplexes were formed at N/P ratio 12 and 200 ng pDNA in 20µL. siRNA 
polyplexes were formed at N/P ratio 20 and 500 ng siRNA in 20µL. After polyplex 
incubation, 5 µL of a GSH solution were added to 20 µL of the polyplex solution. The 
GSH stock solution had a concentration of 50 mM and pH was adjusted to 7.4. It was 
diluted to concentrations of 5 mM and 0.5 mM. Consequently, the resulting solutions 
had the final concentrations 0.1 mM, 1 mM and 10 mM, respectively. HBG was used 
as negative control (0 mM GSH). The solutions were incubated at 37 °C for 90 min. 
5 µL loading buffer was added and a binding assay (see 2.2.8 and 2.2.9) was 
performed. 
 
2.2.11 pDNA and siRNA polyplex stability in 90 % serum  
Polyplexes were formed using 1.0 µg of pDNA or 2.5 µg siRNA in 6.25 µL HBG mixed 
with the oligomer at N/P 12 resulting in a total volume of 12.5 µL. Afterwards, the 
incubation 112.5 µl fetal bovine serum (FBS) was added to the samples. All samples 
had a final concentration of 90 % FBS. The samples were incubated at 37 °C for 2 h. 
20 µL of the samples and 4 µL loading buffer were carefully mixed and a binding assay 
(see 2.2.8 and 2.2.9) was performed. 
 
2.2.12 Particle size and zeta potential 
For dynamic light scattering (DLS) measurements the polyplex solution was measured 
in a folded capillary cell (DTS 1070) using a Zetasizer Nano ZS with backscatter 
detection (Malvern Instruments, Worcestershire, UK). Polyplexes were formed using 
1.5 µg siRNA and the oligomer at indicated N/P ratio. In case of concentrated polyplex 
solutions, samples were diluted with HBG resulting in a total volume of 60 µL. For size 
measurements, the equilibration time was 0 min, the temperature was 25 °C and an 
automatic attenuator was used. The refractive index of the solvent was 1.330 and the 
viscosity was 0.8872 mPa•s. Each sample was measured 3 times. For zeta potential 
measurements with at least 6 runs. The sample was diluted to 800 µL with 20 mM 
HEPES buffer or 10 mM NaCl to measure zeta potential. Zeta potentials were 
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calculated by the Smoluchowski equation. Ten to fifteen sub runs lasting 10 s each at 
25 °C (n = 3) were measured.  
2.2.13 Ellman´s assay 
The oligomers containing ssbb elements were diluted to a concentration of 
1.67 mg/mL. 30 µL of the solution was mixed with 170 µL working solution (2.44 mL 
Ellman´s buffer (0.2 M Na2HPO4, 1 mM EDTA, pH 8.0) and 60 µL DTNB solution in 
methanol (c = 4 mg/mL)). After 15 min incubation at 37 °C absorption was measured 
at 412 nm using a GENESYSTM UV-VIS spectrophotometer (Thermo Scientific). The 
percentage of free mercapto groups is based on the theoretical amount (100 %) of 
thiols in case of complete cleavage. 
 
2.2.14 Buffer capacity of oligomers 
The oligomer sample, containing 15 µmol protonatable amines, was diluted in a total 
volume of 3.5 mL NaCl solution (50 mM) and the pH was adjusted to 2 by addition of 
hydrochloric acid. Afterwards, a back titration with 0.05 M NaOH was performed with 
an automatic titration system (Titrando 905 from Metrohm, Germany) equipped with a 
Biotrode pH electrode (METROHM GmbH & Co. KG, Filderstadt, Germany), until a pH 
of 11 was reached. To distinguish oligomer and solvent effects, a control titration of 
50 mM sodium chloride solution without oligomer was performed. Volume differences 
(ΔV) between defined pH values were determined. Total endolysosomal buffer 
capacity C in the pH range between 5 and 7.4 was calculated according to the following 
formula: 
CpH 5−pH 7.4 =
[∆𝑉(Sample)pH 5−pH 7.4 −  ∆𝑉(NaCl)pH 5−pH 7.4]  ∙ 50 mM
15 μmoles
 ∙ 100 % 
 
2.2.15 Erythrocyte leakage assay with or without previous reductive treatment 
Fresh, citrate-buffered human blood was washed with phosphate-buffered saline 
(PBS). The washed human erythrocyte suspension was centrifuged and the pellet was 
diluted to 5 × 107 erythrocytes per mL with PBS (pH 7.4, 6.5 and 5.5). In case of GSH 
treatment, oligomers were incubated in 10 mM GSH in HEPES (pH adjusted to 7.4) at 
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a concentration of 1 mg/mL at 37 °C for 90 min. A volume of 75 μl of erythrocyte 
suspension and 75 µL of oligomer solution (previously diluted with PBS of the 
respective pH) were added to each well of a V-bottom 96-well plate (NUNC, Denmark), 
resulting in a final concentration of 7.5 µM oligomer per well. The plates were incubated 
at 37 °C under constant shaking for 1 h. After centrifugation, 100 µL of the supernatant 
was analyzed for hemoglobin release at 405 nm wavelength using a microplate reader 
(Spectrafluor Plus, Tecan Austria GmbH, Grödig, Austria). 
 
2.2.16 Ethidium bromide compaction assay with incubated polyplexes 
A Cary Eclipse spectrophotometer (Varian, Germany) was used for the quantification 
of ethidium bromide (EtBr) fluorescence at the excitation wavelength λex = 510 nm 
and emission wavelength λem = 590 nm. pDNA polyplexes were incubated with 2 µg 
pDNA and the oligomer at N/P 12 in 200 µL HBG for 40 minutes. siRNA polyplexes 
were incubated with 5 µg siRNA and the oligomer at N/P 20 in 200 µL HBG for 
40 minutes. Before the measurement 800µL of EtBr solution (c = 0.4 µg/mL) was 
added. 200 µL HBG buffer + 800 µL of EtBr solution (c = 0.4 µg/mL) was used as blank. 
200µL of nucleic acid solution (2 µg pDNA or 5 µg siRNA) + 800 µL of EtBr solution 
(c = 0.4 µg/mL) was assigned to 100 %. The fluorescence intensity of EtBr measured 
after 3 minutes of incubation was determined in relation to the 100 % value. Triplicates 
were measured. 
 
2.2.17 Confocal fluorescence microscopy 
KB cells or Neuro2A cells were seeded into an 8-well Labtek chamber slide coated 
with collagen at a density of 3 × 104 cells/well in 300 μL of growth medium 24 h prior 
to treatment. Polyplexes were formed as described using a mixture of 80 % unlabeled 
and 20 % Cy5 labeled nucleic acid (in total 0.6 µg DNA, 1.2 µg siRNA for PEGylated 
polyplexes and 1.5 µg siRNA for non-PEGylated polyplexes) and oligomer at N/P 12 
(pDNA) or oligomer at N/P 20 (siRNA) in 60 μL of HBG. The medium was replaced 
with 240 μL of fresh growth medium, and the polyplex solution was added. For 
PEGylated polyplexes, the chamber slide was incubated at 37°C for 45 min. 
Afterwards, the medium was changed and cells were incubated again for 4h. Then 
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cells were washed twice with 500 µl PBS and fixed with 4 % PFA solution for 30 min 
at room temperature.  For non-PEGylated polyplexes, cells were incubated for 24 h 
and washed and fixed as described before. Cell nuclei were stained with DAPI and 
actin was stained with rhodium phalloidin (Life Technologies). A Leica TCS SP8 
confocal microscope was used for image acquisition. 
 
2.2.18 Cellular internalization of pDNA polyplexes 
KB or KB/eGFPLuc cells were seeded into 24-well plates coated with collagen at a 
density of 5 × 104 cells/well. After 24 h, the culture medium was replaced with 400 μL 
fresh growth medium. pDNA polyplexes (N/P 12) in 100 μL HBG, containing 1 μg pDNA 
(20 % of the nucleic acid was Cy5-labeled) were added to each well and incubated at 
37 °C for 45 min. All experiments were performed in triplicates. Subsequently, cells 
were washed with 500 μL PBS containing 500 IU of heparin for 15 min to remove any 
polyplexes sticking to the cell surface. After an additional PBS washing step, cells were 
detached with trypsin/EDTA and taken up in growth medium, centrifuged to receive a 
cell pellet, and taken up in PBS with 10 % FBS. Cellular internalization was assayed 
by excitation of Cy5 at 635 nm and detection of emission at 665 nm. Cells were 
appropriately gated by forward/sideward scatter and pulse width for the exclusion of 
doublets. DAPI (4′,6-diamidino-2-phenylindole) was used to discriminate between 
viable and dead cells. Data were recorded by Cyan™ ADP flow cytometer (Dako, 
Hamburg, Germany) using Summit™ acquisition software (Summit, Jamesville, NY, 
USA) and analyzed by FlowJo® 7.6.5 flow cytometric analysis software. 
 
2.2.19 Cell association and cellular internalization of siRNA polyplexes 
Neuro2A cells or KB cells were seeded in 24-well plates with 5 × 104 cells/well at 24 h 
before the experiment, and fresh media were provided before the experiment. 
Polyplexes containing 1.5 µg siRNA (including 20 % Cy5 labeled siRNA) per well were 
added into each well incubated 30 min on ice or 45 min at 37 oC in 5 % CO2 for cell 
association or cellular internalization respectively. Cells were washed with PBS for 
3 times to remove free polyplexes. For cellular internalization, cells were then 
incubated with 500 I.U. heparin to remove polyplexes non-specifically associated to 
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the cell surface. Finally, cells were collected and resuspended in PBS buffer with 10 % 
FBS. For folate competition experiment, cells were incubated with folate acid (1 mM) 
for 30 min on ice to block FA receptor before polyplexes added. All samples were 
measured by flow cytometry with CyanTM ADP (Dako, Hamburg, Germany) through 
excitation at 635 nm, and detection of emission at 665 nm. Dead cells were detected 
by DAPI fluorescence and removed by gating in order to analyze polyplex uptake into 
living cells. Data were analyzed by FlowJo® 7.6.5 flow cytometric analysis software. 
 
2.2.20 Luciferase gene transfer 
Neuro2A cells or KB cells were seeded 24 h prior to pDNA delivery using 1 × 104 
Neuro2A cells/well or 8000 KB cells/well in 96-well plates. In vitro transfection 
efficiencies of the oligomers were evaluated using 200 ng pCMVLuc per well. All 
experiments were performed in quintuplicate. Before transfection medium was 
replaced with 80 μL fresh medium containing 10 % FBS. Transfection complexes 
formed at different protonatable nitrogen/phosphate (N/P) ratios in 20 μL HBG were 
added to each well and incubated at 37 °C. For targeted oligomers medium was 
replaced 45 min after transfection by fresh medium or chloroquine (0.1 mM) containing 
medium. After 4 h incubation at 37 °C, the medium was replaced again with fresh 
medium. For both, targeted and untargeted oligomers, 24 h after initial transfection, 
the medium was removed and cells were treated with 100 μL cell lysis buffer (25 mM 
Tris, pH 7.8, 2 mM EDTA, 2 mM DTT, 10 % glycerol, 1 % Triton X-100). Luciferase 
activity in the cell lysate was measured using a luciferase assay kit (100 mL Luciferase 
Assay Buffer, Promega, Mannheim, Germany) and a Centro LB 960 plate reader 
luminometer (Berthold Technologies, Bad Wildbad, Germany). Transfection efficiency 
was evaluated as relative light units (RLU) per well. 
 
2.2.21 Gene silencing with siRNA 
Gene silencing experiments were performed in Neuro2A/eGFPLuc, KB/eGFPLuc cells 
or DU145/eGFPLuc cells. Applied siRNAs were either the unmodified siRNA against 
eGFP for silencing the eGFPLuc fusion protein, its control sequence siCtrl, or the lytic 
peptide modified INF7-siGFP, with its control sequence INF7-siCtrl. Silencing 
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experiments were performed in triplicates in 96-well plates with 5000 cells for 
Neuro2A/eGFPLuc cell line and DU145/eGFPLuc cell line or 4000 cells for 
KB/eGFPLuc cell line and 500 ng siRNA for untargeted oligomers or 200 ng siRNA for 
targeted oligomers per well. In case of concentrated formulations, polyplexes were 
diluted with cell culture medium to facilitate handling. Cells were seeded 24 h prior to 
transfection and then medium was replaced with 80 μL fresh growth medium 
containing 10 % FBS. Transfection complexes for siRNA delivery (20 μL in HBG, 
prepared as described above) at different N/P ratios were added to each well and 
incubated at 37 °C. At 45 min, medium was replaced by fresh medium in case of 
targeted oligomers. In both cases 48 h after initial transfection. Luciferase activity in 
the cell lysate was measured using a luciferase assay kit (Promega, Mannheim, 
Germany) and a Centro LB 960 plate reader luminometer (Berthold Technologies, Bad 
Wildbad, Germany). The experiments were performed in triplicates, and the relative 
light units (RLU) were presented as percentage of the luciferase gene expression 
obtained with HBG-treated control cells. 
 
2.2.22 Cell cycle analysis after EG5 siRNA transfection 
L1210 cells transfected with EG5 siRNA (1.5 µg/well) were collected by centrifugation 
at 24 h after transfection and washed with PBS, then incubated with 100 µL propidium 
iodide staining solution (0.1 % sodium citrate, 0.1 % Triton-X100, 50 µg/mL propidium 
iodide in Millipore water) for 3 h on ice in dark. Cells were centrifuged after adding 1 mL 
PBS buffer and resuspended in 500 µL PBS and measured with the CyanTM ADP flow 
cytometer. Data were analyzed by FlowJo® 7.6.5 flow cytometric analysis software. 
 
2.2.23 Cell viability assay (MTT) 
Neuro2A or KB cells were seeded into 96-well plates at a density of 1 × 104 Neuro2A 
cells/well or 8000 KB cells/well. After 24 h, the culture medium was replaced with 80 μL 
fresh growth medium containing 10 % FBS and transfection complexes (20 μL in HBG) 
at different N/P ratios were added according to transfections. All studies were 
performed in quintuplicates. For targeted oligomers, the medium was replaced 45 min 
after transfection by fresh medium or medium containing chloroquine (0.1 mM). After 
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4 h incubation at 37 °C, the medium was replaced again with fresh medium. For both, 
targeted and untargeted oligomers, 24 h post transfection, 10 μl 3-(4,5-Dimethylthiazol-
2-yl)-2,5-diphenyltetrazolium bromide (MTT, 5 mg/mL) were added to each well 
reaching a final concentration of 0.5 mg MTT/mL. After an incubation time of 2 h at 
37 °C, unreacted dye and medium were removed and cells were lysed by freezing at  
-80 °C. 100 µl of DMSO were added and plates were incubated at 37 °C for 30 min 
under shaking. The purple formazan product was quantified by a microplate reader 
(Tecan, Switzerland) at 530 nm with background correction at 630 nm. The relative cell 
viability (in %) related to control wells containing cell culture medium with 20 µL HBG 
was calculated by [A] test/[A] control × 100. 
 
2.2.24 Mouse tumor model 
Female 8-week-old nude mice, Rj: NMRI-nu (nu/nu) (Janvier, Le Genest-Saint-Isle, 
France), were housed in isolated ventilated cages under specific pathogen-free 
condition with a 12 h light/dark interval and were acclimated for at least 7 days prior to 
experiments. Food and water were provided ad libitum. Animals were injected with 
1 × 106 L1210 cells or 5 × 106 Neuro2A cells subcutaneously. The body weight was 
recorded, and the tumor volume was measured by caliper and calculated as 
[0.5 × (longest diameter) × (shortest diameter)2]. All animal experiments were 
performed according to guidelines of the German law for the protection of animal life 
and were approved by the local animal ethics committee. 
 
2.2.25 Biodistribution study 
For near infrared (NIR) in vivo imaging, unlabeled control siRNA (siCtrl) was spiked 
with 50 % of Cy7-labeled siRNA (Cy7-siAHA1) in HBG. When tumors reached the size 
of 500 - 1000 mm3, the mice (n = 2-3/per group) were anesthetized with 3 % isoflurane 
in oxygen. siRNA polyplexes containing 50 µg of Cy7-labeled siRNA (N/P 10) in 250 µL 
(100 µL siRNA solution, 100 µL oligomer solution, 50 µL agent solution or buffer) of 
HBG were injected intravenously (i.v.), and fluorescence was measured with a CCD 
camera at different time points. For evaluation of images, the efficiency of fluorescence 
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signals was analyzed after color bar scales were equalized using the IVIS Lumina 
system with Living Image software 3.2 (Caliper Life Sciences, Hopkinton, MA, USA). 
 
2.2.26 Gene silencing mediated by EG5-siRNA in vivo 
When tumors reached 500 mm3, mice (n = 5) were injected i.v. with siRNA polyplexes 
containing 50 µg of siEG5 or siCtrl (N/P 10) 48 h and 24 h before euthanasia. As a part 
of the terminal procedure, blood samples were obtained by cardiac puncture for blood 
biochemistry examinations. After tumors had been harvested and homogenized, total 
RNA was extracted using Trifast (Peqlab, Erlangen, Germany) according to the 
manufacturer’s protocol.  
 
2.2.27 qRT-PCR 
Quantitative real-time polymerase chain reaction (qRT-PCR) was performed to 
determine the mRNA level of EG5 gene in the tumor samples. 1 µg of total RNA was 
used to generate cDNA using qScript cDNA Synthesis Kit (Quanta Biosciences, 
Beverly, MA, USA). Quantitative RT-PCR was performed on a LightCycler 480 system 
(Roche, Mannheim, Germany) using UPL Probes (Roche, Mannheim, Germany) and 
Probes Master (Roche, Mannheim, Germany) with GADPH as housekeeping gene. 
The following probes and primer sequences were used: murine GAPDH (ready-to-use 
in UPL), and EG5 (UPL Probe #100) forward: TTCCCCTGCATCTTTCAATC, reverse: 
TTCAGGCTTATTCATTATGTTCTTTG). Results were analyzed by the ΔCT method. 
CT values of GAPDH were subtracted from CT values of EG5. ΔCT values of treated 
animals were calculated as percentage of untreated control animals. 
 
2.2.28 Blood biochemistry examinations 
To isolate plasma, blood samples were collected in EDTA-coated tubes (Multivette 
600, Sarstedt, Nümbrecht, Germany) and centrifuged at 3000 rpm for 7 minutes. The 
supernatant was analyzed for clinical biochemistry parameters: alanine 
aminotransferase (ALT), aspartate aminotransferase (AST), blood urea nitrogen (BUN) 
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and creatinine in the Clinic of Small Animal Medicine, Faculty of Veterinary Medicine, 
Ludwig-Maximilians-Universität München. 
 
2.2.29 HPLC analysis 
The redox-sensitivity of oligomer 740 was analyzed by RP-HPLC using a Waters HPLC 
system equipped with a Waters 600E multisolvent delivery system and a Waters 
996 PDA detector. The compounds were analyzed using a Xbridge C18 column (5 μm, 
4.6 × 150 mm) and a water/acetonitrile gradient (95:5 – 0:100) containing 0.1 % TFA. 
For detection, the extinction at 280 nm was monitored. 
 
2.2.30 Proton 1H NMR spectroscopy 
1H NMR spectra were recorded using a Jeol JNMR-GX 400 (400 MHz) by Jeol or an 
AVANCE III HD 500 (500 MHz) by Bruker with a 5 mm CPPBBO probe. All spectra 
were recorded without TMS as internal standard and therefore all signals were 
calibrated to the residual proton signal of the deuterium oxide (D2O) solvent, or 
methanol-d4 (MeOD). Chemical shifts are reported in ppm and refer to the solvent as 
internal standard (D2O at 4.79, MeOH at 3.31). Integration was performed manually. 
The spectra were analyzed using MestreNova (Ver. 5.2.5, Ver. 8.1.1, Ver. 9.0 and 
Ver. 10.0 by MestReLab Research). 
 
2.2.31 MALDI mass spectrometry 
One μL matrix droplet consisting of a saturated solution of Super-DHB (sum of 2,5-
dihydroxybenzoic acid and 2-hydroxy-5-methoxybenzoic acid) in acetonitrile / water 
(1 : 1) containing 0.1 % (v/v) TFA was spotted on an MTP AnchorChip (Bruker 
Daltonics, Bremen, Germany). After the Super-DHB matrix had crystallized, one µL of 
the sample solution (10 mg/mL in water) was added to the matrix spot. Samples were 
analyzed using an Autoflex II mass spectrometer (Bruker Daltonics, Bremen, 
Germany). All spectra were recorded in positive mode. 
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2.2.32 Statistical analysis 
The results are presented as mean values of experiments performed in at least 
triplicates. Unless otherwise stated error bars show standard deviation (SD). In case 
of in vivo data statistical analysis of the results are presented as mean ± SEM. was 
evaluated by unpaired t test: *p<0.05; **p<0.01; ***p<0.001. Two-tailed Student's           
t-test, calculations and graphical presentation were performed with Prism 5 & 6 
(GraphPad Software Inc.) and Microsoft Excel 2007 & 2010 (Microsoft Corp.). 
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3 Results 
3.1 Twin disulfides as opportunity for improving stability and 
transfection efficiency 
This chapter has been adapted from: 
Klein PM, Müller K, Gutmann C, Kos P, Krhac Levacic A, Edinger D, Höhn M, Leroux 
JC, Gauthier MA, Wagner E. Twin disulfides as opportunity for improving stability and 
transfection efficiency of oligoaminoethane polyplexes. J Control Release. 2015 May 
10;205:109-19 
 
Recently Wu et al. introduced a new bioreducible dynamic covalent bond, called the 
twin disulfide, which has orthogonal disulfide pairing characteristics to the standard 
single disulfide [43]. Peptides containing CXC (cysteine  any amino acid  cysteine) 
motifs were found to selectively form stable twin disulfide dimers with other CXC 
peptides. The process was particularly enhanced when the central amino acid is 
arginine (i.e., CRC or cysteine  arginine  cysteine). 
Based on the discovery of this new type of bioreducible bond, this chapter describes 
the influence of replacing single cysteine residues with a CRC motif in 
oligoaminoethane carriers on the stability and transfection efficiency of pDNA and 
siRNA polyplexes. Oligomer structures were selected based on their ability to 
efficiently transfect as established in our previous work [67, 68, 72, 82, 83, 113]. These 
were chosen to demonstrate structure-activity relations, also in the presence of other 
polyplex stabilizing motifs or nanoparticle destabilizing polyethylene glycol (PEG) 
chains [114]. 
 
3.1.1 Influence of stabilizing CRC motifs on pDNA and siRNA polyplex stability 
In previous studies, our laboratory has established a library of polycationic structures, 
prepared by solid-supported synthesis, as precise carriers for gene delivery [66, 67, 
83]. These structures consist of natural amino acids combined with artificial building 
blocks. For example, succinoyl-tetraethylene-pentamine (Stp) has been used as 
artificial polyamino acid for nucleic acid complexation and for endosomal buffering. 
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Lysine residues are exploited as branching units within the structures, and cysteine 
residues as disulfide forming units [68, 82, 83]. In addition, hydrophobic domains 
containing fatty acids [82, 83] and hydrophilic domains containing PEG shielding units 
or targeting peptides [62, 113, 114] can be incorporated.  
 
Fig. 8 Sequence-defined oligomers with T-shape (ts), 3-arm (3arm) and PEGylated 2-arm (PEG) 
topology. Schematic overview of the structures with different modifications (C: cysteine, CRC: cysteine-
arginine-cysteine, OleA: oleic acid, YYY: tyrosine-tyrosine-tyrosine, SucA: succinic acid, FolA: folic acid, 
Stp: succinoyl-tetraethylene-pentamine, K: lysine). Each structure has a short name used for 
identification in this study and an internal database identification number. The formation of disulfide 
bonds, respectively twin disulfide bonds (bottom of figure), occurs during the incubation with nucleic 
acid. T-shape oligomers were synthesized by Christina Gutmann (PhD study C. Troiber, Pharmaceutical 
Biotechnology, LMU). 
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Due to the rather low molecular weight (usually below 5 kDa) of the sequence-defined 
cationic oligomers, cytotoxicity is very low. However, nucleic acid polyplex stability 
becomes a critical issue [13]. This is of great concern for polyplexes of siRNA because 
the size of this nucleic acid is significantly smaller than pDNA, resulting in less inter-
electrolyte interactions. This known polyplex stability problem has been solved by us 
and others in several ways [13, 69, 115-118]. For example, the size of the cationic 
oligomer can be increased by branching into three or four arms.  Incorporation of 
cysteine residues at the end of each arm was found to be crucial for the formation of 
bioactive siRNA polyplexes stabilized by disulfide crosslinks [68, 82]. Alternatively,      
T-shape oligomers with two terminal cysteine residues and two central fatty acids [82, 
83] were prepared given that the fatty acids stabilize the polyplex via hydrophobic 
interactions and additionally improve its endosomal escape (by pH-dependant lysis of 
the endosomal membrane). Recently, tyrosine trimers were shown to improve the 
transfection properties of siRNA polyplexes by stabilizing them via aromatic 
interactions [119, 120]. 
In the present study, six T-shape structures with increasing integration of oleic acid 
and tyrosine units in the periphery or the center were chosen to analyze the effect of 
replacing the two single terminal cysteine residues with CRC motifs (Fig. 8). Cysteines 
of oligomers were kept in reduced state until oligomers were incubated with nucleic 
acid. The stabilizing formation of disulfide bonds, respectively twin disulfide bonds, 
occurs during the subsequent polyplex incubation. At first, to compare nucleic acid 
binding ability, pDNA and siRNA agarose gel shift assays were performed at different 
N/P ratios (ratio between protonatable nitrogen atoms within the oligomer and 
phosphate atoms of the nucleic acid). 
Free nucleic acid migrates in the gel due to its negative charge, whereas polyplexes 
are retained and can even remain in the loading pockets of the agarose gel (Fig. 9). 
For all of the tested oligomers, an improvement in binding ability and stability was 
observed for the twin versus the single disulfide. 
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Fig. 9 Stability of polyplexes with T-shape (ts) oligomers determined in agarose gel shift assays.  
A) pDNA binding of single disulfide forming oligomers (top) and corresponding twin disulfide forming 
analogs (bottom).  Left lane: free pDNA.  B) siRNA binding of single disulfide forming oligomers (top) 
and corresponding twin disulfide forming analogs (bottom). Left lane: free siRNA. Gel shift assays were 
performed by Christina Gutmann (PhD study C. Troiber, Pharmaceutical Biotechnology, LMU). 
 
The basic structure ts, bearing terminal cysteine residues for stabilization, shows low 
pDNA binding. Insertion of the CRC motif led to complete binding from N/P ratios of 6 
and up. In contrast, despite a strong enhancement in the siRNA binding ability of 
oligomer ts containing CRC motifs (CRC-ts), it remained insufficient. Nevertheless,   
T-shape structures with central oleic acid displayed good binding properties for both 
the single and twin disulfide analogs (CRCOleA-ts and OleA-ts). Tyrosine trimers in 
the central position (Y3C-ts) positively influenced nucleic acid binding, which in 
conjunction with the CRC motif became complete for pDNA and very good for siRNA 
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(CRCY3C-ts). The addition of tyrosine trimers to the periphery (Y3P-ts, Y3POleA-ts, 
Y3PY3C-ts) led to very good pDNA complexation and could be further improved using 
twin disulfides. The twin disulfide structure CRCY3P-ts without central modification 
outperformed the other T-shapes. It could even bind siRNA completely. The addition 
of oleic acid or tyrosine residues in the central position to Y3P-ts further improved 
siRNA complexation, but diminished binding ability of the CRC analog. 
Size measurements revealed smaller, more compact sizes and higher zeta potentials 
for all structures without hydrophobic stabilization (Table 8). For example, the 
incorporation of twin disulfides in siRNA polyplexes with sizes above 1500 nm (Y3P-ts) 
or that could not be detected (Y3C-ts) led to the formation of particles smaller than 
200 nm (analyzed for N/P 12). The small size of siRNA particles with oleic acid 
(<100 nm) increased with the replacement of single cysteine residues by CRC motifs. 
For the pDNA polyplexes, the same tendency was observed, although less distinct 
(Table 8). 
 
Table 8 Particle size (Z-average) and zeta potential of pDNA and siRNA polyplexes formed in HEPES 
buffer determined with DLS. Polyplexes were diluted 1:20 before measurement. Variations refer to the 
median of three measurements of the same sample. DLS measurements were performed by Christina 
Gutmann (PhD study C. Troiber, Pharmaceutical Biotechnology, LMU). 
DNA 
polyplex 
Z-average 
[nm] 
Zeta 
potential 
[mV] 
DNA 
polyplex 
Z-average 
[nm] 
Zeta 
potential 
[mV] 
CRC-ts 285 ± 22 23.9 ± 0.5 ts 358 ± 8 16.2 ± 1.3 
CRC-OleA-ts 121 ± 1 38.2 ± 1.2 OleA-ts 114 ± 1 43.6 ± 1.3 
Y3C-ts 105 ± 2 35.8 ± 0.4 Y3C-ts 542 ± 22 12.7 ± 1.8 
CRCY3P-ts 188 ± 3 27.4 ± 1.3 Y3P-ts 244 ± 18 14.0 ± 2.5 
CRCY3POleA-ts 100 ± 1 41.3 ± 1.2 Y3POleA-ts 99 ± 1 53.2 ± 2.8 
CRCY3PY3C-ts 115 ± 2 33.3 ± 0.8 Y3PY3C-ts 180 ± 5 21.5 ± 1.8 
 
siRNA 
polyplex 
  
 
siRNA 
polyplex 
  
CRC-ts n. d.* n. d.* ts n. d.* n. d.* 
CRC-OleA-ts 672 ± 76 33.5 ± 0.9 OleA-ts 23 ± 4 24.9 ± 1.0 
Y3C-ts 160 ± 6 24.7 ± 0.9 Y3C-ts n. d.* n. d.* 
CRCY3P-ts 197 ± 1 20.0 ± 1.2 Y3P-ts 1570 ± 194 11.8 ± 0.7 
CRCY3POleA-ts 162 ± 5 37.4 ± 1.4 Y3POleA-ts 99 ± 2 50.7 ± 0.8 
CRCY3PY3C-ts 192 ± 2 17.5 ± 0.6 Y3PY3C-ts 243 ± 12 13.3 ± 0.4 
* n.d. = not detectable by DLS; 
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Three-armed oligomers containing one terminal cysteine residue on each arm were 
also evaluated. Oxidation of the cysteine residues is expected to provide a                        
3-dimensional disulfide-cross-linked network that stabilizes polyplexes. This approach 
has been previously demonstrated to lead to efficient nucleic acid binding and efficient 
pDNA and siRNA delivery [33]. In the current study, the single cysteine residues in 
each arm of 3arm were sequentially replaced by CRC motifs, resulting in three novel 
oligomers with the potential to form one, two or three twin disulfides (Fig. 8). Since the 
standard 3arm forms stable pDNA polyplexes and shows complete binding and good 
transfection efficiency, no further improvements could be observed in the gel 
retardation assay (Fig. 10A). 
 
Fig. 10 Stability of polyplexes with three-armed oligomers in agarose gel shift assay.  A) pDNA binding 
and B) siRNA binding.  Left lanes: free pDNA or free siRNA, respectively. 
 
In addition, the compaction of nucleic acid into a condensed polyplex form was 
evaluated by ethidium bromide exclusion assays (Fig. 20A). Such a compaction is 
mainly influenced by the cationic backbone and not necessarily linked to polyplex 
stability. As the binding region within the 3-arm topology consists of the same cationic 
backbone made of Stp, only minor differences were found. A slight tendency towards 
more compact pDNA polyplexes with increasing numbers of CRC-motifs was 
observed. Polyplex stabilization is more critical for siRNA and complete binding of 
siRNA by 3arm was only observed for N/P ratios higher than 6. Moreover, rather large 
(almost micrometer) particles were formed [83]. In this case, the introduction of CRC 
motifs led to better binding (Fig. 10B). Particle size and zeta potential of these siRNA 
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polyplexes were analyzed by dynamic light scattering (DLS). A successive decrease 
of the particle size from more than 800 nm (3arm) to less than 200 nm (3CRC-3arm) 
was observed for the structures with twin disulfides (Table 9). An enhanced 
compaction ability in the ethidium bromide exclusion assay was observed only for the 
3-arm structure with 3 CRC-motifs incorporated (3CRC-3arm – Fig. 20B). 
  
Table 9 Particle size (Z-average) and zeta potential of siRNA polyplexes formed in HEPES buffer 
determined with DLS. Polyplexes were diluted 1:20 before measurement. Variations refer to the median 
of three measurements of the same sample. 
siRNA 
polyplex 
N/P Z-average [nm] Mean PDI 
Mean Zeta 
Potential [mV] 
3arm* 12 951± 26 0.34 ± 0.03 17.7 ± 0.4 
3arm* 20 806 ± 21 0.36 ± 0.04 20.0 ± 0.6 
1CRC-3arm 16 450 ± 8 0.26 ± 0.01 22.8 ± 0.5 
2CRC-3arm 16 358 ± 1 0.19 ± 0.01 23.4 ± 0.4 
3CRC-3arm 16 191 ± 2 0.09 ± 0.01 28.3 ± 0.3 
*Data from published work [83]; PDI: Polydispersity index. 
Thus, the number of CRC motifs correlated inversely to the size of the resulting 
polyplexes. The zeta potential increased and the polydispersity decreased. This 
implies that 3arm polyplexes rich in CRC motifs are smaller, more defined and provide 
a higher positive charge on the surface.  
 
3.1.2 pDNA and siRNA transfection efficiency  
Regarding pDNA transfection activity, all tested T-shape oligomer polyplexes were 
efficient at N/P 12 (Fig. 11A). Oligomers with low stability (ts, Y3C-ts) demonstrated a 
slight improvement with the CRC motif. In contrast, gene transfer efficiency of all other 
pDNA polyplexes, especially the ones with oleic acid, was lower than for the structural 
analogs with single cysteine residues. Cell viability assays did not reveal any 
cytotoxicity for tested pDNAoligomer complexes (Fig. 12).  
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Fig. 11 Gene transfer (A) and gene silencing (B) of T-shape oligomers in neuroblastoma cells. 
Luciferase pDNA polyplexes were tested for luciferase expression in Neuro2A cells, eGFP-targeted 
siRNA (eGFP) or control siRNA (Mut) polyplexes for eGFPLuc gene silencing in Neuro2A-eGFPLuc 
cells, both at N/P 6 and 12. Top: polyplexes of previously published oligomers [34] with single disulfides. 
Bottom: polyplexes of analogous oligomers with twin disulfides. Linear PEI (LPEI) and succinylated 
branched PEI (PEI-Suc-10 %) served as positive controls for pDNA or siRNA transfections, respectively. 
HBG, buffer negative control. Data are presented as mean value (±SD) out of quintuplicate for pDNA 
and triplicates for siRNA; notes on top of pDNA transfections (A) indicate if there is statistical significance 
between single cysteine structure and its corresponding CRC analogous for same N/P ratio 
(n. s. = p>0.05; *p<0.05; **p<0.01; ***p<0.001, student’s t-test, two-tailed). Transfections were 
performed by Daniel Edinger (PhD study, Pharmaceutical Biotechnology, LMU). 
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Fig. 12 Cell viability tested with MTT Assay for T-Shape structures with pDNA. Top: polyplexes of 
previously published oligomers [119] with single disulfides. Bottom: polyplexes of analogous oligomers 
with twin disulfides. The assay was performed by Daniel Edinger (PhD study, Pharmaceutical 
Biotechnology, LMU). 
 
For siRNA delivery, standard polyplexes with peripheral tyrosine residues and single 
cysteine residues were very good at gene knockdown. Interestingly, for the majority of 
the T-shape oligomers, the addition of twin disulfides reduced siRNA transfection 
efficiency (Fig. 11B). In fact, silencing for the two polyplexes formed with CRC-ts and 
CRCY3P-ts was abolished. 
Consistent transfection results were obtained with three-armed oligomers (Fig. 13). 
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Fig. 13 Gene transfer (A) and gene silencing (B) of 3-arm structures. Luciferase pDNA polyplexes were 
tested for luciferase expression in Neuro2A cells, eGFP-targeted siRNA (eGFP) or control siRNA (Mut) 
polyplexes were tested for eGFPLuc gene silencing in Neuro2A-eGFPLuc cells, polyplexes were tested 
at N/P 3, 6, 12 and 20. Linear PEI (LPEI) and succinylated branched PEI (PEI-Suc-10 %) served as 
positive controls for pDNA or siRNA transfections, respectively. Data are presented as mean value 
(±SD) out of quintuplicate for pDNA and triplicates for siRNA. All pDNA transfections significantly (at 
least p<0.05) differ from HGB control; (**p<0.01; ***p<0.001, student’s t-test, two-tailed). Transfections 
were performed by Petra Kos and Katharina Müller (PhD studies, Pharmaceutical Biotechnology, LMU). 
 
 
Fig. 14 Cell viability tested with MTT Assay for 3-arm structures with pDNA. Assay was performed by 
Petra Kos (PhD study, Pharmaceutical Biotechnology, LMU). 
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For pDNA delivery, incorporation of one to three CRC motifs did not significantly alter 
the efficient transfection levels or toxicity (Fig. 13A, Fig. 14). Confocal microscopy data 
indicate intracellular uptake of polyplexes, with less particle aggregation for the 
polyplexes including the CRC-motif (Fig. 15). 
 
 
Fig. 15 Intracellular distribution of 3-arm pDNA polyplexes in Neuro2A cells acquired by confocal laser 
scanning microscopy. Nuclei were stained with Hoechst 33342 (blue), actin cytoskeleton was stained 
with rhodamine phalloidin (green) and pDNA was spiked with 20 % Cy5-labeled pDNA (red). The images 
show the overlay of the different channels. Transfections were performed by Ana Krhac Levacic (PhD 
study, Pharmaceutical Biotechnology, LMU), confocal microscopy was performed by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU). 
 
For siRNA delivery, incorporation of CRC resulted in loss of gene silencing activity 
(Fig. 13B). The reasons for the reduced silencing activity of CRC T-shape and 3-arm 
   Results 
   65 
oligomers, despite the more compact and stable nature of the formed polyplexes, are 
not completely clear. Reduced cell uptake, reduced endosomal escape into the 
cytosol, or reduced release of siRNA from polyplexes are possible reasons. Changes 
in cellular uptake are unlikely since confocal microscopy data (Fig. 16) for 3-arm 
structures showed similar nucleic acid uptake. 
 
 
Fig. 16 Intracellular distribution of 3-arm siRNA polyplexes in Neuro2A cells acquired by confocal laser 
scanning microscopy. Nuclei were stained with Hoechst 33342 (blue), actin was stained with rhodamine 
phalloidin (green) and siRNA was spiked with 20 % Cy5-labeled siRNA (red). The images show the 
overlay of the different channels. Transfections were performed by Katharina Müller (PhD study 
Pharmaceutical Biotechnology, LMU), confocal microscopy was performed by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU). 
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We can rule out an unfavorable change in endosomal buffer capacity between the 
endosomal pH ≈ 5.5 and the physiological pH 7.4, which for all oligomers are in the 
same range of 16 % – 17 % (Table 10).  
Table 10 Buffer capacity of T-shape and 3-arm oligomers between pH 5.0 and 7.4 determined by 
acidification to pH 2 and back titration with NaOH. Measurements for T-shape structures were performed 
by Christina Gutmann (PhD study C. Troiber, Pharmaceutical Biotechnology, LMU). 
Oligomer Buffer capacity [%] Oligomer Buffer capacity [%] 
CRC-ts 14.9 ts - 
CRC-OleA-ts 19.9 OleA-ts 19.0 
Y3C-ts 22.4 Y3C-ts 21.1 
CRCY3P-ts 19.2 Y3P-ts 19.0 
CRCY3POleA-ts 21.2 Y3POleA-ts 22.2 
CRCY3PY3C-ts 21.5 Y3PY3C-ts 21.4 
3arm 17.0 
1CRC-3arm 15.8 
2CRC-3arm 16.1 
3CRC-3arm 16.3 
LPEI 22kDa 20.9 
 
A striking difference was the observation of larger aggregated polyplexes in cellular 
vesicles for the standard 3-arm polyplexes but not the stabilized CRC polyplexes (Fig. 
16). It is known from the study of PEI polyplexes that larger particle size may favorably 
promote endosomal escape in cell culture transfections [121]. In fact, performing 
transfections of CRC T-shapes in the presence of the endolysosomotropic agent 
chloroquine [122, 123] recovers the siRNA transfection activity (Fig. 17), suggesting 
endosomal escape as the main bottleneck. Chloroquine can also facilitate polyplex 
dissociation [124, 125]. Cytosolic release from the oligomers might also be beneficial 
especially for siRNA. 
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Fig. 17 Gene silencing of T-shape oligomers in KB/eGFPLuc cells. eGFP-targeted siRNA (eGFP) or 
control siRNA (Mut) polyplexes for eGFPLuc gene silencing in KB/eGFPLuc cells, polyplexes were 
tested at N/P 10 or 12 with and without chloroquine. Data are presented as mean value (±SD) out of 
triplicates; (**p<0.01; ***p<0.001, student’s t-test, two-tailed). Transfections were performed by 
Katharina Müller (PhD study, Pharmaceutical Biotechnology, LMU). 
 
3.1.3 Stability of CRC-containing oligomer polyplexes in serum 
Since some T-shape oligomers (e.g., CRCY3C-ts) possessed improved stability 
(versus single disulfide analogs), suitable sizes and good transfection efficiency, which 
are all important criteria for future in vivo application, serum gel shift assays were 
performed in the presence of 90 % fetal bovine serum (FBS) (see Fig. 18). For this 
experiment, polyplexes were first formed in HEPES buffer, and then FBS was added. 
Samples were incubated at room temperature or 37 °C for up to 90 minutes and gel 
electrophoresis was performed to investigate the stability of polyplexes. This showed 
that siRNA migration was only observable for the labile polyplex CRC-ts. In contrast, 
all other CRC-polyplexes were stable in 90 % FBS. These data show that the twin 
disulfides may promote favorable stabilization and improved resistance to serum 
protein-mediated disassembly. This is particularly important for labile structures 
without hydrophobic modifications, as the stabilizing effect of twin disulfides influences 
the properties of polyplexes in a positive way and may make it possible to use them in 
in vivo conditions. 
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Fig. 18 Stability of siRNA polyplexes with T-shape oligomers (at N/P 12) in agarose gel shift assay after 
up to 90 min incubation at room temperature or 37°C in 90 % FBS. Top: single cysteine oligomers. 
Bottom: corresponding twin disulfide-forming analogs. Polyplexes were incubated at room temperature 
for 40 min before FBS was added. Heparin (50 I.U.) was added to dissociate polyplexes. Left lanes: free 
pDNA or free siRNA, respectively. Gel shifts were performed by Christina Gutmann (PhD study 
C. Troiber, Pharmaceutical Biotechnology, LMU). 
 
3.1.4 Twin disulfides in PEG-shielded and targeted structures 
One feature of gene carriers important for in vivo applications is targeting to specific 
cell populations. To minimize unspecific interactions, shielding agents like PEG are 
coupled to cationic systems (so-called “PEGylation”). A ligand is conjugated to the 
PEG-chain to achieve specific uptake into cells. PEGylation, however, may influence 
polyplex stability [24, 114, 126, 127] depending on the types and molecular weights of 
polycation – PEG blocks. For smaller oligomers as investigated in the current study, 
the PEG units within a polyplex can reduce the binding and compaction ability of 
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ethylenimine units [113, 114]. The findings reported above suggest that introduction of 
CRC motifs might improve the biophysical properties of polyplexes. For this reason, 
PEGylated structures with either targeting ligands or negative control ligands were 
analyzed next. Based on effective targeting in previous studies [87], we chose folic 
acid (FolA) as targeting ligand and succinic acid (SucA) as control ligand connected to 
a PEG24 unit. Folic acid has a high affinity for folate receptors, which are commonly 
over-expressed on the surface of many human cancers [128, 129]. The succinic acid 
control has the same negative charge as folic acid, but should not mediate receptor-
promoted cellular uptake. Oligomeric structures consisting of a cationic backbone with 
2 arms (each with 4 Stp units and either a single terminal cysteine residue or CRC 
motif) were used to bind nucleic acid (Fig. 8). Agarose gel shifts were performed for 
both, pDNA and siRNA. In both cases, improved binding was observed for the CRC 
motif containing polyplexes (Fig. 19). 
 
Fig. 19 Stability of polyplexes with PEGylated oligomers in agarose gel shift assay.  A) pDNA binding 
and B) siRNA binding of single cysteine oligomers (top) and corresponding twin disulfide-forming 
analogs (bottom).  Left lanes: free pDNA or free siRNA, respectively. 
 
The retention of siRNA was particularly increased by incorporation of the CRC motif. 
Ethidium bromide exclusion assay showed a tendency towards more compact pDNA 
polyplexes including twin disulfides, whereas compaction of siRNA polyplexes was not 
influenced (Fig. 20). 
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Fig. 20 Nucleic acid compaction within polyplexes as determined in an ethidium bromide exclusion 
assay. At 40 min after formation, polyplexes were incubated with EtBr for 3 min. Lower intensity of EtBr 
fluorescence indicates better compaction of the nucleic acid with the cationic oligomer and less nucleic 
acid intercalation of EtBr. 100 % would represent pDNA or siRNA, respectively, without cationic 
oligomers. A) pDNA compaction at oligomer N/P 12 and LPEI (N/P 6) as control;  B) siRNA compaction 
at oligomer N/P 20 and LPEI (N/P 6) as a control. 
 
Polyplex surface charge is an important property of PEGylated particles since it allows 
drawing inferences about the degree of shielding. Zeta potential measurements of 
pDNA and siRNA polyplexes revealed near neutral values, between -0.1 and 0.2 mV, 
indicating excellent shielding (Table 11). With regards to size, siRNA particles were 
smaller than pDNA particles. 
Table 11 Particle size (Z-average) and zeta potential of pDNA and siRNA polyplexes formed in HEPES 
buffer determined with DLS. Polyplexes were diluted 1:20 before measurement. Variations refer to the 
median of three measurements of the same sample. 
pDNA polyplex N/P Z-average [nm] Mean PDI 
Mean Zeta Potential 
[mV] 
PEG-Cont 12 277 ± 49 0.97 ± 0.03 0.00 ± 0.16 
PEG-FolA 12 354 ± 36 0.26 ± 0.04 -0.03 ± 0.14 
CRC-PEG-Cont 12 292 ± 47 0.73 ± 0.09 0.04 ± 0.1 
CRC-PEG-FolA 12 350 ± 22 0.25 ± 0.03 -0.02 ± 0.03 
siRNA polyplex 
    
PEG-Cont 20 65 ± 23 0.42 ± 0.12 0.17 ± 0.27 
PEG-FolA 20 105 ± 7 0.08 ± 0.02 0.06 ± 0.07 
CRC-PEG-Cont 20 95 ± 9 0.18 ± 0.02 -0.11 ± 0.34 
CRC-PEG-FolA 20 171 ± 24 0.12 ± 0.03 -0.10 ± 0.06 
PDI: Polydispersity index. 
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The insertion of the CRC motif did not cause any changes for pDNA polyplexes, 
whereas the size of siRNA polyplexes increased. For folate-targeted structures, there 
was a clear tendency towards the formation of bigger particles in comparison to 
untargeted controls. 
Transfection of pDNA polyplexes into folate receptor-expressing KB cells in the 
presence of chloroquine showed high efficiency for the targeted oligomers PEG-FolA 
and CRC-PEG-FolA, whereas the negative control complexes did not show any effect 
(Fig. 21A). The highest efficiency was achieved for CRC-PEG-FolA at a low N/P ratio 
of 6, whereas higher ratios led to a reduction. Once again, no significant cytotoxicity 
was observed (Fig. 22).  
 
Fig. 21 A) Luciferase pDNA polyplexes were tested for luciferase expression in KB cells. Grey bars 
show transfection efficiency without chloroquine, black bars with chloroquine. Linear PEI (LPEI) served 
as positive control for pDNA transfection. B) eGFP-targeted INF7-siRNA (eGFP) or control INF7-siRNA 
polyplexes (Mut) were analyzed for eGFPLuc gene silencing in KB/eGFPLuc cells. Positive control 
siRNA (eGFP) transfections with Lipofectamine in these cells were reported in our recent paper Dohmen 
et al. [87]. Polyplexes were formed at indicated N/P ratios. Top: polyplexes with single cysteine 
oligomers. Bottom: polyplexes with twin disulfide-forming oligomers. Data are presented as mean value 
(±SD) out of quintuplicate for pDNA and triplicates for siRNA; notes on top of transfections bars without 
arrow indicate if there is statistical significance between single cysteine structure and its corresponding 
CRC analogous for same N/P (n. s. = p>0.05; *p<0.05; **p<0.01; ***p<0.001, student’s t-test, two-tailed). 
Transfections were performed by Ana Krhac Levacic and Katharina Müller (PhD studies, Pharmaceutical 
Biotechnology, LMU). 
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Fig. 22 Cell viability tested with MTT Assay for PEGylated structures with pDNA. The experiment was 
performed with and without chloroquine. Assay was performed by Ana Krhac Levacic (PhD study, 
Pharmaceutical Biotechnology, LMU). 
 
In the absence of chloroquine, well consistent with previous findings [116], no gene 
transfer could be observed, which indicates that polyplexes could not escape 
endosomes. This limitation can be overcome by various means [62, 87]. For this 
reason, siRNA transfections were performed with a lytic peptide INF7 covalently 
coupled to siRNA via a disulfide bond [87]. This led to improved transfection efficiency 
and thus to gene knockdown. Gene silencing with the targeted oligomers could be 
improved up to 70 % for N/P 20 by the insertion of twin disulfides (CRC-PEG-FolA; 
Fig. 21B). The non-targeted control structures mediated only moderate gene 
knockdown which proved target-specific transfection. Polyplexes with siRNA lacking 
INF7 also did not mediate any gene silencing (Fig. 23). 
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Fig. 23 eGFP-targeted siRNA (eGFP) or control siRNA polyplexes (Mut) were tested for eGFPLuc gene 
silencing in Neuro2A-eGFPLuc cells at indicated N/P ratios. Top: polyplexes with single cysteine 
oligomers. Bottom: polyplexes with twin disulfide-forming oligomers. Data are presented as mean value 
(±SD) out of triplicates for siRNA. Transfections were performed by Katharina Müller (PhD study, 
Pharmaceutical Biotechnology, LMU). 
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Cellular internalization studies of PEGylated polyplexes formed with Cy5-labeled 
pDNA and siRNA were performed using folate receptor-rich KB cells (Fig. 24). 
 
 
Fig. 24 Cellular internalization of Cy5-labeled pDNA (N/P 12) or Cy5-labeled siRNA (N/P 20) polyplexes 
after 45 min determined by flow cytometry. The intensity of the Cy5 signal indicates the amount of 
polyplexes being internalized by KB cells (pDNA) or KB/eGFPLuc (siRNA). A) pDNA, PEG-Cont 
(gMFI = 7.2) in solid gray, PEG-FolA (gMFI = 222.0) in solid black and HBG buffer only treated cells in 
dotted gray. B) pDNA, CRC-PEG-Cont (gMFI = 21.1) in solid gray, CRC-PEG-FolA (gMFI = 468.0) in 
solid black and HBG buffer only treated cells in dotted gray. C) siRNA, PEG-Cont (gMFI = 8.1) in solid 
gray, PEG-FolA (gMFI = 15.9) in solid black and HBG buffer only treated cells in dotted gray. D) siRNA, 
CRC-PEG-Cont (gMFI = 18.3) in solid gray, CRC-PEG-FolA (gMFI = 31.4) in solid black and HBG 
buffer (gMFI = 4.5) only treated cells in dotted gray. gMFI indicates the geometric mean fluorescence 
intensity. Experiments were performed by Ana Krhac Levacic and Katharina Müller (PhD studies, 
Pharmaceutical Biotechnology, LMU). 
 
In all cases folate-targeted structures showed a higher cellular internalization than non-
targeted control structures. 
Beneficial uptake of targeted versus nontargeted PEGylated structures into cells could 
also be observed by confocal microscopy (Fig. 25, Fig. 26). The results are consistent 
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with the transfection data and confirm that the targeting effect is the reason for 
superiority in transfection. 
 
 
Fig. 25 Intracellular distribution of PEGylated pDNA polyplexes in KB cells acquired by confocal laser 
scanning microscopy. Nuclei were stained with Hoechst 33342 (blue), actin was stained with rhodamine 
phalloidin (green) and pDNA was spiked with 20 % Cy5-labeled pDNA (red). The images show the 
overlay of the different channels. Transfections were performed by Ana Krhac Levacic (PhD study, 
Pharmaceutical Biotechnology, LMU), confocal microscopy was performed by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU). 
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Fig. 26 Intracellular distribution of PEGylated siRNA polyplexes in KB cells acquired by confocal laser 
scanning microscopy. Nuclei were stained with Hoechst 33342 (blue), actin was stained with rhodamine 
phalloidin (green) and siRNA was spiked with 20 % Cy5-labeled siRNA (red). The images show the 
overlay of the different channels. Transfections were performed by Katharina Müller (PhD study, 
Pharmaceutical Biotechnology, LMU), confocal microscopy was performed by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU). 
 
Gel-shift assays in the presence of serum at 37 °C did not reveal any major differences 
between single cysteine structures and the ones with CRC motifs (Fig. 27). The pDNA 
complexes with and without CRC motifs were stable in serum at N/P 12. The siRNA 
structures were less stable and incorporation of CRC only slightly improved this 
though, even at 90 min, the majority of siRNA remained complexed (see 90 min time 
point plus/minus heparin treatment). 
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Fig. 27 Stability of polyplexes with PEGylated oligomers in agarose gel shift assay after up to 90 min 
incubation at 37°C in 90 % FBS. A) pDNA binding at N/P 12 and B) siRNA binding at N/P 20 of single 
cysteine oligomers (top) and corresponding twin disulfide-forming analogs (bottom). Polyplexes were 
incubated at room temperature for 40 min before FBS was added. Heparin (50 I.U.) was added to 
dissociate polyplexes. 
 
To better understand polyplex response towards physiological reducing agents, a 
reducing gel-shift with different concentrations of glutathione (GSH) at 37 °C was 
performed. Polyplexes should be stable at lower GSH concentrations that occur 
outside a cell (0.02 mM GSH) and disulfide should degrade at higher concentrations 
inside the cell (1  11 mM GSH) [37]. For pDNA polyplexes with single cysteine 
residues, disassembly could be observed at N/P 12 with 10 mM GSH (Fig. 28A –  
PEG-Cont, PEG-FolA). The analogs with CRC motifs (CRC-PEG-Cont,                   
CRC-PEG-FolA) did not show any sensitivity towards the analyzed GSH 
concentrations. The siRNA binding ability for N/P 20 for single cysteine polyplexes was 
weak for all GSH concentrations (Fig. 28B; PEG-Cont, PEG-FolA). 
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Fig. 28 Stability of polyplexes with PEGylated oligomers in agarose gel shift assay after 2 h incubation 
at 37 °C at different concentrations of glutathione (GSH).  A) pDNA binding at N/P 12 and B) siRNA 
binding at N/P 20 of single cysteine oligomers (top) and corresponding twin disulfide-forming analogs 
(bottom).  Left lanes: free pDNA or free siRNA, respectively. 
 
Nevertheless, with increasing GSH concentrations a tendency towards weaker binding 
could be observed. Incorporation of the CRC motif increased the stability of the siRNA 
polyplexes significantly and did not decrease in the presence of GSH. All data indicate 
that the introduction of the CRC motif leads to a significant increase in stability. For 
oligomer structures with sufficient stability in the absence of CRC, this increase of 
stability did not improve but often decreased transfection efficiency. Labile siRNA 
polyplexes with PEGylated oligomers, like PEG-FolA, however, may benefit from twin 
disulfides. 
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3.2 Precise redox-sensitive cleavage sites for improved bioactivity of 
siRNA lipopolyplexes 
This chapter has been adapted from: 
Klein PM*, Reinhard S*, Lee DJ, Müller K, Ponader D, Hartmann L, Wagner E. Precise 
redox-sensitive cleavage sites for improved bioactivity of siRNA lipopolyplexes. 
Nanoscale. 2016 Oct 27;8(42):18098-18104 
*contributed equally 
 
Cysteine-based disulfide formation during polyplex formation by air oxygen is a poorly 
controllable, incomplete process [83, 130]. Alternatively, integration of bioreducible 
bonds into carriers can be achieved before nanoparticle formation [115, 131, 132]. 
Disulfide bonds can be accurately integrated during SPS of polymers, as already 
demonstrated by Hartmann et al. [63]. Cleavable cationic domains, as well as 
disassembly of stabilizing domains, have been demonstrated to improve delivery 
systems [133]. 
In this chapter, we designed novel bioreducible cationic lipo-oligomers. By precisely 
positioning the disulfide bond between the fatty acid and polycationic domain (and not 
into the polycationic domain) via a Fmoc-succinoyl-cystamine building block, we 
intended to obtain a most drastic molecular change upon bioreduction. The 
amphiphilic, detergent-like character, which is considered favorable for endosomolysis 
but might also be associated with cytotoxicity, should be abolished upon entry into the 
reductive cytosol by the split into separate pure lipidic and cationic fragments; the latter 
have insufficient ability to bind siRNA. 
We evaluate three lipo-oligomer topologies (T-shape, i-shape and U-shape) and 
different representatives of fatty acids as variables, which previously were found [82] 
to affect polyplex characteristics such as siRNA binding and lytic potential of oligomers, 
gene silencing efficacy and toxicity of polyplexes. Compared with their nonreducible 
lipo-oligomer analogs, the favorable polyplex characteristics should remain indifferent 
until intracellular release into the cytosol, where improved siRNA release and 
biocompatibility would be expected. 
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3.2.1 Synthesis of the bioreducible Fmoc-succinoyl-cystamine building block 
and evaluation of its sensitivity towards reducing conditions 
A building block applicable for standard Fmoc solid-phase peptide synthesis requires 
a protected amino group and a free carboxylic acid function. The synthesis of the 
disulfide building block (ssbb) was carried out starting from cystamine by selective 
protection of one terminal amine with Fmoc in the first step avoiding change of 
protecting groups as was previously presented [134]. To achieve reaction selectivity 
towards mono-functionalization, 0.8 eq. Fmoc-succinimide (Fmoc-OSu) was added 
dropwise to a cooled solution (-80 C) of cystamine dihydrochloride in THF with DIPEA 
as a base. The carboxylic acid function was introduced in the second step by addition 
of 1.8 eq. succinic anhydride (Succ anhydride) solved in THF with DIPEA (Fig. 29A). 
The ssbb structure was purified via column chromatography and the identity confirmed 
by 1H-NMR. 
 
Fig. 29 A) Synthesis of the disulfide building block Fmoc-succinoyl-cystamine (Fmoc-ssbb). B) 
Glutathione (GSH) triggered cleavage of the test structure (740) with a hydrophilic (Stp2) and a 
hydrophobic (L3) part connected by ssbb. C) Test structure monitored by HPLC (280 nm wavelength) 
after incubation for 90 min at 37 °C in 0.1 mM GSH- (top) and 10 mM GSH- (bottom) containing HEPES 
buffer pH 7.4. 
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A test structure (740) was synthesized on solid phase to prove the applicability for SPS. 
Here the ssbb connects a lipophilic peptide sequence containing three leucines (L3) to 
a hydrophilic sequence with two succinoyl-tetraethylene pentamine (Stp) units (Fig. 
29B). Tryptophane (W) was incorporated into both parts to facilitate photometric 
analysis. The product structure was confirmed by mass spectrometry and 1H-NMR. 
The product was incubated with increasing concentrations of the physiological 
antioxidant glutathione (GSH) at 37 °C to simulate the behavior of the ssbb at different 
extra- and intracellular milieus. A GSH concentration of 0.1 mM mimics the barely 
reducing extracellular environment. As expected, the test oligomer mostly retained its 
structural integrity. Increasing the GSH concentration to 10 mM resembling the 
cytosolic reducing conditions resulted in cleavage of the test structure without 
detectable fractions of the intact oligomer (Fig. 29C). 
 
 
3.2.2 Design and synthesis of cationic lipo-oligomers to form siRNA 
polyplexes 
The ssbb unit was applied in SPS of lipo-oligomers supposed to form siRNA polyplexes 
that are stable in the extracellular and labile in the intracellular environment. Lipo-
oligomers with three different topologies, T-shape, i-shape, and U-shape, were 
synthesized (Fig. 30 top and Fig. 31). As shown in our previous work, topologies, as 
well as specific moieties of structures, may influence the biophysical and biological 
properties of the resulting polyplexes [82, 83, 119, 135]. For bioreducible crosslinking 
between oligocations, previous oligomers were designed with cysteines terminating 
the cationic backbone [82, 83, 119]. Differently, in the current work, the ssbb unit was 
positioned between the ionizable oligocationic part of the molecule and a bis (fatty acid) 
unit. 
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Fig. 30 Sequence-defined oligomers with T-shape topology. Top: schematic overview of the structures 
with different modifications (Y: tyrosine, K: lysine, G: glycine, Stp: succinoyl-tetraethylene-pentamine, 
ssbb: succinoyl-cystamine, MyrA: myristic acid, SteA: stearic acid, CholA: 5β-Cholanic acid). The broken 
lines represent amide linkages. IDs are unique database identification numbers. Bottom: cellular uptake, 
acidic pH-triggered endosomal escape, and GSH triggered cytosolic disassembly of siRNA polyplexes. 
Structures 1081, 1082, 989 and 990 were synthesized by Sören Reinhard (PhD study, Pharmaceutical 
Biotechnology, LMU). 
 
 
Fig. 31 Sequence-defined oligomers with i-shape and U-shape topology. Schematic overview of the 
structures with different modifications (K: lysine, H: histidine, Stp: succinoyl-tetraethylene-pentamine, 
ssbb: succinoyl-cystamine, CholA: 5β-Cholanic acid). IDs are unique database identification numbers. 
i-shape structures were synthesized by Sören Reinhard (PhD study, Pharmaceutical Biotechnology, 
LMU). 
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Thus, upon reductive cleavage maximum destabilization of the polyplex on the one 
hand, and abolition of the membrane-active amphiphilic character on the other hand, 
should be achieved. The oligocation part contains several Stp units as artificial 
oligoamino acids for nucleic acid binding and endosomal protonation [66], and lysines 
(K) as branching units. Additionally, the cationic part was equipped with tyrosine trimers 
(Y3) [119] for further hydrophobic stabilization of the T-shape oligomers (Fig. 30), and 
with histidine blocks (H6) for increased endosomal buffering of the i-shape oligomers. 
The saturated C14 short chain myristic acid (MyrA), the stearic acid (SteA) with the 
longer C18 chain, and the bulky cholanic acid (CholA) were incorporated as fatty acids 
for hydrophobic polyplex stabilization. For all oligomers, the corresponding non-
reducible control structures lacking ssbb were synthesized. The ssbb was incorporated 
into various different structures to proof the concept independently of shape and other 
functional domains and to put this work into a broader context. The structures were 
analyzed with mass spectrometry and 1H-NMR (Appendix 6.4.2). To exclude that lipo-
oligomers contain significant amounts of reduced fragments, Ellman´s assay was 
performed to detect free thiols (Table 12). Lack of free thiols (< 3 %) indicate high 
integrity of the ssbb linkage. 
 
Table 12 Determination of free thiols in reducible T-shape, i-shape and U-shape structures via Ellman´s 
assay 
Oligomer Ratio of free thiols (in %) 
1082 (MyrA-ss-t) 2.0 
990 (SteA-ss-t) 2.3 
992 (CholA-ss-t) 2.7 
969 (CholA-ss-i) 1.2 
782 (CholA-ss-u) 0.6 
 
 
3.2.3 Formulation of siRNA polyplexes and biophysical characterization 
Polyplexes were formed by mixing the cationic oligomers with siRNA, followed by 
40 minutes incubation and biophysical characterization (Fig. 32 shows a summery for 
stable and reducible CholA T-shapes 991 and 992). The siRNA binding ability of 
oligomers was determined by measuring the electrophoretic mobility of siRNA in a 
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2.5 % agarose gel. Different N/P values depict the ratio of protonatable amines (N) of 
the oligomer to phosphates (P) of the siRNA. 
 
Fig. 32 A) Analytical characterization of stable oligomer 991 and bioreducible oligomer 992 by mass 
spectrometry. B) Agarose gel shift assays. Left: siRNA binding at different N/P ratios. Right: 
Lipopolyplexes formed at N/P 20 and subsequent 90 min treatment at 37 °C with different 
concentrations of GSH in HEPES buffer pH 7.4. C) Biophysical characterizations of lipopolyplexes 
formed with oligomers and siRNA at N/P 12 by DLS. Mass spectrometry and gel shifts were performed 
by Sören Reinhard (PhD study, Pharmaceutical Biotechnology, LMU). 
 
This does not present charge ratios, as only a fraction of the protonatable amines are 
protonated at physiological pH. All T-shape, i-shape and U-shape structures showed 
sufficient binding at N/P ≥ 12 (Fig. 33, Fig. 34). 
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Fig. 33 siRNA binding ability of T-shape structures analyzed with an agarose gel shift assay. The left 
lane shows the running distance of free siRNA in HBG that is not complexed by lipo-oligomers. 
Polyplexes were tested for siRNA binding ability at different N/P ratios. Top: stable structures, bottom: 
reducible structures. Gel shifts were performed by Sören Reinhard (PhD study, Pharmaceutical 
Biotechnology, LMU). 
 
 
Fig. 34 siRNA binding ability of i-shape and U-shape structures analyzed with an agarose gel shift 
assay. The left lane shows the running distance of free siRNA in HBG that is not complexed by lipo-
oligomers. Polyplexes were tested for siRNA binding ability at different N/P ratios. Top: stable structures, 
bottom: reducible structures. Gel shifts for i-shape structures were performed by Sören Reinhard (PhD 
study, Pharmaceutical Biotechnology, LMU). 
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Neither stable nor reducible polyplexes released free siRNA when exposed to 90 % 
full serum at 37 °C for two hours, indicating a high extracellular stability (Fig. 35). 
 
Fig. 35 Gel retardation assay of siRNA polyplexes incubated at N/P 12 for 40 min, followed by treatment 
with 90 % full serum for two hours at 37 °C. The black arrow points at a band that is caused by serum 
(see serum blank in band one). Running distance of free siRNA in HBG buffer and in 90 % serum are 
shown in band two and three. 
 
In contrast, treatment of polyplexes with the physiological reducing agent GSH at 37 °C 
resulted in a dose-dependent loss of siRNA binding efficacy for the reducible but not 
the stable oligomers (Fig. 36, Fig. 37). Due to the particular position of the ssbb unit, 
reductive cleavage leads to the release of the lipid as the most important stabilization 
motif, thus keeping only a weak binding ability of the remaining cationic backbone 
[119]. This destabilization of polyplexes is expected to provide better accessibility of 
siRNA at intracellular GSH concentrations (~10 mM). 
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Fig. 36 siRNA binding ability of T-shape structures under reducing conditions analyzed with an agarose 
gel shift assay. The left lane shows the running distance of free siRNA in HBG that is not complexed by 
lipo-oligomers. Lipopolyplexes were formed at N/P 20 followed by 90 min treatment at 37 °C with 
different concentrations of GSH in HEPES buffer pH 7.4. Top: stable structures, bottom: reducible 
structures. Gel shifts were performed by Sören Reinhard (PhD study, Pharmaceutical Biotechnology, 
LMU). 
 
 
Fig. 37 siRNA binding ability of i-shape and U-shape structures under reducing conditions analyzed with 
an agarose gel shift assay. The left lane shows the running distance of free siRNA in HBG that is not 
complexed by lipo-oligomers. Lipopolyplexes were formed at N/P 20 followed by 90 min treatment at 
37 °C with different concentrations of GSH in HEPES buffer pH 7.4. Top: stable structures, bottom: 
reducible structures. Gel shifts for i-shape structures were performed by Sören Reinhard (PhD study, 
Pharmaceutical Biotechnology, LMU). 
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The particle sizes of siRNA lipopolyplexes were measured by dynamic light scattering 
(DLS). All T-shape polyplexes showed uniform sizes between 105 - 138 nm z-average 
(Table 13). 
 
Table 13 Particle size (Z-average) and zeta potential of siRNA polyplexes determined with a DLS 
zetasizer. Measurements for i-shape structures were performed by Sören Reinhard (PhD study, 
Pharmaceutical Biotechnology, LMU). 
Oligomer N/P z-average [nm] Mean PDI 
Mean Zeta 
Potential [mV] 
1081 (MyrA-t) 12 105.0 ± 1.8 0.15 ± 0.01 27.0 ± 0.8 
1082 (MyrA-ss-t) 12 107.7 ± 0.5 0.14 ± 0.02 28.6 ± 0.8 
989 (SteA-t) 12 125.3 ± 1.0 0.12 ± 0.01 29.3 ± 1.6 
990 (SteA-ss-t) 12 137.9 ± 1.6 0.13 ± 0.01 26.8 ± 0.9 
991 (CholA-t) 12 131.7 ± 0.5 0.13 ± 0.01 29.4 ± 4.2 
992 (CholA-ss-t) 12 128.3 ± 0.5 0.13 ± 0.01 30.9 ± 0.7 
871 (CholA-i) 12 275.0 ± 7.2 0.24 ± 0.01 23.4 ± 0.7 
969 (CholA-ss-i) 12 237.8 ± 4.2 0.20 ± 0.01 25.2 ± 0.3 
783 (CholA-u) 12 122.7 ± 2.0 0.26 ± 0.02 31.5 ± 0.7 
782 (CholA-ss-u) 12 181.2 ± 4.7 0.27 ± 0.01 29.1 ± 3.3 
 
The sizes of i-shape and U-shape polyplexes showed higher polydispersity. All 
formulations revealed a positive zeta potential of around 23 – 32 mV due to an excess 
of cationic oligomer (Table 13). T-shape oligomers were found as well-suited for the 
evaluation of structure-activity relationships, since all of them formed polyplexes with 
reliable sizes and low polydispersity. 
 
3.2.4 siRNA transfection efficiency 
Gene silencing experiments were performed in Neuro2A neuroblastoma cells stably 
expressing an eGFP-Luciferase fusion protein (Fig. 38). Silencing by siGFP (light bars) 
can be quantified by a standard luciferase assay. In all cases, gene silencing was more 
effective for the bioreducible T-shape oligomers (Fig. 38B) as compared to their stable 
analogs (Fig. 38A). A reduced luciferase expression in control experiments using siCtrl 
(dark bars) is caused by unspecific cytotoxic effects and not by a specific knockdown 
of the eGFPLuc gene. Thus, from evaluating the luciferase levels of the siCtrl 
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polyplexes, an enhanced biocompatibility of the reducible structures (Fig. 38B) can be 
concluded. 
 
Fig. 38 Gene silencing of T-shape oligomers in neuroblastoma cells. Lipopolyplexes with 500 ng / 
37 pmol eGFP-targeted siRNA (siGFP) / well respectively control siRNA (siCtrl) at N/P 6, 12 and 20 
were tested for eGFPLuc gene silencing in Neuro2A-eGFPLuc cells. A) Lipopolyplexes made of stable 
structures 1081, 989 and 991 B) Lipopolyplexes made of bioreducible structures 1082, 990 and 992. 
The luciferase activity of siRNA-treated cells is presented related to buffer-treated cells. HBG-treated 
cells were set to 100 %. Data are presented as mean value (± SD) out of triplicates. Dose-dependent 
gene silencing transfections are shown in Fig. S8 and S9. Transfections were performed by Dian-Jang 
Lee (PhD study, Pharmaceutical Biotechnology, LMU). 
 
Similar findings, an enhanced gene silencing and especially the reduction of 
cytotoxicity, were also made for bioreducible i-shape and U-shape lipo-oligomers (Fig. 
39). 
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Fig. 39 Gene silencing of i-shape and U-shape oligomers in neuroblastoma cells. Lipopolyplexes with 
500 ng / 37 pmol eGFP-targeted siRNA (siGFP) / well respectively control siRNA (siCtrl) at N/P 6, 12 
and 20 were tested for eGFPLuc gene silencing in Neuro2A/eGFPLuc cells. A) Lipopolyplexes made of 
stable structures 871 and 783 B) Lipopolyplexes made of bioreducible structures 969 and 782. The 
luciferase activity of siRNA-treated cells is presented related to buffer-treated cells. HBG-treated cells 
were set to 100 %. Data are presented as mean value (± SD) out of triplicates. Transfections for i-shapes 
were performed by Dian-Jang Lee, transfections for u-shapes were performed by Katharina Müller (PhD 
studies, Pharmaceutical Biotechnology, LMU). 
 
For the best-performing T-shape structures with MyrA and CholA, dose-dependent 
gene silencing experiments were carried out. Based on the starting formulation of 
37 pmol siRNA (370 nM) with 1.44 nmol oligomer (N/P 12), the dose of siRNA was 
reduced either at a constant N/P 12 (Fig. 40) or a constant dose of 1.44 nmol oligomer 
(Fig. 41). In the latter case, significant gene silencing was still observed for reducible 
MyrA polyplexes at 1.2 pmol / 12 nM siRNA. 
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Fig. 40 Dose-dependent gene silencing of T-shape oligomers at N/P 12 in neuroblastoma cells. 
Lipopolyplexes with eGFP-targeted siRNA (siGFP) respectively control siRNA (siCtrl) were examined 
for eGFPLuc gene silencing in Neuro2A/eGFPLuc cells. The oligomer amount was adjusted for each 
formulation to keep it constant at N/P 12. Formulations including siRNA from 6, 12, 27, 47, 93, 185, 370 
up to 740 nM were tested. A) Lipopolyplexes made of stable structures 1081 and 991 B) Lipopolyplexes 
made of bioreducible structures 1082 and 992. The luciferase activity of siRNA-treated cells is presented 
related to buffer-treated cells. HBG-treated cells were set to 100 %. Data are presented as mean value 
(± SD) out of triplicates. Transfections were performed by Dian-Jang Lee (PhD study, Pharmaceutical 
Biotechnology, LMU). 
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Fig. 41 Dose-dependent gene silencing of T-shape oligomers in neuroblastoma cells. Lipopolyplexes 
with eGFP-targeted siRNA (siGFP) respectively control siRNA (siCtrl) at constant oligomer amount of 
1.44 nmol (N/P 12 at 500 ng siRNA) were examined for eGFPLuc gene silencing in Neuro2A/eGFPLuc 
cells. Formulations including siRNA from 6, 12, 27, 47, 93, 185, 370 up to 740 nM were tested.                   
A) Lipopolyplexes made of stable structures 1081 and 991   B) Lipopolyplexes made of bioreducible 
structures 1082 and 992. The luciferase activity of siRNA-treated cells is presented related to buffer-
treated cells. HBG-treated cells were set to 100 %. Data are presented as mean value (± SD) out of 
triplicates. Transfections were performed by Dian-Jang Lee (PhD study, Pharmaceutical Biotechnology, 
LMU). 
 
The beneficial effects of reducible polyplexes are also confirmed in DU145/eGFPLuc 
prostate cancer cells (Fig. 42).  
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Fig. 42 Gene silencing of T-shape oligomers in prostate cancer cells. Lipopolyplexes with 500 ng eGFP-
targeted siRNA (siGFP) respectively control siRNA (siCtrl) at N/P 12 were tested for eGFPLuc gene 
silencing in DU145/eGFPLuc cells. Lipopolyplexes made of stable structures (1081, 989 and 991) and 
bioreducible structures (1082, 990 and 992) are shown. The luciferase activity of siRNA treated cells is 
presented related to buffer-treated cells. HBG-treated cells were set to 100 %. Data are presented as 
mean value (± SD) out of triplicates. Transfections were performed by Dian-Jang Lee (PhD study, 
Pharmaceutical Biotechnology, LMU). 
 
Nevertheless, not all cell lines profit from the bioreducible character of oligomers. 
Testing the structures on KB/eGFPLuc cells (derived from the cervical cancer cell line 
HeLa) revealed that the bioreducible character can even have a negative influence on 
gene silencing. In contrast to the stable structures that mediate gene silencing, the 
efficiency for all bioreducible structures was strongly decreased (Fig. 43). One 
explanation for this finding is disulfide cleavage occurring at the extracellular cell 
surface. High extracellular disulfide cleavage was actually previously reported for HeLa 
cells [108]. 
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Fig. 43 Gene silencing of T-shape oligomers in KB cells. Lipopolyplexes with 500 ng/37 pmol eGFP-
targeted siRNA (siGFP) per well respectively control siRNA (siCtrl) at N/P 12 were tested for eGFPLuc 
gene silencing in KB-eGFPLuc cells. Lipopolyplexes made of stable structures 1081, 989 and 991 
(- ssbb) and lipopolyplexes made of bioreducible structures 1082, 990 and 992 (+ ssbb) were tested. 
The luciferase activity of siRNA-treated cells is presented related to buffer-treated cells. HBG-treated 
cells were set to 100 %. Data are presented as mean value (± SD) out of triplicates. Transfections were 
performed by Dr. Dian-Jang Lee (Pharmaceutical Biotechnology, LMU). 
 
When focusing on the comparison of the three different fatty acids, SteA and CholA 
lipo-oligomers (no or only moderate silencing for the stable versions) strongly benefited 
from the incorporation of the ssbb with regard to gene silencing in Neuro2A and DU145 
cell lines. In contrast, the stable MyrA lipo-oligomer displayed gene silencing activity 
combined with significant cytotoxicity (Fig. 38A); here the reducible ssbb unit 
eliminated the cytotoxicity without reducing the gene silencing activity (Fig. 38B). The 
findings for non-reducible lipo-oligomers are consistent with our earlier observations 
[82], where SteA derivatives showed poor gene silencing activity and MyrA derivatives 
exhibited not only gene silencing activity but cytotoxicity. For non-reducible structures, 
the unsaturated C18 fatty acids oleic acid and linoleic acid were the optimum lipid units 
with regard to transfection efficacy and cell tolerability [82, 83, 119]. Still, due to the 
higher stability during synthesis and storage, in the current work saturated fatty acids 
were the preferred option for integration into solid phase synthesized lipo-oligomers.  
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Nevertheless, incorporation of the bioreducible linker into oleic acid containing 
oligomers was also found to further enhance transfection efficacy and cell tolerability 
(Fig. 44). 
 
Fig. 44 Gene silencing of oleic acid containing T-shape oligomers in neuroblastoma cells. 
Lipopolyplexes with 500 ng / 37 pmol eGFP-targeted siRNA (siGFP) / well respectively control siRNA 
(siCtrl) at N/P 6, 12 and 20 were tested for eGFPLuc gene silencing in Neuro2A/eGFPLuc cells. The 
luciferase activity of siRNA-treated cells is presented related to buffer-treated cells. HBG-treated cells 
were set to 100 %. Data are presented as mean value (± SD) out of triplicates. Transfections were 
performed by Dian-Jang Lee (PhD study, Pharmaceutical Biotechnology, LMU). 
 
The different fatty acids may influence the extent of hydrophobic stabilization of siRNA 
polyplexes, but do also strongly affect the lytic properties of the lipo-oligomers, both in 
the stable and reducible setting. At endosomal pH, the cationic parts receive increased 
cationization, which in combination with the hydrophobic domain facilitates endosomal 
membrane destabilization and escape into the cytosol. An erythrocyte leakage assay 
compared the different fatty acid versions of stable (Fig. 45A) and the ssbb containing 
reducible (Fig. 45B) lipo-oligomers. MyrA structures displayed a far higher leakage 
activity (highest at pH 5.5) than the SteA structures, whereas oligomers with the bulky 
CholA did not display lytic effects. 
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Fig. 45 Erythrocyte leakage of oligomers at different pH and under reducing conditions. A) Stable lipo-
oligomers 1081, 989 and 991. B) bioreducible lipo-oligomers 1082, 990 and 992. The final concentration 
of oligomers was 7.5 µM. GSH treated lipo-oligomers were incubated with 10 mM GSH in PBS adjusted 
to pH 7.4 at 37 °C for 90 min (right-hand side). PBS-treated erythrocytes were set to 0 %. Triton X 
served as positive control and was set to 100 %. Data are presented as mean value (± SD) out of 
quadruplicates. Erythrocyte leakage assay performed by Sören Reinhard (PhD study, Pharmaceutical 
Biotechnology, LMU). 
 
This finding is in agreement with literature, showing that cationic dimyristyl lipids 
strongly promote membrane fusion events. Deviations of hydrophobic volume and 
hydrophilic-lipophilic ratio from an optimum hampered membrane interactions [136]. 
Treatment with GSH did not affect the stable analogs but extinguished the lytic activity 
of the reducible lipo-oligomers, consistent with their lower cytotoxicity. This observation 
can be attributed to the integration of the ssbb as a linker between the cationic and the 
lipophilic part, as reductive cleavage results in an uncharged fatty acid structure and 
an oligocationic part with significantly reduced amphiphilic character. Both compounds 
alone were not able to lyse membranes anymore. 
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3.3 Functionalized poly(sarcosine) as shielding agent for lipopolyplexes 
In this chapter, optimized redox-sensitive lipo-oligomers (presented in 3.2) were 
extended by azido functionalities to serve as reactants for click chemistry. After 
formation of siRNA lipopolyplexes, the azido groups were used to covalently modify 
the nanoparticle surface with DBCO-modified poly(sarcosine) (PSar). Polymerized 
sarcosine (N-methylglycine) is hydrophilic and biodegradable. These PSar-modified 
lipopolyplexes were tested for shielding properties in terms of reduction of zeta 
potential and cellular uptake. Folic acid functionalized PSar agents were tested for their 
in vitro targeting ability. In vivo bioimaging studies were performed in mice to assess 
the distribution of intravenously injected siRNA lipopolyplexes with 8 kDa 
poly(sarcosine) or 5 kDa poly(ethylene glycol) shields. 
 
3.3.1 Design and synthesis of a lipo-oligomer for click chemistry 
In previous work, we have established a new class of redox-sensitive lipo-oligomers 
prepared by solid-phase supported synthesis (SPSS) to serve as carriers for siRNA 
delivery [137]. The T-shape structure 992 introduced in this work, was chosen as 
starting point for further modifications because it forms stable siRNA polyplexes with 
sizes below 200 nm hydrodynamic diameter that have high transfection efficiency. This 
structure combines natural amino acids and artificial building blocks (Fig. 46 - top). It 
consists of four repeats of the cationic polyamino acid succinoyl-tetraethylene-
pentamine (Stp) used for complexation of nucleic acid and for endosomal buffering. 
Two tyrosine trimer units flanking the cationic domain stabilize the polyplex due to their 
hydrophobicity and π–π stacking ability. In the center of the cationic Stp units two 
hydrophobic cholanic acids branch off the cationic backbone (T-shape) for lipopolyplex 
stabilization. The lipid and cationic domains are connected via a bioreducible linking 
unit (ssbb) [137]. In the new approach, the structure was extended by azidolysines 
placed at the N- and/or C-terminal end of the backbone (structures 1073 and 1076, 
Fig. 46 - top). This enables the structure to be subsequently further conjugated with 
an alkyne via click chemistry. Strain promoted copper-free click reaction of a 
cyclooctyne derivate, instead of a standard alkyne, with an azide [138-140] has several 
advantages towards other reactions. No catalyst is needed, no side reactions with 
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other functional domains of the oligomer can occur, and no toxic by-products are 
generated. 
 
 
Fig. 46 Overview of chemical compounds. Top: schematic illustration of sequence-defined oligomers 
with T-shape topology; 992, 1073 and 1086 with no, one or two terminal azidolysines K(N3). Other units 
of the oligomers: Y: tyrosine, K: lysine, G: glycine, Stp: succinoyl-tetraethylene-pentamine, ssbb: 
succinoyl-cystamine, CholA: 5β-Cholanic acid. The broken lines represent amide linkages. IDs are 
unique database identification numbers. Bottom: structure of the shielding agents DBCO-PSar119 (abbr.: 
PSar), DBCO-PSar119-Ac (abbr.: PSarAc) and DBCO-PSar110-FolA (abbr.: PSarFolA). All pSar 
shielding agents were synthesized by Kristina Klinker (PhD study, Institute of Organic Chemistry, JGU 
Mainz) under supervision of PD Dr. Matthias Barz.  
 
3.3.2 DBCO-modified poly(sarcosine) as a click shielding agent 
Polymerized sarcosine (N-methylglycine) is a hydrophilic, nonionic peptidic structure, 
which is a weak hydrogen bond acceptor. These properties provide a high resistance 
against protein adsorption [141] and make it an ideal material for shielding electrostatic 
complexes [142]. Importantly, it has been reported that poly(sarcosine) has a low 
immunogenicity in various animal models [143, 144]. Poly(sarcosine) can be 
functionalized at its N- and C-terminal end. It is obtained by ring opening polymerization 
of α-amino acid N-carboxyanhydrides (NCA) with a low degree of polydispersity [145]. 
Initiating the reaction with a dibenzocyclooctyne-amine (DBCO-amine) leads to a C-
terminal DBCO tail group. A DBCO function can efficiently react with azide-modified 
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structures in aqueous solutions. Mixing azido modified cationic oligomers with siRNA 
leads to spontaneous assembly of polyplexes. Due to oligomer excess, several azido 
functions remain free in solution. Others are located in the core of the nanoparticle or 
on its surface. Azido functions on the surface of siRNA polyplexes serve as anchors 
for functionalization with DBCO-modified poly(sarcosine). The N-terminal free amine 
can further be modified with a nonionic acetyl residue or a targeting ligand like folic 
acid. All shielding agents are presented in Fig. 46 on the bottom. The syntheses and 
analyses of those agents were performed by Kristina Klinker within her PhD study at 
the laboratory of PD Dr.Matthias Barz, Institute of Organic Chemistry, University of 
Mainz, Germany. 
3.3.3 Biophysical evaluation of poly(sarcosine) shielded lipopolyplexes 
The structures (1073 and 1086) were incubated with siRNA for 40 min with a final 
concentration of 25 ng siRNA/µL to form polyplexes. The electrophoretic mobility of 
incorporated siRNA was measured with an agarose gel shift assay to test the new 
oligomers’ ability to bind nucleic acid. Different N/P values depict the ratio of 
protonatable amines (N) of the oligomers to phosphates (P) of the siRNA. Like its 
analog 992 (Fig. 33 [137]), the oligomers showed complete retention of siRNA in the 
pockets of the gel at an N/P ratio of 12 (Fig. 47). No changes in binding ability were 
observed for the incorporation of one or two azidolysines. 
 
Fig. 47 siRNA binding ability of T-shape structures analyzed with an agarose gel shift assay. The left 
lane shows the running distance of free siRNA in HBG that is not complexed by lipo-oligomers. 
Polyplexes were tested for siRNA binding ability at different N/P ratios. 2.5 % agarose gel, 100V, 40 min 
runtime. 
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Next, we wanted to evaluate the influence of the DBCO poly(sarcosine) (PSar) 
shielding agent on electrophoretic mobility of the polyplex. For all formulations modified 
with PSar, an N/P ratio of 12 was used to ensure complete complexation of siRNA 
(Fig. 48). First, polyplexes formed with the structures differing in the amount of azido 
functions (N3 = 0, 1, 2) were incubated with a fixed amount of PSar (Fig. 48) for 16 h. 
The siRNA concentration of the functionalized formulations was 20 ng / µL. The azido-
bearing polyplexes migrated in the gel towards the cathode, whereas the polyplex 
without azido function remained in the pocket. This showed that a covalent bond 
connecting the shielding agent to the nanoparticle was required to mediate this effect. 
The migration of the integrated siRNA against its own negative charge demonstrated 
that it was not accessible to the electric field inside a polyplex covered with shielding 
agent. When increasing the equivalents of PSar, stronger migration could be observed 
indicating that this effect can be related to the degree of surface modification of the 
polyplex (Fig. 48B). For the oligomer with one azido function (1073), maximum 
migration was achieved with equimolar amounts of DBCO click agent (1 eq / oligomer). 
More PSar (2 eq), did not increase the effect. 1086 siRNA polyplexes with two azido 
functions within the carrier also showed the maximum migration for equimolar ratios of 
azide to DBCO (2 eq PSar). 
 
Fig. 48 Electrophoretic mobility of siRNA polyplex formulations analyzed with an agarose gel shift assay 
A) siRNA polyplexes formed with oligomers bearing no (992), one (1073) and 2 (1086) azide functions 
incubated with 0.75 equivalents of DBCO-PSar119 (PSar) 1 % agarose gel, 70 V, 80 min runtime. B) 
Formulations with increasing equivalents (eq mol/mol) of DBCO-PSar119 (PSar). 0.75 % agarose gel, 
100V, 80 min runtime. All polyplexes were incubated for 40 min at N/P 12, followed by PSar addition for 
16 h at room temperature. The right lane shows the running distance of free siRNA in HBG that is not 
complexed by lipo-oligomers. 
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The degree of surface modification and shielding of a nanoparticle can also be 
evaluated by determining its zeta potential by measuring its mobility under electric field 
with light scattering. Hereby, we showed that the positive zeta potential of an 
unshielded particle could be strongly reduced with poly(sarcosine) (Table 14). By using 
0.5 eq PSar / oligomer, the zeta potential can already be reduced by 50 %. Due to the 
N-terminal cationic head group, the zeta potential always remains slightly positive. 
Table 14 Particle size (z-average) and zeta potential of poly(sarcosine) siRNA formulations determined 
with the DLS zetasizer. 
siRNA 
formulation 
eq PSar N/P z-average [nm] Mean PDI 
Mean Zeta 
Potential [mV] 
1073 
0 12 81.0 ± 5.0 0.26 ± 0.02 20.9 ± 0.9 
0.5 12 86.7 ± 2.8 0.24 ± 0.02 9.4 ± 0.5 
1 12 91.8 ± 2.9 0.26 ± 0.02 8.5 ± 0.6 
2 12 96.8 ± 4.0 0.27 ± 0.02 6.0 ± 1.1 
1086 
0 12 90.6 ± 0.9 0.15 ± 0.03 17.2 ± 0.8 
0.5 12 98.7 ± 1.3 0.15 ± 0.01 7.7 ± 0.6 
1 12 102.3 ± 2.1 0.19 ± 0.01 6.3 ± 1.0 
2 12 105.1 ± 1.9 0.17 ± 0.01 2.5 ± 0.3 
 
The hydrodynamic diameters of the polyplexes, determined by dynamic light scattering 
(DLS), are in the area of 100 nm. With increasing amounts of PSar, the nanoparticle 
size increases by up to 16 nm in diameter. A layer of PSar covering the particle surface 
seems to be the most plausible explanation for the increase in size. 
 
3.3.4 Evaluation of poly(sarcosine) shielding agents in vitro 
A reduced interaction of nanoparticles with cell membranes is an important indication 
of shielding. Therefore, we performed uptake studies with the poly(sarcosine) shielded 
polyplexes. Polyplex formulations were prepared with Cy5-labled siRNA for this assay. 
We incubated Neuroblastoma Neuro2A cells with the formulations for 4 h at standard 
culture conditions and analyzed them by flow cytometry. The signal intensity of cells 
labeled with fluorescent dye correlates with the amount of polyplexes being 
internalized (Fig. 49 and Table 15). Unshielded material and material shielded with 
low equivalents of PSar showed significant uptake into cells after 4 h incubation time 
for both polyplex formulations prepared with one and two azido bearing backbones 
(1073 and 1086). 
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Fig. 49 Cellular internalization of siRNA formulations (left: 1073; right: 1086) shielded with increasing 
equivalents (eq mol/mol) of DBCO-PSar119 (PSar) determined by flow cytometry. All polyplexes were 
incubated for 40 min at N/P 12 with siRNA (20 % Cy5-labeled), followed by PSar for 16 h at room 
temperature. Cells were incubated with the formulations for 4 h at 37°C and washed with PBS buffer 
and heparin solution. The intensity of the Cy5 signal indicates the amount of polyplexes being 
internalized by Neuro2A-eGFP-Luc cells. Control: HBG buffer treated cells. Experiments were 
performed by Dr. Wei Zhang (Pharmaceutical Biotechnology, LMU). 
 
For 1073 formulations a significant reduction in fluorescence intensity was observed 
for 1 eq of PSar per oligomer, whereas 2 eq of PSar were needed for 1086 formulations 
to reach similar levels (Table 15). The increase of azido functions in the 1086 
backbone did not mediate a better surface modification of the polyplexes. Apart from 
that, more PSar is required to achieve the same shielding effect. 
 
Table 15 Mean fluorescence intensity (MFI) data for cellular internalization of Cy5-labeled siRNA 
formulations (left: 1073; right: 1086) shielded with increasing equivalents (eq mol/mol) of DBCO-PSar119 
(PSar) determined by flow cytometry. Performed by Dr. Wei Zhang (Pharmaceutical Biotechnology, 
LMU). 
siRNA 
formulation 
eq PSar MFI 
siRNA 
formulation 
eq PSar MFI 
1073 
0 780.5 ± 2.5 
1086 
0 883.0 ± 86.0 
0.25 881.5 ± 25.5 0.25 870.5 ± 62.5 
0.5 715.0 ± 24.0 0.5 785.5 ± 38.5 
1 359.0 ± 14.0 1 602.5 ± 37.5 
2 245.5 ± 8.0 2 263.5 ± 4.5 
 
This is most probably because more azides are free in solution scavenging the DBCO 
click agents. 
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Next, the cells were incubated with 1073 formulations in a similar way and confocal 
laser scanning microscopy was performed. Again, the Cy5-labeled siRNA (red) 
represents the polyplexes internalized into the cells (Fig. 50). Compared to the 
unshielded material, which was avidly taken up by cells, 0.5 eq of PSar showed a 
reduction in cellular internalization. For 1 eq of PSar, only a few polyplexes were taken 
up by cells, indicating a strong shielding ability. This experiment confirmed the 
observations made in the previously described flow cytometry studies. 
 
Fig. 50 Intracellular distribution of siRNA formulations in Neuro2A-eGFP-Luc cells with increasing 
equivalents (eq mol/mol) of DBCO-PSar119 (PSar) acquired by confocal laser scanning microscopy. 
Cells were incubated with the formulations for 4 h and washed with PBS buffer. Nuclei were stained with 
DAPI (blue) and siRNA was spiked with 20 % Cy5-labeled siRNA (red). The overlay image shows the 
merged channels and the light microscope image. Transfections were performed by Dr. Wei Zhang 
(Pharmaceutical Biotechnology, LMU), confocal microscopy was performed by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU). 
 
3.3.5 Distribution of poly(sarcosine) functionalized polyplexes in vivo 
The evaluation of poly(sarcosine) functionalized polyplexes in biophysical and in vitro 
assays highlights their shielding ability. For in vivo distribution, a siRNA polyplex 
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formulation prepared with DBCO-PEG5k (abbr. PEG), with acetylated poly(sarcosine) 
(DBCO-PSar119-Ac; abbr. PSarAc, Fig. 46, bottom) and an unshielded siRNA polyplex 
were compared. In terms of surface charge, the uncharged terminal head group of 
PsarAc is more similar to the commercial PEG agent, which has a terminal methoxy 
head group (for detailed biophysical analytics see chapter 3.3.6). 1073 siRNA 
polyplexes were prepared with 50 % Cy7-labeled siRNA and incubated with 1 eq of 
the respective shielding agent per oligomer for 4 h. A concentration of 
200 ng siRNA / µL was used for this experiment. 50 µg of siRNA and oligomers at an 
N/P ratio of 10 were used. 
The formulations were injected into Neuro2A tumor-bearing mice via i. v. tail-vain 
injection and the distribution of the NIR (near infrared) fluorescent dye was monitored 
at various time points for one day by bioimaging in living mice (Fig. 51). The unshielded 
polyplex started accumulating in the liver after 15 min. Such finding was also observed 
for other unmodified T-shape backbone structures in previous work [119, 146]. In 
contrast to the unshielded lipopolyplexes, both shielded formulations showed a much-
expanded in vivo distribution. At 60 minutes after injection of the material, the shielded 
formulations were still detectable in all areas of the body including the tumor site. A 
strong signal was detected in the exposed periphery, such as the paws of mice injected 
with shielded polyplexes after more than 4 hours. In comparison, formulations with the 
8 kDa poly(sarcosine) and the 5 kDa poly(ethylene glycol) displayed only minor 
differences. The PSarAc formulation showed a slightly better distribution in ears, flanks 
and abdomen. After 4 h the intensity of the signals decreased. The strongest signals 
remained in liver and bladder. An enhanced permeability and retention (EPR) effect at 
the tumor site was not observed. This effect was reported for nanoparticles that 
circulate for a prolonged period and thereby have a higher probability to extravasate 
through leaky vasculature at the tumor site [147]. Since the size of particles was in a 
suitable range for the EPR effect, the short half-life of shielded polyplexes, as well as 
the lack of active targeting ligands, might be the limiting factors. 
Summing up, poly(sarcosine) represents a suitable shielding agent and an at least 
adequate alternative for PEG that extends the circulation of lipopolyplexes in mice and 
reduces unspecific cellular interactions. 
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Fig. 51 Biodistribution of 1073 formulations at N/P 10 in NMRI-nude mice bearing Neuro2A tumors via 
i.v. administration. Biodistribution determined by NIR fluorescence bioimaging of 50 μg siRNA (50 % 
Cy7-labeled) with 1073 with 1 eq DBCO-PEG5k (PEG), 1 eq acetylated DBCO-PSar119Ac (PSarAc) or 
hepes buffered glucose (HBG). Experiments were performed with two animals per group for time points 
until 60 min and one animal per group for later time points; a representative animal of each group is 
shown. Animals are presented in the dorsal, ventral and lateral view. Experiment was performed by 
Sarah Kern and Eva Kessel (veterinary MD studies, Pharmaceutical Biotechnology, LMU). 
 
 
3.3.6 Functionalization of the poly(sarcosine) head group with folic acid for 
receptor targeting 
A shielding agent should prevent unspecific interaction with proteins and biological 
surfaces such as cell membranes. This inhibition of unspecific cell binding is an 
important requirement for specific cell targeting. A targeting ligand needs to be 
attached to its surface to enable the nanoparticle to only target specific receptors on 
cell membranes. PSar offers the possibility to be further functionalized at its free 
secondary amino function. The targeting ligand folic acid (FolA) was chosen to be 
conjugated to the N-terminal amino head group of DBCO-PSar110 (Kristina Klinker 
/Dr.Matthias Barz, University of Mainz). The conjugation was performed with folic acid 
and HBTU/HOBt/DIPEA in DMSO and the product was purified via size exclusion 
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chromatography. This reaction results in α- and γ-glutamyl conjugated agents (DBCO-
PSar110-FolA (abbr. PSarFolA), Fig. 46, bottom). As a negative control, PSar 
acetylated with acetic anhydride and TEA in DMF (DBCO-PSar119-Ac (abbr. PSarAc), 
Fig. 46, bottom) was used. Beside the untargeted shielding agents PSar and PSarAc, 
the commercially available DBCO-PEG5k (abbr. PEG) was included for evaluation. 
The PEG standard we chose has a DBCO tail group, a chain of ~5 kDa of poly(ethylene 
glycol) and a methoxy head group. 
For further experiments, the formulations were prepared at the same conditions used 
for the in vivo experiment in the last chapter (200 ng siRNA per µL in the final 
formulation, N/P 10). The electrophoretic mobility of incorporate siRNA was measured 
with an agarose gel assay. All formulations form stable polyplexes at increased in vivo 
concentrations at N/P 10. siRNA lipopolyplexes shielded with DBCO-PEG5k showed 
migration in the gel towards the cathode similar to PSar shielded formulations. The 
acetyl-PSar control formulation (PSarAc) revealed a shorter migration distance than its 
uncapped analog with a positively charged head group (Fig. 52).  
 
Fig. 52 Electrophoretic mobility of formulations with 1 eq DBCO-PSar119 (PSar), 1 eq DBCO-PSar119-
Ac (PSarAc), 1 eq DBCO-PSar110-FolA (PSarFolA), 1 eq DBCO-PEG5k (PEG) or hepes buffered 
glucose (HBG) analyzed with an agarose gel shift assay. All polyplexes were incubated at in vivo 
concentrations (200µg/µl) at N/P 10 for 40 min, followed by HBG, PEG or PSar incubation for 4 h at 
room temperature. The solutions were diluted 1 : 8 with HBG and loaded onto the gel. The left lane 
shows the running distance of free siRNA in HBG that is not complexed by lipo-oligomers. 1 % agarose 
gel, 70 V, 80 min runtime. 
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In contrast to the other formulations, the siRNA within the targeted PSarFolA polyplex 
migrated in the gel towards the anode. This can be explained by the negatively charged 
folic acid head group of the PSarFolA shielding agent. 
Due to acetylation of the N-terminal PSar head group (Table 16), the zeta potential of 
formulations reduced from ~10 mV to ~0 mV. This reduction in surface charge is most 
probably responsible for the weaker migration in the gel. For the PEG shielded 
formulation, a low zeta potential of ~4 mV was measured. Compared to lower 
concentrations used in the first section, the incubation at high in vivo concentrations 
led to much higher zeta potential of the unshielded material (~33 mV). The zeta 
potential of the targeted PSarFolA formulation was reduced with increasing 
equivalents. For one equivalent, a neutral surface charge of ~1 mV was measured. 
 
Table 16 Particle size (z-average) and zeta potential of siRNA formulations determined with a DLS 
zetasizer. Formulations were prepared at 200 ng siRNA/µL concentration with DBCO-PSar119 (PSar), 
acetylated DBCO-PSar119Ac (PSarAc), DBCO-PEG5k (PEG), targeted DBCO-PSar110FolA 
(PSarFolA), or hepes buffered glucose (HBG) and diluted 1 : 8 with HGB before size measurements 
1073 siRNA formulation N/P z-average [nm] Mean PDI 
Mean Zeta 
Potentianl [mV] 
+ HBG buffer 10 161.2 ± 5.3 0.15 ± 0.01 33.3 ± 0.3 
+ 1 eq Psar 10 173.8 ± 1.1 0.13 ± 0.02 9.9 ± 0.2 
+ 1 eq PSarAc 10 188.6 ± 3.8 0.17 ± 0.01 0.1 ± 0.5 
+ 1 eq PEG 10 169.9 ± 1.4 0.15 ± 0.01 3.9 ± 0.2 
+ 0.25 eq PSarFolA 10 171.2 ± 3.9 0.22 ± 0.01 7.7 ± 0.3 
+ 0.5 eq PSarFolA 10 1013.8 ± 195.1 0.79 ± 0.09 5.8 ± 0.2 
+ 0.75 eq PSarFolA 10 4092.3 ± 384.4 0.66 ± 0.30 3.4 ± 0.1 
+ 1 eq PSarFolA 10 25.4 ± 0.7 0.20 ± 0.01 1.5 ± 0.4 
 
The sizes of all untargeted formulations are in the same range (~160 – 190 nm) and 
increased by ~70 % due to increasing concentrations to 200 ng siRNA/µL (Table 16). 
For the targeted PSarFolA formulation apparently, a rearrangement of polyplexes with 
increasing equivalents was observed, affecting their sizes measured by DLS. With 0.25 
eq of folic acid agent, the particles keep their original size. For increasing equivalents, 
aggregates were measured (high polydispersity). Similar findings were observed for 
PEG-shielded folic acid targeted lipo-polyplexes before [148] Surprisingly, with one 
equivalent of PSarFolA, nanoparticles became very small with a hydrodynamic 
diameter of ~25 nm and a small polydispersity was small again. This can only be 
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explained with PSarFolA induced instability following a complete rearrangement of 
particles into a uniform nano-sized population. 
The KB/eGFPLuc cell line was used for evaluating the folic acid receptor binding ability 
of formulations. This human cervix carcinoma cell line overexpresses the folic acid 
receptor and can therefore be targeted using the vitamin folic acid. KB cells were 
incubated with 1073 formulations spiked with 20 % Cy5-labled siRNA for 30 min on 
ice. The short incubation on ice prevented the active uptake of the polyplexes into the 
cells. After washing the cells with PBS, cells were analyzed by flow cytometry. The 
fluorescent dye intensity signal is assumed to correlate with the amount of polyplexes 
bound to the cell membrane (Fig. 53A). For the formulations further modified with 
acetylated PSar (PSarAc), only a very weak binding was found. The PSar 
functionalized with folic acid (PSarFolA) showed a high binding to KB cells. Unshielded 
1073 polyplexes were also able to bind to the membranes. This can be explained by 
the high positive charge of the particles. 
To further evaluate the binding specificity of PSarFolA formulations, the cellular folate 
receptors were blocked by using 1 mM free folate in the cell culture medium. Hereby, 
the binding of the folate-targeted formulations could be inhibited, indicating that the 
binding is receptor mediated. For receptor-mediated endocytosis, binding of a ligand 
is one requirement but not necessarily sufficient. Cells were incubated with the 
formulations for 45 min at 37 °C and washed with PBS and heparin to analyze if cellular 
internalization works with the folate-targeted polyplexes. The negatively charged 
heparin dissociates material from the cell membranes. Afterwards, cells were analyzed 
by flow cytometry and Cy5 intensity was quantified (Fig. 53B). In contrast to the strong 
binding of folic acid targeted nanoparticles (PSarFolA), the receptor-mediated uptake 
was found as very weak (MFI = 93.4 ± 3.1). It is even weaker than the acetylated 
PSarAc (MFI = 157.0 ± 13.1). 
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Fig. 53   A) Cellular binding of Cy5-labled (20 %) unshielded siRNA formulations with HBG buffer instead 
of agent or shielded with 1 eq (mol/mol) of DBCO-PSar119-Ac (PSarAc), DBCO-PSar110-FolA 
(PSarFolA) determined by flow cytometry. KB cells were incubated with the formulations for 30 min on 
ice and washed with PBS buffer. For the FolA receptor block cell culture medium with 1 mM free folate 
was used.   B) Cellular internalization of Cy5-labled (20 %) unshielded siRNA formulations or shielded 
with 1 eq (mol/mol) of DBCO-PSar119-Ac (PSarAc), DBCO-PSar110-FolA (PSarFolA) determined by flow 
cytometry. KB cells were incubated with the formulations for 45 min and washed with PBS buffer and 
heparin solution.   C) Lipopolyplex formulations with eGFP-targeted siRNA (siGFP) or control siRNA 
(siCtrl) were tested for eGFPLuc gene silencing in KB-eGFPLuc cells. Formulations with 1073 siRNA 
polyplex modified with increasing equivalents (eq mol/mol) of DBCO-PSar119-Ac, DBCO-PSar110-FolA 
or unshielded 1073 siRNA polyplex (addition of HBG buffer instead of agent). Cells were incubated with 
formulations for 45 min and washed; the luciferase readout was after 48 h.   D) Experiment performed 
like in C), but after incubation of the cells with formulations for 45 min, chloroquine was added and cells 
were washed after 4 h, the luciferase readout was after 48 h. The luciferase activity of siRNA-treated 
cells is presented related to HBG-treated cells. Data are presented as mean value (±SD) out of 
triplicates. All polyplexes were incubated for 40 min at N/P 10 with siRNA, followed by shielding agent 
for 4 h at room temperature. Formulations were prepared at a concentration of 200 ng siRNA/µL and 
diluted 1 : 8 with cell culture medium before incubation with the cells. Experiments were performed by 
Dr. Wei Zhang (Pharmaceutical Biotechnology, LMU). 
 
This finding shows that binding does not always lead to internalization. The vitamin 
folate that usually binds the folic acid receptor is a small molecule with less than 500 Da 
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weight. It is likely that the mechanism for the uptake of much bigger nanoparticles is 
different. It has often been reported that folic acid targeted cationic delivery systems 
can get internalized into cells [87, 148, 149]. The trafficking of folate via the folate 
receptors is thought to occur by independent of clathrin or caveolae (CLIC/GEEC 
endocytosis pathway) [150, 151]. For folate-targeted nanoparticles uptake pathways 
like caveolae- and clathrin-mediated endocytosis were found [152-154]. The size of 
the nanoparticle and the ligand density on their surface were reported to influence the 
cellular uptake pathway. The reasons for ~8 kDa poly(sarcosine) to prevent the 
internalization despite the presence of a folate ligand are not yet understood. 
Unshielded 1073 siRNA polyplexes again showed considerable uptake (MFI = 1041.7 
± 104.4). The cationic surface charge of the unshielded material can interact with cell 
membranes and promotes internalization. 
Finally, the siRNA delivery efficiency of formulations was tested by performing gene 
silencing experiments in KB/eGFPLuc cells stably expressing an eGFP-Luciferase 
fusion protein (Fig. 53C + D). As in several related experiments [148], incubation of 
cells with siRNA lipopolyplexes was restricted to a short period of only 45 min before 
removal of the nanoparticles, to emphasize receptor-mediated uptake processes. After 
further incubation for 48 hours, silencing of the eGFP-Luciferase fusion protein 
mediated by siRNA against eGFP (siGFP - gray bars) was quantified by a luciferase 
assay. After this 45 min short-time contact, neither the unshielded negative control nor 
the formulations modified with the negative control shield PSarAc and the targeted 
PSarFolA mediated gene silencing in KB cells (Fig. 53C). This finding can be explained 
by insufficient cellular uptake of the formulations. The unshielded siRNA lipopolyplexes 
showed no silencing activity despite notable uptake. The same finding was previously 
made for 454 siRNA nanoparticles which trigger efficient gene silencing only upon 48 h 
long-term incubation with cells [148]. For endosomal escape [62, 72, 120], a critical 
minimum amount of pH sensitive carriers needs to be internalized into endosomes to 
mediate the rupture of endosomal membranes. This threshold apparently was not 
reached with the 45 min incubations. In cell culture, however, this limitation of 
endosomal escape can be overcome by coincubation with the lysosomotropic agent 
chloroquine (Fig. 53D) [122-125]. Therefore, we transfected cells with the formulations 
again and added chloroquine after 45 min for 4 h. (Fig. 53D). For unshielded 1073 
formulations, this treatment led to gene silencing, demonstrated by a ~60 % reduction 
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of luciferase activity. Weakly shielded formulations (0.25 – 0.5 eq) showed some minor 
gene silencing efficiency, particles shielded with high equivalents did not mediate any 
silencing. Well shielded delivery systems are known to have reduced endosomal 
escape ability [92, 151-154]. Based on the luciferase levels of the analogous siCtrl 
polyplexes, we can exclude that the tested formulations mediate unspecific cell toxicity. 
In summary, 1073 siRNA nanoparticles functionalized with poly(sarcosine) and folic 
acid ligands attached to the surface of cells, but cannot be found to be internalized by 
KB cells. The transfection efficiency is limited because of a lack of internalization and 
endosomal escape. It also has to be kept in mind that 1073 contains the bioreducible 
disulfide building block (ssbb), which previously was found to delete gene silencing 
ability in KB cells by premature disulfide cleavage (see section 3.2, Fig. 43, compare 
991 with 992). In sum, further work (for example removal of ssbb unit) needs to be 
performed to combine nice in vivo shielding with functional receptor-targeted gene 
silencing. 
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3.4 Folate receptor-directed orthogonal click-functionalization of siRNA 
lipopolyplexes for tumor-targeted gene silencing in vivo 
 
3.4.1 Design and synthesis of an azide-bearing lipo-oligomer for click 
chemistry 
During the last years, our laboratory established a library of more than 1000 
polycationic structures, prepared by solid-supported synthesis (SPS), to serve as 
carriers for gene delivery [68, 82, 83, 119]. These structures are combinations of 
natural amino acids and artificial building blocks. A topological subclass of carriers, so 
called T-shapes, was found to be very potent for siRNA delivery. Typically, a T-shape 
structure consists of 4-6 repeats of a cationizable polyamino acid like succinoyl-
tetraethylene-pentamine (Stp) for complexation of nucleic acid and for endosomal 
buffering and a hydrophobic domain branching off the cationic backbone in the 
oligomer center. Usually two fatty acids [82, 83, 119] or cholanic acids are attached via 
branching lysines and are supposed to augment siRNA complexes by hydrophobic 
stabilization and endosomal membrane destabilization. Optionally, other stabilization 
motifs like tyrosine trimers or cysteines terminate the cationic backbone on both sides. 
The current work is based on the T-shape structure 991, which was published in 
Nanoscale 2016 [137]. Formation of stable siRNA polyplexes with sizes below 150 nm 
it is an ideal starting position for further modification. Furthermore, 991 is a potent 
oligomer for transfecting the folic acid receptor-positive KB cell line (Fig. 43), which 
was used for screening the efficiency of formulations. To improve the circulation and 
to equip the delivery system with targeting functionality, copper-free click chemistry 
was used to modify the surface of the nanoparticles. The high ring strain of a 
cyclooctyne derivate facilitates click reaction with an azide [138-140]. The reaction is 
orthogonal to all other functional domains of the oligomer, very efficient, and no 
byproducts are generated. The azido function was incorporated into the oligomer 
during standard Fmoc solid-supported synthesis via an azido lysine at the N-terminal 
end (Fig. 54, top). The free amino function at the N-terminus increases hydrophilicity 
of the microenvironment and can thereby increase the accessibility of the azide on the 
nanoparticle surface in aqueous solution. In previous work, this position has been 
shown to be well suitable for systems using other post-modifications [146, 148, 155]. 
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By mixing these azido-oligomers with siRNA, polyplexes will spontaneously assemble. 
Due to oligomer excess, part of azido carriers remain free in solution. Others are 
located in the core of the nanoparticle or on its surface. Azido functions on the surface 
of siRNA polyplexes serve as anchors for functionalization with shielding agents. 
DBCO was chosen as the azide’s reaction partner. It can be incorporated into the 
shielding agents via SPS by using DBCO acid. The use of SPS allows for changes to 
each unit of the shielding agent. Thereby we synthesized structures containing PEG of 
different lengths (24, 48 and 72 ethylene glycol repetitions), the targeting ligand folic 
acid (FolA), and one or two DBCO units in the final SPS assembly step (structures 
shown in Fig. 54, bottom). For the structures with two DBCO compounds, a 
bioreducible linker was added next to the final DBCO units. This linker is supposed to 
i) increase the distance of the two units for facilitating a crosslinking reaction with a 
second oligomer and ii) to enable the structures to faster disassemble in the reductive 
cellular compartments including the cytosol [133, 137]. One critical part of the synthesis 
of shielding agents is the cleavage of the structures from the resin, because DBCO is 
labile towards high concentrations of trifluoro acetic acid (TFA) [156]. For this reason 
only 5 % of TFA had to be used in the cleavage cocktail. 
   Results 
   114 
 
Fig. 54 Overview of chemical compounds. Top: schematic illustration of the sequence-defined oligomer 
1106 (azidolysine K(N3) bearing analog of the T-shape oligomer 991). Other units of the oligomers: Y: 
tyrosine, K: lysine, G: glycine, Stp: succinoyl-tetraethylene-pentamine, CholA: 5β-cholanic acid. The ID 
1106 is the database identification number. Bottom: structure of the shielding agents varying in PEG 
(poly ethylene glycol) length, modification of ss (succinoyl-cystamine) and amount of DBCO 
(dibenzocyclooctyne). The triangle (▲) indicates the starting point for SPS syntheses: 1106 at C-
terminal Y; folate-targeted compounds at C-terminal K; DBCO-PEG24 at PEG24 amino acid. DBCO-
PEG5k is commercially available. 
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Fig. 55 Reaction of azido-containing oligomer and DBCO-containing post-PEGylation agent. Oligomer 
1106 and 0.5 eq of DBCO-PEG24-FolA were mixed and incubated for 4 h. MALDI mass spectrometry 
of the single compounds (left) and the reaction mixture (right) was performed. Mass spectrometry was 
performed by Stephan Morys (PhD studies, Pharmaceutical Biotechnology, LMU). 
 
To show the integrity and reactivity of the structures, the cationic azido oligomer 1106 
was mixed with DBCO-PEG24-FolA, incubated for 4 h and mass spectrometry was 
performed. The mass of the conjugate could be detected (Fig. 55), which was the proof 
that both compounds are intact. 
 
3.4.2 Modification of siRNA polyplexes and biophysical characterization 
After confirming the successful click reaction of the two compounds in solution, the 
next step was to perform the reaction on the surface of particles formed with siRNA. 
For this purpose, the oligomer 1106 was incubated with siRNA for 40 min to form 
lipopolyplexes. The siRNA binding ability of oligomer 1106 was determined by 
measuring the electrophoretic mobility of siRNA in a 1 % agarose gel. Different N/P 
values depict the ratio of protonatable amines (N) of the oligomer 1106 to phosphates 
(P) of the siRNA. This N/P ratio does not present the charge ratio, as only a fraction of 
the protonatable amines is protonated at physiological pH. The oligomer showed 
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complete retention of siRNA in the pockets of the gel at N/P ≥ 6, demonstrating largely 
electroneutral 1106 siRNA complex formation (Fig. 57). 
  
Fig. 56 Electrophoretic mobility of 1106 siRNA polyplexes analyzed with an agarose gel shift assay at 
different N/P ratios. The left lane shows the running distance of free siRNA in HBG that is not complexed 
by a lipo-oligomer. 1 % agarose gel, 70 V, 60 min running time. 
 
An N/P ratio of 10 was used for all formulations to ensure complete complexation of 
siRNA. After siRNA complex formation, indicated amounts of click shielding agent were 
added to the lipopolyplex solution. The amount of added DBCO shielding agent is 
indicated as molar equivalents (eq) of agent related to the cationic oligomer (mol/mol). 
Interestingly, all formulations with longer PEG shields show mobility in the gel (Fig. 
57). Click reaction with the control shielding agent DBCO-PEG5k resulted in migration 
of the lipopolyplex in the unusual, opposite direction to the cathode of the gel 
electrophoresis (Fig. 57A). This is consistent with intact nanoparticles sufficiently 
shielded to migrate within the gel and an overall slightly positive net charge. Higher 
mobility is observed for higher equivalents of applied shielding agent, indicating a 
relation to the degree of surface modification of the polyplex. In contrast to all other 
shielding agents, DBCO-PEG5k has no negative terminal charge. This explains 
movement to the opposite direction. 
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Fig. 57 Electrophoretic mobility of 1106 siRNA polyplex formulations analyzed with an agarose gel shift 
assay.  A) Unshielded 1106 siRNA polyplex (HBG buffer instead of agents) and modified with increasing 
equivalents (eq mol/mol) of the control agents DBCO-PEG24 or DBCO-PEG5k.  B) Formulations with 
1106 siRNA polyplex modified with increasing equivalents (eq mol/mol) of DBCO-PEG24-FolA, DBCO-
PEG48-FolA or DBCO-PEG72-FolA  C) Formulations with 1106 siRNA polyplex modified with increasing 
equivalents (eq mol/mol) of DBCO2-ss2-PEG24-FolA, DBCO2-ss2-PEG48-FolA or DBCO2-ss2-PEG72-
FolA. All polyplexes were incubated for 40 min at N/P 10, followed by addition of a post-PEGylation 
agent for 4 h at room temperature. The left lane shows the running distance of free siRNA in HBG that 
is not complexed by a lipo-oligomer. 1 % agarose gel, 70 V, 60 min running time.  
 
The other click agents show no or slow mobility in the gel towards the anode, but by 
far not as strong as free siRNA (Fig. 57B + C). The mobility observed for nanoparticles 
with negatively charged folate-containing shielding agents showed an analog effect 
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observed for DBCO-PEG5k that the migration correlates with the degree of 
nanoparticle modification. To further evaluate the in vivo relevance of click agent 
mediated instability, the formulations were incubated in 88 % fetal bovine serum for 
24 h before agarose gel electrophoreses were performed (Fig. 58). 
 
Fig. 58 Electrophoretic mobility of 1106 siRNA polyplex formulations after incubation in serum analyzed 
with an agarose gel shift assay.  A) Unshielded 1106 siRNA polyplex (HBG) and modified with increasing 
equivalents (eq mol/mol) of the control agents DBCO-PEG24 or DBCO-PEG5k.  B) Formulations with 
1106 siRNA polyplex modified with increasing equivalents (eq mol/mol) of DBCO-PEG24-FolA, DBCO-
PEG48-FolA or DBCO-PEG72-FolA or  C) increasing equivalents (eq mol/mol) of DBCO2-ss2-PEG24-
FolA, DBCO2-ss2-PEG48-FolA or DBCO2-ss2-PEG72-FolA. All polyplexes were incubated for 40 min at 
N/P 10, followed by addition of a post-PEGylation agent for 4 h at room temperature. The formulations 
were mixed with FBS (fetal bovine serum) to a final concentration of 88 % and incubated for 24 h. The 
left lanes show the band of serum alone, the running distance of free siRNA in HBG and the running 
distance of free siRNA in serum. 1 % agarose gel, 70 V, 60 min running time. 
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Interestingly, the PEG length seems to be the most relevant parameter for stability in 
serum. Significant siRNA release from polyplexes was observed for 24 h long-term 
incubations of lipopolyplexes with higher equivalents of shielding agents. 
Nevertheless, all formulations seem to be quite stable, if less than 0.75 eq of click 
agents were used. 
 
Table 17 Particle size (z-average) and zeta potential of 1106 siRNA formulations determined with a DLS 
zetasizer. The 1106 siRNA polyplexes were prepared at N/P 10 and modified with the indicated agents. 
Formulations were incubated at in vivo conditions and diluted with HBG before the size measurement, 
followed by 10 mM NaCl for zeta measurement. 
1106 siRNA 
formulation 
eq 
agent 
z-average [nm] Mean PDI 
Mean Zeta 
Potential [mV] 
Unshielded - 188.3 ± 1.4 0.26 ± 0.01 34.5 ± 0.8 
     
DBCO-PEG24-FolA 
0.25 246.7 ± 47.0 0.24 ± 0.04 20.2 ± 1.1 
0.5 253.3 ± 2.5 0.24 ± 0.02 23.9 ± 0.4 
0.75 397.4 ± 9.1 0.30 ± 0.02 21.7 ± 0.7 
1 1437.3 ± 34.8 0.43 ± 0.16 15.9 ± 1.0 
     
DBCO-PEG48-FolA 
0.25 219.0 ± 14.9 0.24 ± 0.03 15.8 ± 0.7 
0.5 919.6 ± 168.4 0.26 ± 0.01 13.3 ± 0.7 
0.75 1598.0 ± 408.9 0.93 ± 0.09 11.9 ± 0.5 
1 345.7 ± 65.8 0.34 ± 0.10 9.5 ± 0.2 
     
DBCO-PEG72-FolA 
0.25 230.8 ± 6.0 0.36 ± 0.01 11.7 ± 0.8 
0.5 923.1 ± 266.3 0.40 ± 0.13 9.2 ± 0.3 
0.75 835.2 ± 114.2 0.64 ± 0.06 4.8 ± 1.7 
1 512.2 ± 59.9 0.50 ± 0.04 5.4 ± 0.4 
     
DBCO2-ss2-PEG24-FolA 
0.25 179.8 ± 0.4 0.22 ± 0.02 23.8 ± 0.9 
0.5 191.8 ± 1.3 0.25 ± 0.01 22.8 ± 0.4 
0.75 201.4 ± 2.2 0.24 ± 0.02 22.6 ± 0.5 
     
DBCO2-ss2-PEG48-FolA 
0.25 219.4 ± 2.4 0.36 ± 0.01 16.4 ± 0.8 
0.5 502.9 ± 97.8 0.30 ± 0.03 12.5 ± 0.6 
0.75 1606.0 ± 334.9 0.64 ± 0.32 10.5 ± 0.7 
     
DBCO2-ss2-PEG72-FolA 
0.25 218.9 ± 3.6 0.30 ± 0.03 12.2 ± 0.7 
0.5 854.6 ± 185.8 0.59 ± 0.16 10.2 ± 0.9 
0.75 4330.7 ± 1992.3 1.00 ± 0.01 2.9 ± 1.7 
     
DBCO-PEG24 
0.25 169.2 ± 1.7 0.21 ± 0.02 17.2 ± 2.0 
0.5 367.4 ± 8.0 0.31 ± 0.06 14.6 ± 0.5 
0.75 637.1 ± 25.9 0.34 ± 0.06 12.1 ± 0.6 
1 1048.6 ± 56.0 0.40 ± 0.26 11.5 ± 0.5 
     
DBCO-PEG5k 
0.25 170.9 ± 1.3 0.22 ± 0.02 6.9 ± 0.5 
0.5 165.4 ± 0.9 0.16 ± 0.02 4.1 ± 0.9 
0.75 194.0 ± 2.3 0.25 ± 0.01 3.8 ± 0.7 
1 168.5 ± 2.1 0.17 ± 0.02 2.3 ± 0.3 
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The size and shape of siRNA polyplexes were evaluated by dynamic light scattering 
(DLS) and transmission electron microscopy (TEM). The sizes of the unshielded, the 
DBCO-PEG5k shielded and the DBCO2-ss2-PEG24-FolA modified particles ranged 
around 200 nm and showed a low polydispersity for all tested equivalents (Table 17). 
The other FolA-containing formulations showed bigger sizes and aggregations for 
higher equivalents of click agents when measured with DLS. The formation of 
aggregates could not be confirmed by particle analysis with TEM (Fig. 59). Hence, we 
think that aggregates were rare and/or only loose and may disassemble. Since large 
particles strongly contribute to scatter light in DLS measurements, such measurements 
are very sensitive to even small fractions of aggregates. All particles visualized by TEM 
have a spherical shape and sizes range between 50 and 200 nm independent of the 
PEG agent they were modified with (Fig. 59). 
 
Fig. 59 TEM micrographs of formulations. Top: 1106 siRNA polyplex (alone); Middle: 1106 siRNA 
polyplex modified with DBCO agents with short PEG (control DBCO-PEG24, DBCO-PEG24-FolA and 
DBCO2-ss2-PEG24-FolA); Bottom: 1106 siRNA polyplex modified with DBCO agents with longer PEG 
(control DBCO-PEG5k, DBCO-PEG72-FolA and DBCO2-ss2-PEG72-FolA). Black scale bar indicates 
200 nm (left image of the set); gray scale bar indicates 100 nm (right image of the set). TEM grids were 
incubated with the sample solution (polyplexes incubated at N/P 10 as described and diluted with water 
to 25 ng siRNA/µL) for 2.5 minutes, washed with water and stained with uranyl acetate solution for 
5 seconds. TEM was performed by Susanne Kämpter (Faculty of Physics, LMU). 
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The degree of surface modification and shielding of a nanoparticle can also be 
evaluated by determining its zeta potential by measuring its mobility under electric field 
with light scattering. We can show that an unshielded particle’s zeta potential is 
reduced from 34.5 mV by more than 35 % using a PEG24 agent (Table 17). Longer 
PEG chains (PEG72 and PEG5k) reduced the zeta potential to less than 5 mV, 
indicating efficient shielding.  
 
3.4.3 Targeted delivery of siRNA formulations and gene silencing in vitro 
Gene silencing experiments were performed in KB/eGFPLuc cells stably expressing 
an eGFP-Luciferase fusion protein (Fig. 60) to evaluate the targeting and transfection 
efficiency of formulations. This human cervix carcinoma cell line overexpresses the 
folic acid receptor and can therefore be targeted using the vitamin folic acid. Silencing 
of the eGFP-Luciferase fusion protein mediated by siRNA against eGFP (siGFP - light 
bars) can be quantified by a standard luciferase assay. Well consistent with zeta 
potential data the untargeted siRNA polyplexes with short PEG24 (DBCO-PEG24) 
mediate moderate gene silencing, whereas the long 5 kDa PEG (DBCO-PEG5k) 
completely prevented gene silencing (Fig. 60A). For the targeted formulations the two 
main findings with this cell line were: i) folic acid ligands strongly increase the silencing 
efficiency and ii) longer PEG shields decrease silencing efficiency (Fig. 60B + C). 
Higher equivalents of a shielding and targeting agent enhanced the respective effects. 
The effects overlap for surface modifying compounds that combine longer PEG and 
folic acid targeting ligand. Altogether, PEG24 structures with folic acid (DBCO-PEG24-
FolA and DBCO2-ss2-PEG24-FolA) provided the highest efficiency. Both structures 
provided very efficient gene silencing (far better than without targeting) but still do not 
perfectly shielded the polyplex. We can exclude unspecific cell toxicity of formulations 
by evaluation of the luciferase levels of the analogous siCtrl polyplexes, which did not 
significantly change luciferase expression.  
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Fig. 60 Gene silencing of targeted formulations in KB cells. Lipopolyplex formulations with eGFP-
targeted siRNA (siGFP) or control siRNA (siCtrl) at N/P 10 were tested for eGFPLuc gene silencing in 
KB-eGFPLuc cells.   A) Unshielded 1106 siRNA polyplex (addition of HBG buffer only) and modified 
with increasing equivalents (eq mol/mol) of the control agents DBCO-PEG24 and DBCO-PEG5k. 
Formulations with 1106 siRNA polyplex modified with     B) increasing equivalents (eq mol/mol) of 
DBCO-PEG24-FolA, DBCO-PEG48-FolA or DBCO-PEG72-FolA   C) increasing equivalents (eq mol/mol) 
of DBCO2-ss2-PEG24-FolA, DBCO2-ss2-PEG48-FolA or DBCO2-ss2-PEG72-FolA. Cells were incubated 
for 45 min with formulations and washed. The luciferase activity of siRNA-treated cells was measured 
after 48 h. It is presented related to HBG-treated cells. Data are presented as mean value (±SD) out of 
triplicates. Transfections were performed by Dr. Wei Zhang (Pharmaceutical Biotechnology, LMU). 
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Fig. 61 Cellular association of siRNA formulations in KB cells acquired by confocal laser scanning 
microscopy. Cells were incubated with the 1106 formulations shielded with 0.5 eq (mol/mol) of DBCO-
PEG24-FolA, DBCO-PEG72-FolA, DBCO2-ss2-PEG24-FolA, DBCO2-ss2-PEG72-FolA and DBCO-
PEG5k for 30 min on ice and washed with PBS buffer. The FolA block samples were incubated with 100 
µM free folic acid solution prior to incubation with the formulation. Nuclei were stained with DAPI (blue) 
and actin cytoskeleton was stained with rhodamine phalloidin (green). siRNA was spiked with 20 %  
Cy5-labeled siRNA (red). Scale bars indicate 25 µm. Transfections were performed by Dr. Dian-Jang 
Lee (Pharmaceutical Biotechnology, LMU), confocal microscopy was performed by Miriam Höhn 
(Pharmaceutical Biotechnology, LMU). 
 
To analyze if the transfection result is folic acid receptor mediated, microscopy studies 
were performed with and without folic receptor block by free folate. Polyplexes shielded 
with short PEG24 and long PEG72 agents were used. KB cells were incubated with 
formulations formed with Cy5-labled siRNA for 30 min on ice (Fig. 61). The short 
incubation on ice prevents the active uptake of the polyplexes into the cell. After 
washing the cells, imaging was performed using confocal laser scanning microscopy. 
The particles modified with folic acid bearing agents showed strong colocalization with 
the membrane of the cells, except for DBCO2-ss2-PEG72-FolA, which had a much 
weaker binding to the cell surface. If the cells were pre-incubated with free folate before 
incubation with the formulations, no cellular association of the polyplexes was 
detected. Demonstrating that the binding of formulations could be blocked indicates a 
receptor-mediated association to the membrane. The negative control (DBCO-
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PEG5k), lacking the folic acid ligand, did not show any interaction with the cell 
membrane. 
To quantify the results, the cell binding was analyzed by flow cytometry. PEG48 agents 
with medium PEG length ware included this time. The data confirmed the microscopy 
results. All mono-DBCO agents bound sufficiently to KB cell membranes (Fig. 62A). 
For bis-DBCO structures, the binding ability decreased with increasing PEG length. It 
cannot be excluded that bioreducible spacer blocks incorporated into the bivalent 
DBCO structures might be responsible for the weak cell binding. Premature cleavage 
on the cell surface might cause dissociation from the cell. 
 
 
Fig. 62 Binding and uptake of folic acid containing polyplexes.      A) Cellular binding of Cy5-labled 
(20 %) siRNA 1106 formulations without (unshielded – HBG buffer instead of agent) or with shielding 
agents; 0.5 eq (mol/mol) of DBCO-PEG24-FolA, DBCO-PEG48-FolA, DBCO-PEG72-FolA, DBCO2-ss2-
PEG24-FolA, DBCO2-ss2-PEG48-FolA, DBCO2-ss2-PEG72-FolA and DBCO-PEG5k determined by flow 
cytometry. KB cells were incubated with the formulations for 30 min on ice and washed with PBS buffer. 
B) Cellular internalization of the same Cy5-labled (20 %) 1106 siRNA formulations determined by flow 
cytometry. KB cells were incubated with the formulations for 45 min and washed with PBS buffer and 
heparin solution. Experiments were performed by Dr. Wei Zhang (Pharmaceutical Biotechnology, LMU). 
 
To analyze if cellular internalization is the limiting factor for transfection efficiency, cells 
were incubated with the formulations for 45 min at 37 °C and washed with PBS and 
heparin. The negatively charged heparin dissociates material from the cell 
membranes. Afterwards, cells were analyzed by flow cytometry and Cy5 intensity was 
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quantified (Fig. 62B). In contrast to well cell binding of mono-DBCO functionalized folic 
acid targeted nanoparticles, the receptor-mediated uptake is strongly decreased for 
the longer PEG48 and PEG72 (mono- and bis-DBCO) agents. This finding shows that 
binding to the folate receptor does not necessarily lead to internalization. The 
trafficking of the vitamin folate via folate receptors is thought to occur by a nonclathrin, 
noncaveolar pathway also known as CLIC/GEEC endocytosis pathway [150, 151]. 
Previously caveolae were thought to be the involved in the uptake pathway [157]. It 
could be demonstrated that the uptake pathway indeed changes to caveolae-mediated 
endocytosis when glycosyl-phosphatidylinositol-anchored proteins (GPI-AP), like the 
folate receptor, were cross-linked on cell surfaces [150, 158]. For folate-targeted 
nanoparticles, uptake pathways like caveolae- and clathrin-mediated endocytosis were 
found [152-154]. The size of the nanoparticle and the ligand density on their surface 
were reported to influence the cellular uptake pathway. Both parameters also changed 
for longer PEG48 and PEG72 chains in targeted 1106 siRNA polyplexes. The resulting 
particle properties might be unfavorable for the polyplex internalization. 
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Fig. 63 Cell cycle analysis of siRNA formulations targeting Eg5 in L1210 cells. Folic acid-targeted 
lipopolyplex formulations with siRNA targeting the mitotic kinesin Eg5 were prepared at N/P 10 and 
tested on folic acid receptor-positive L1210 cells. The knockout of Eg5 is known to lead to an arrest in 
G2 phase. The cell cycle status of untreated cells was compared with cells treated with unshielded 1106 
siRNA polyplex (addition of HBG buffer instead of agent), with 1106 siRNA polyplexes modified with 
increasing equivalents (eq mol/mol) of the DBCO-PEG24-FolA and formulations with 0.5 eq of        
DBCO-PEG48-FolA, DBCO-PEG72-FolA or negative control DBCO-PEG5k. All cells were incubated 
with the formulations for 24 h. The phase of the cells was determined by propidium iodide staining 
followed by flow cytometry analysis. Statistics: unpaired t-test with Welch’s correction: * p<0.05, 
** p<0.005, *** p<0.001. Experiment was performed by Dr. Wei Zhang (Pharmaceutical Biotechnology, 
LMU). 
 
To test the system with another cell line and another siRNA, we established a cell cycle 
analysis assay with siRNA targeting the mitotic kinesin Eg5 (siEG5). A knockout of Eg5 
leads to an arrest in G2 phase. Afterwards, in case of tumor cells such as L1210, the 
cell usually undergoes apoptosis. The folic acid receptor overexpressing mouse 
lymphocytic leukemia suspension cell line L1210 was used for this assay. The analysis 
of the cell cycle revealed that the formulation with 0.5 eq DBCO-PEG24-FolA promoted 
the strongest arrest in G2 phase (Fig. 63). Analog to the previous silencing study, 
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longer PEG shields decrease the silencing efficiency. The well-shielded formulation 
with 0.5 eq DBCO-PEG5k did not change the cell cycle. 
 
3.4.4 Delivery of siRNA formulations in vivo 
Systemic delivery of siRNA is a major challenge, since siRNA is readily degraded by serum 
endonucleases and due to the small size also quickly eliminated by glomerular filtration 
with plasma half-life of less than ten minutes [159]. For systemic in vivo tumor targeting, 
formulations with 0.5 eq of click agent with short PEG24 and folic acid ligand were 
chosen, because they efficiently transfect folic acid receptor-positive cells (DBCO-
PEG24-FolA and DBCO2-ss2-PEG24-FolA). Those formulations also show high serum 
stability and suitable sizes [160]. In addition, the folic acid positive formulations with 
PEG72 (DBCO-PEG72-FolA and DBCO2-ss2-PEG72-FolA) were included, because 
longer PEG chains might be beneficial for the circulation in mice. The short-chained 
DBCO-PEG24 and the commercially available, long-chained DBCO-PEG5k served as 
untargeted control. The formulations were prepared with Cy7-labeled siRNA, injected 
into tumor-bearing NMRI-nude mice via tail-vein injection and the distribution of the 
dye was monitored at various time points for 1 day by NIR bioimaging in living mice 
(Fig. 64 and Fig. 65). The unshielded polyplex accumulated in the liver after 1 h. This 
finding could be observed for other T-shape structures in previous work as well [119, 
146]. No improvement in circulation was determined for the control DBCO-PEG24. 
Interestingly, the folic acid ligand strongly improved blood circulation, with the DBCO-
PEG24-FolA formulation displaying an expanded in vivo distribution after 3 hours. The 
bis-DBCO function (DBCO2-ss2-PEG24-FolA) further improved the residence in 
circulation. After 4 hours, signals could be detected in most parts of the body including 
the tumor site. The long-chained PEG control formulation with DBCO-PEG5k fulfilled 
our expectations and improved the distribution of the siRNA polyplexes. A strong signal 
was detected at superficial peripheral sites such as in paws of mice after 4 hours. In 
contrast to this untargeted formulation, the DBCO-PEG72-FolA formulation with long 
PEG and folic acid showed a weaker distribution and retention in the mouse’s body. 
When bis-DBCO was attached to the agent (DBCO2-ss2-PEG72-FolA), the formulation 
first retained in the lung and then slowly diffused out into the whole body. After 2 hours, 
this formulation is also widely distributed all over the body, however, in contrast to the 
other targeted formulations, it did barely reach the subcutaneous tumor site. 
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Fig. 64 Biodistribution of 1106 siRNA formulations at N/P 10 in L1210 tumor-bearing NMRI nude mice 
after i. v. administration. Biodistribution determined by NIR fluorescence bioimaging of 50 μg siRNA 
(50 % Cy7-labeled siRNA) with 1106 alone (unshielded – addition of HBG buffer instead of shielding 
agent), with 0.5 eq DBCO-PEG24, 0.5 eq DBCO-PEG5k, 0.5 eq DBCO-PEG24-FolA, 0.5 eq DBCO-
PEG72-FolA, 0.5 eq DBCO2-ss2-PEG24-FolA  and 0.5 eq DBCO2-ss2-PEG72-FolA. Experiments were 
performed with three animals per group for time points until 1 h, one animal per group for time points 
2 h and 3 h and two animals for the 4 h time point; a representative animal of each group is shown. See 
Fig. 65 for all animals. Animals are presented in lateral view to present the tumor sites. Green circles 
indicate the tumor site. Experiment was performed by Dr. Dian-Jang Lee (Pharmaceutical 
Biotechnology, LMU) and Sarah Kern (veterinary MD study, Pharmaceutical Biotechnology, LMU). 
 
In sum, the agent combining short PEG24, bis-DBCO and folic acid targeting ligand 
showed the best circulation in vivo and the longest retention at the tumor site.  
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Fig. 65 Overview of biodistribution of all animals injected with 1106 siRNA formulations at N/P 10 in 
L1210 tumor-bearing NMRI nude mice after i. v. administration. Biodistribution determined by NIR 
fluorescence bioimaging of 50 μg siRNA (50 % Cy7-labeled siRNA) Experiments were performed with 
three animals per group for time points until 1 h, one animal per group for time points 2 h and 3 h and 
two animals for time points 4 h and 24 h; Animals are presented in lateral view to present the tumor 
sites. Experiment was performed by Dr. Dian-Jang Lee (Pharmaceutical Biotechnology, LMU) and 
Sarah Kern (veterinary MD study, Pharmaceutical Biotechnology, LMU). 
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The influence of folic acid on improved biodistribution for short PEG agents, but 
decreased distribution for long PEG agents, was an unexpected finding. One 
explanation for the prolonged retention of targeted polyplexes in other tissues might 
be targeting of L1210 tumor cells disseminated from subcutaneous to systemic sites; 
L1210 tumors are known to rapidly metastasize to other parts of the body. In this 
experiment pathogenic enlargement in size of spleen was frequently noticed in tumor-
bearing animals. Bis-DBCO structures might have the ability to crosslink two lipo-
oligomers on the surface of polyplexes. Although previous experiments did not indicate 
an increased stability of formulations with structures with two attached DBCO units (at 
least in the absence of reducing agents), the bivalent attachment might be a possible 
explanation of their advantage, for example by reducing the risk of premature 
disassembly of the coat.  
The best performing candidate DBCO2-ss2-PEG24-FolA was then analyzed for gene 
silencing in vivo. 1106 polyplexes were prepared with active siEG5 or siCtrl (50 μg of 
siRNA) and 0.5 eq DBCO2-ss2-PEG24-FolA. As the untargeted delivery control, 1106 
polyplexes were prepared with siEG5 and 0.5 eq DBCO-PEG24. Five mice per group 
were prepared with L1210 tumor and the weight and the tumor size of the animals were 
monitored (Fig. 66). When tumors reached a size of 500 mm3, the formulations were 
administered via tail vain injection twice at daily interval. At 24 h after the second 
treatment, tumors were harvested, RNA was extracted and the EG5 mRNA levels were 
quantified by qRT-PCR (Fig. 67A). 
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Fig. 66 Body weight of mice after injection of L1210 tumor cells. The arrows indicate the time of the 
injection of 1106 formulations. 50 µg siRNA were injected per mouse twice with a delay of 24 h. 24 h 
after the second injection the mice were sacrificed and tumors were harvested. Day 0 indicates the day 
of tumor cell inoculation. Body weight of 5 animals per group is presented as mean ± SEM. Experiment 
was performed by Dr. Dian-Jang Lee (Pharmaceutical Biotechnology, LMU) and Sarah Kern (veterinary 
MD study, Pharmaceutical Biotechnology, LMU). 
 
Compared to untreated controls, the 1106 siEG5 DBCO2-ss2-PEG24-FolA induced a 
significant downregulation of EG5 mRNA expression by ~60 %. 1106 siCtrl DBCO2-
ss2-PEG24-FolA showed a weak, but not significant reduction of EG5 mRNA levels as 
compared to untreated tumors. Untargeted 1106 DBCO-PEG24 siEG5 polyplexes 
revealed negligible effects on EG5 mRNA levels, demonstrating the superiority of the 
folate-PEG agent with the bivalent attachment for delivery of the nanoparticles into the 
tumor. 
Systemic circulation of siRNA polyplexes might also cause potential side effects when 
they reach non-target tissues. Therefore, blood biochemistry examinations were 
carried out helping to realize the biocompatibility of the carriers (Fig. 67B).  
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Fig. 67 Tumor-targeted gene silencing efficiency of 1106 DBCO2-ss2-PEG24-FolA in L1210 tumor-
bearing mice. A) mRNA level of EG5 gene after twofold i.v. injection of 1106 siRNA polyplexes with 
DBCO2-ss2-PEG24-FolA with 50 μg of siEG5 or siCtrl, and DBCO-PEG24 with 50 μg of siEG5 at N/P 10. 
B) Clinical biochemistry parameters (ALT, AST, BUN and creatinine). Plasma was obtained from the 
treated animals 24 h after the second injection compared to untreated tumor-bearing mice. The in vivo 
gene silencing assay was performed by Dr. Dian-Jang Lee (Pharmaceutical Biotechnology, LMU). The 
blood biochemistry was measured in Small Animal Clinic (Faculty of Veterinary Medicine, LMU). 
 
Blood samples were collected 24 h after the treatments with siRNA formulations to 
determine four relevant clinical biochemistry parameters (creatinine, BUN, AST and 
ALT). The liver enzymes (ALT and AST) were slightly, but not significantly increased 
for the two formulations prepared with siEG5. High values for those parameters 
indicate liver damage or acute hepatitis. The parameters BUN and creatinine, which 
are related to renal function, did not show any difference as compared to untreated 
controls. The unobtrusive body weight of animals, presented in Fig. 66, indicated that 
the formulations were well-tolerated compared to untreated controls. 
In sum, the systemic delivery of a siRNA formulation functionalized with a targeted, 
bis-reactive DBCO agent into tumor tissue induced specific RNAi-mediated 
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degradation of EG5 mRNA of tumors. No significant side effects were recognized 
based on the body weight analysis and clinical chemistry of blood samples. 
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4 Discussion 
4.1 Twin disulfides as opportunity for improving stability and 
transfection efficiency 
The stability of a carrier system is one important requirement for efficient delivery of 
nucleic acids in vivo. Especially cationic carrier systems that complex nucleic acid via 
interelectrolytic forces often require additional moieties for stabilization [127, 146, 148]. 
For small nucleic acids like siRNA, that consist of only 21 bp, stability is a bigger issue 
than for large nucleic acids like pDNA with about 6000 bp. This can be explained by a 
smaller gain in entropy due to the exchange of less counter ions during polyplex 
formation [13, 161, 162]. Therefore stability is more critical for siRNA polyplexes than 
for polyplexes formed with pDNA. Fatty acids and tyrosine trimers for hydrophobic 
interactions and terminal cysteine residues for disulfide bridge formation have 
previously been used to stabilize polyplexes [82, 87, 119]. In this work, the CRC motif 
was integrated into sequence defined oligomers and examined for its ability to stabilize 
siRNA polyplexes. As CRC offers faster disulfide formation kinetics, higher stability of 
formed twin disulfides and orthogonal pairing in the presents of single cysteines [43], 
this motif offers the opportunities to serve as a new stability motif. 
The comparison of the CRC motif with single cysteines did indeed show improved 
stability of the resulting polyplexes. This was observed at different N/P ratios, in the 
presence of serum and under reducing conditions. Especially for PEGylated CRC-
polyplexes, a better siRNA binding ability was observed. PEG is known to reduce the 
binding ability of ethylenimine motifs in polyplexes [113, 114, 163]. An increase of 
stability does not necessarily result in better transfection efficiency. For pDNA 
polyplexes, the inclusion of twin disulfides triggers only minor overall differences. The 
influence of the motif on siRNA transfection efficiency ranges from total abolishment to 
significant increase. While T-shape lipo-oligomer and 3-arm structures lose efficiency 
for siRNA, PEGylated structures profit from the addition of twin disulfide motifs. Both 
findings can be explained by the stability profile of the corresponding polyplexes.          
T-shape and 3-arm structures already offer a suitable stability. Further increase of 
stability decreases transfection efficiency, most probably because the accessibility of 
the nucleic acid inside the cell is hindered. For PEGylated structures, the stability is 
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lower and seems to be a limiting factor. In this case, the increase of stability by the 
incorporation of the CRC motif increased the transfection efficiency. The lack of 
endosomal escape that was observed for PEGylated oligomers could be solved with 
INF7-modification in case of siRNA or chloroquine in case of pDNA. Since chloroquine 
is not suitable for in vivo applications, the incorporation of motifs increasing buffer 
capacity would be a valuable addition for pDNA delivery vehicles. This has been shown 
before. [62, 164]. The targeting effect of PEGylated polyplexes could be demonstrated 
by fluorescence microscopy. Particles could only be found in FR overexpressing KB 
cells when structures were equipped with folic acid. This result could be confirmed by 
flow cytometry. In addition to stability, the most important impact on biophysical 
properties can be observed in the size of the complexes. In general, cationic oligomers 
with cysteine residues and tyrosine trimers decreased in size by incorporation of CRC 
motifs. The influence of the decrease in size could nicely be observed in microscopy, 
where big particles were found for 3-arm oligomers. With the insertion of three CRC 
motifs small and equal distributed particles were found. In contrast, CRC incorporation 
into oleic acids-containing T-shape oligomers does not change the size of polyplexes. 
T-shape structures with hydrophobic stabilization are known to form uniform particles 
of small sizes even without cysteines [119, 137]. PEGylated structures with CRC form 
polyplexes with nucleic acid that are slightly bigger in size. For the polyplexes that 
decreased in size due to the incorporation of CRC, the zeta potential of particles 
increased. The influence on size and zeta potential of the particles might also be 
related to the protonated amino acid arginine that comes with the CRC motif. Twin 
disulfides might be a valuable tool to improve the stability and tune the size of cationic 
delivery systems to make them more suitable for different requirements. Improved 
serum stability and medium sizes (20 - 200 nm), big enough to minimize renal 
clearance and small enough to prevent capillary clogging, are important for in vivo 
studies. For oligoaminoethane-based oligomers, the most promising use for twin 
disulfides seems to be the enhancement of stability and transfection efficiency of PEG 
shielded, targeted structures. 
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4.2 Precise redox-sensitive cleavage sites for improved bioactivity of 
siRNA lipopolyplexes 
In the first chapter, some oligomers were found to form polyplexes that are highly stable 
but showed decreased transfection efficiency. The carrier systems presented in this 
chapter are based on lipo-oligomers that already form stable polyplexes with siRNA. 
Beside high stabilization, the hydrophobic domains in these formulations offer 
endosomal membrane destabilization. Although high stability of siRNA polyplexes is 
desirable in the extracellular space and for cellular uptake, intracellular disassembly is 
important for the cytosolic release of siRNA and RNA-induced silencing complex 
formation. To improve the release, bioreducible sequence-defined lipo-oligomers were 
synthesized by solid-phase assisted synthesis using the disulfide building block Fmoc-
succinoyl-cystamine for precise positioning of a disulfide unit between a lipophilic 
diacyl (bis-myristyl, bis-stearyl or bis-cholestanyl) domain and an ionizable 
oligocationic siRNA binding unit. The redox-triggered disassembly of lipopolyplexes 
could be demonstrated with gel shifts under reducing conditions. Whereas bioreducible 
structures showed a release of siRNA at intracellular concentrations of glutathione, the 
stable analogs did not respond. Major differences in membrane lytic activity could be 
observed for the different hydrophobic diacyl units used. Cholanic acid and stearic acid 
showed only moderate lytic activity. In contract, myristic acid revealed high lytic activity, 
especially at endosomal pH. Higher rates of membrane fusion events for dimyristyl 
lipids were reported in literature [136]. The pH sensitivity of the structures can be 
explained by the ionizable cationic backbone that is used for nucleic acid binding. With 
further protonation the interaction of structures with cell membrane increases. Only for 
bioreducible structures, the lytic activity could be abolished after incubation with 
glutathione at intracellular concentrations (10 mM). Consistent with glutathione-
triggered siRNA release and reduced lytic activity, the reducible siRNA polyplexes 
show lower cytotoxicity and higher gene silencing efficacy in Neuro2A and DU145 cells 
than their stable analogs. In case of HeLa cell - derived KB cells, these properties 
decreased gene silencing efficiency. High extracellular disulfide cleavage was actually 
previously reported for HeLa cells [108]. Disulfide cleavage occurring at the 
extracellular cell surface might be an explanation for this finding. Reduction of the lipo-
oligomer results in a short cationic strand and an uncharged lipid. The separated units 
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do not have amphiphilic character anymore, which can be responsible for 
endosomolytic activity but also enhanced cytotoxicity.  
In sum, those siRNA carriers offer increased gene silencing efficacy in certain cell lines 
by combining extracellular polyplex stability, siRNA release under cytosolic conditions, 
and a high lytic activity under endosomal conditions with low cytotoxicity. Nevertheless, 
for cell lines with exceptional redox environments, the redox-sensitivity of carriers can 
also be a disadvantage. 
4.3 Functionalized poly(sarcosine) as shielding agent for lipopolyplexes 
In the previous chapter, a new class of redox-sensitive lipo-oligomers was successfully 
established for siRNA delivery. Beside beneficial effects of lipid-based delivery 
systems such as enhanced nanoparticle stability and endosomal escape capability, 
the distribution in vivo is often limited to certain tissues such as liver, lung and spleen 
[146, 165, 166]. In previous studies, it has been shown that T-shape oligomers similar 
to the ones that were synthesized in this approach show the strongest retention in liver 
tissue [119, 146]. Those effects might be related to a high stickiness of unshielded 
particles, but it is also possible that particular serum proteins incorporate on 
nanoparticle surfaces and impair tissue specificity [166-169]. An efficient shielding 
should reduce both interactions and enables a better distribution in the body. For this 
reason, one of the best performing candidates from redox-sensitive lipo-oligomers was 
chosen and extended by a click-reactive azido-function, resulting in carrier 1073. After 
the formation of siRNA lipopolyplexes, the particle surface was further modified with 
the shielding agent poly(sarcosine). The shielding ability was demonstrated in several 
assays. Poly(sarcosine) shielded particles were able to migrate in agarose gels under 
electric field, whereas unshielded polyplexes were immobile. The property of particles 
to migrate in gel structures is beneficial. Particles which are well migrating through the 
extracellular matrix, for instance, can reach cells more easily. The surface charge of 
polyplexes was strongly decreased when particles were shielded. As a result, the 
unspecific interaction with cells and thereby also the uptake was decreased. The 
biodistribution in mice revealed that 8 kDa poly(sarcosine) can strongly expand the 
circulation of the siRNA lipopolyplexes. Signals in paws of animals could be observed 
even after 24 h. The circulation was similar with 5 kDa PEG. Unshielded polyplexes 
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showed a strong retention in the liver. This shows that a sufficient shielding prevents 
the delivery of particles to certain tissues and changes distribution. 
Besides the reduction of interactions with non-target tissue, a delivery system needs 
to be equipped with a ligand to target specific cells. In this approach folic acid was 
used. An interesting finding was the change in size of nanoparticles when folic acid 
was involved. For small degrees of particle modification with PSarFolA, the size of 
polyplexes did not significantly change compared to unshielded polyplexes (~170 nm). 
For higher amounts, aggregates were measured in DLS. Similar findings were 
observed for folic acid targeted lipo-polyplexes before in our lab by Katharina Müller et 
al. [148]. In this work, aggregation could be avoided by incorporation of tetra-
glutamylated folic acid into the shielding agent. For further increase of PSarFolA to 
equimolar amounts, small defined particles of ~25 nm could be measured. The 
“reassembly process” towards small siRNA polyplexes is hard to explain. The influence 
of folic acid plays a major role in this process, since it was not observed for untargeted 
poly(sarcosine) shielded particles. 
The specific binding of poly(sarcosine) folic acid functionalized polyplexes to FR-
positive KB cell membranes could be demonstrated. Despite, the uptake into the cell 
did not work properly. The reasons for this clear effect are not fully understood. For 
both assays, 1073 polyplexes were functionalized with equimolar amounts of PSarFolA 
to form defined ~25 nm particles. One possible explanation for insufficient uptake is 
the choice of a bioreducible carrier (1073) which was found to be unsuitable for gene 
silencing in KB cells, most likely due to premature lipopolyplex disassembly. Cell 
biology aspects might be the basis for other explanations. In contrast to nonclathrin, 
noncaveolar endocytosis pathways reported for the vitamin folic acid [150, 151], for 
folate-targeted nanoparticles, caveolae- and clathrin-mediated endocytosis pathways 
were found via folate receptors [152-154]. The size of the nanoparticle and the ligand 
density on their surface were reported to influence the cellular uptake pathway. The 
well shielding ~8 kDa poly(sarcosine) seems to prevent the internalization despite the 
presence of a folate ligand. The strong shielding might prevent any further interaction 
of the lipo-cationic core with the cell membrane. The lack of gene silencing activity is 
a consequence of insufficient uptake. It should also be considered that 1073 contains 
the bioreducible disulfide building block (ssbb), which previously was found to delete 
gene silencing ability in KB cells by premature disulfide cleavage (see section 3.2, Fig. 
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43, compare 991 with 992). In conclusion, further work for example removal of the ssbb 
unit or fine-tuning of the shielding agent (see chapter 4.4) needs to be performed to 
combine in vivo shielding with functional receptor-targeted gene silencing. 
 
4.4 Folate receptor-directed orthogonal click-functionalization of siRNA 
lipopolyplexes for tumor-targeted gene silencing in vivo 
The previous chapter indicated that strong shielding might also prevent the uptake via 
certain receptor-mediated pathways. Therefore, the focus of this chapter aims at the 
optimization of a DBCO functionalized PEG shielding agent with folic acid as a ligand. 
Solid phase synthesis was used to obtain sequence defined shielding and targeting 
agents where every unit can precisely be adapted. Mono- and bis-DBCO agents, 
varying in PEG length were analyzed to serve as surface modifying compounds for 
siRNA lipopolyplexes. The lipo-oligomer 991 was chosen for forming core polyplexes 
that are active in folic receptor-positive KB cells (see chapter 3.2) and extended by a 
click-reactive azido-function to yield oligomer 1106. The shielding ability of agents 
increased with increasing equivalents, but the polyplex stability in serum decreased. 
0.5 equivalents of an agent were found to be a suitable compromise. Structural details 
of the agents had a stronger impact on the polyplex properties than the degree of 
modification. Zeta potential strongly decreased with increasing PEG length. A notable 
disadvantage of long PEG chains was the formation of aggregates as detectable with 
DLS. Although those aggregates could not be observed in TEM images, it makes those 
formulations less reliable. Similar findings were observed for folic acid targeted lipo-
polyplexes before [148]. The issues described for DLS size measurements with folic 
acid modified polyplexes have some things in common. Polyplexes with a surface 
charge higher than ~15 mV do not aggregate with folic acid. The hydrophobic character 
of folic acid might explain the clustering of polyplexes by PEG agents. After the reaction 
with the surface of polyplexes, this might result in polyplex accumulation. In case of 
weaker shielding, the positive residual charge of polyplexes might repulse and 
separate particles. When the surface charge is reduced, due to high equivalents of 
agents, or longer PEG chains, the particles might remain clustered together. In other 
work, the aggregation could be prevented by the incorporation of tetra-glutamylated 
folic acid into the shielding agent [148]. Due to the glutamates, an inversion towards 
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negative surface charge could be observed. However, in vivo stability was found to 
limit the formulations biodistribution. 
For mono-DBCO structures, the binding to folic acid receptor (FR) positive KB cells 
was not influenced by the length of PEG. For bis-DBCO structures, the binding ability 
decreased with increasing PEG length. It cannot be excluded that bioreducible spacer 
blocks incorporated into the bivalent DBCO structures might be responsible for the 
weak binding, due to premature cleavage on the cell surface. More critically, only 
polyplexes with short PEG chains were internalized into cells, irrespective of the 
presence/absence of bioreducible linkages. In the previous chapter, we could also 
observe that well shielding poly(sarcosine) folic acid targeted polyplexes bind to KB 
cells, but cannot get internalized (see chapter 4.3). The reasons for insufficient 
internalization into cells are not yet understood. The trafficking of the vitamin folate via 
folate receptors is thought to occur by a non nonclathrin, noncaveolar pathway also 
known as CLIC/GEEC endocytosis pathway [150, 151]. Previously caveolae were 
thought to be involved in the uptake pathway [157]. It could be demonstrated that the 
uptake pathway indeed changes to caveolae-mediated endocytosis when glycosyl-
phosphatidylinositol-anchored proteins (GPI-AP), like the folate-receptor, were cross-
linked on cell surfaces [150, 158]. For folate targeted nanoparticles, uptake pathways 
like caveolae- and clathrin-mediated endocytosis were found [152-154]. The size of 
the nanoparticle and the ligand-density on their surface were reported to influence the 
cellular uptake pathway. Bigger size and higher density of folate on the particle surface 
was reported to shift the internalization pathway from caveolae- to clathrin-mediated 
endocytosis. [152-154]. Both parameters did also change for longer PEG48 and PEG72 
chains in targeted 1106 siRNA polyplexes. Due to more spacious PEG agents, the 
density of the ligands on the surface decreases. The stability of the system decreases 
and the sizes are not reliable (aggregates could be measured in DLS) with longer PEG 
chains. The resulting particle properties seem to be unfavorable for the polyplex 
internalization. Furthermore, shorter PEG agents decrease the distance of the particle 
surface to the lipo-cationic core, resulting in a higher zeta potential. Although cationic 
charges might facilitate additional contacts with the negatively charged cell surface 
(often sugar polymers in membrane proteins like HSPG [170] or syndecan [171]), the 
remaining positive surface charge alone cannot be the explanation for better 
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internalization. Neutral and negatively charged folate-targeted systems are also known 
to be internalized via folate receptors [148, 172]. 
Consistent with the uptake data, the targeted polyplexes with short PEG24 revealed 
much higher gene silencing in KB cells then their long PEG analogs. For L1210 FR-
positive murine leukemic cells, targeted siEG5 formulations with short PEG24 sequence 
were also superior in inducing cell cycle arrest in G2 stage. The folic acid ligand plays 
a crucial role for an efficient gene delivery. Compared to unshielded and partly shielded 
polyplexes without ligand, folic acid targeted polyplexes showed much higher silencing 
efficiency. This influence became even more obvious in biodistribution studies in mice. 
Targeted structures with short PEG24 chain showed strong retention at the tumor site, 
whereas the untargeted analog quickly accumulates in the liver. The advantage of two 
DBCO functions in one shielding agent became clear in biodistribution studies as well. 
Due to crosslinking ability, the stability of polyplexes might be increased, resulting in 
longer circulation and tumor retention. An interesting observation was the longer 
systemic retention of folate-targeted formulations in various tissues different from the 
tumor. In other experiments, we observed L1210 tumor metastases in spleen and liver 
two weeks after subcutaneous injection of leukemia cells into mice. Metastases might 
be a reasonable explanation for the retention of targeted polyplexes at different tumor 
cell-containing parts of the body. For longer PEG chains, instability and quick renal 
clearance of siRNA were observed. With bis-DBCO, this disadvantageous phenomena 
could also be reduced. 
Comparing all experiments, the siRNA polyplex formation with 0.5 equivalents of bis-
DBCO with short PEG24 and folic acid was overall best-performing. This formulation 
has a suitable size of <200 nm by DLS and TEM, high polyplex stability in serum, 
sufficient binding, uptake and transfection efficiency and the best biodistribution and 
tumor retention of all tested formulations. This formulation was then tested for gene 
silencing in vivo and showed ~60 % mRNA knock-down in subcutaneous FR-positive 
leukemic tumors of mice. No significant side effects were recognized based on the 
body weight analysis and clinical chemistry of blood samples. 
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5 Summary 
The therapy with nucleic acids like pDNA or siRNA is a field of major importance and 
continually growing interest. Live threatening, severe diseases including cancer obtain 
a new chance for treatment by the use of gene therapy. Efficient delivery of nucleic 
acids is still a major challenge. There are a lot of requirements for a carrier to work as 
a gene delivery system: A suitable size, big enough to prevent rapid renal elimination 
but not too big to block fine capillaries; low unspecific interactions with blood 
components and non-target cells but high affinity to target cells; high stability outside 
the cell, efficient uptake, an escape mechanism from the endosome and facilitated 
disassembly inside the cytoplasm. The recent development of a solid-phase synthesis 
platform for the assembly of sequence-defined oligo(ethanamino)amides enables 
quick and easy synthesis of cationic oligomers for complexing nucleic acids. Beside 
specialized cationic building blocks, all natural amino acids, and further units can be 
incorporated to customize those delivery systems. The modular synthesis of gene 
delivery vehicles is an effective way to precisely optimize the function of carriers. In 
this thesis, two strategies were tested to enrich the library of oligocationic carriers by 
new redox-sensitive structures. Further, delivery systems were equipped with shielding 
and targeting domains and tested in animal studies. 
The first part reveals that the incorporation of a twin disulfide forming CRC motif into 
various types of sequence-defined oligoamino acid based pDNA and siRNA carriers 
improves the stability of the resulting polyplexes. This was observed in the presence 
of serum and under reducing conditions. This increase of stability does not necessarily 
result in better transfection efficiency. For pDNA polyplexes, the inclusion of twin 
disulfides triggers only minor overall differences. The influence of the motif on siRNA 
transfection efficiency ranges from total abolishment to significant increase. While         
T-shape lipo-oligomer and 3-arm structures lose efficiency for siRNA, PEGylated 
structures profit from the addition of twin disulfide motifs. In addition to stability, the 
most important impact on biophysical properties can be observed in the size of the 
complexes. In general, cationic oligomers with cysteine residues and tyrosine trimers 
decreased in size by incorporation of CRC motifs. In contrast, CRC incorporation into 
oleic acids- or PEG-containing oligomers leads to an increase in size. Twin disulfides 
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might be a valuable tool to improve the stability and tune the size of cationic delivery 
systems to make them more suitable for different requirements. 
In the second part, we presented bioreducible lipo-oligomers as siRNA carriers. In 
certain cell lines, the redox-sensitivity of those carriers strongly increased gene 
silencing efficacy by combining extracellular polyplex stability with siRNA release 
under cytosolic conditions, and a high lytic activity under endosomal conditions with 
low cytotoxicity. These apparently contradictory functional characteristics were 
programmed into the carriers by the introduction of a bioreducible disulfide bond 
between the cationic backbone and the hydrophobic domain. Precise positioning was 
enabled by a Fmoc-protected cystamine building block compatible with solid phase-
assisted synthesis. The use of redox-sensitive carriers should be evaluated separately 
for each cell line, since reductive cleavage conditions may differ in cells with 
exceptional redox environment. 
In the third part, the redox-sensitive lipo-oligomer 992 was extended by a click-reactive 
azido-function, resulting in carrier 1073. After the formation of siRNA lipopolyplexes, 
the particle surface was further modified with the shielding agent poly(sarcosine). 
Poly(sarcosine) shielded particles were able to migrate in agarose gels under electric 
field, whereas unshielded polyplexes were immobile. The surface charge of polyplexes 
was strongly decreased when particles were shielded. As a result, the unspecific 
interaction with cells and thereby also the uptake was decreased. The biodistribution 
in mice revealed that 8 kDa poly(sarcosine) can strongly expand the circulation of the 
siRNA lipopolyplexes. Signals in paws of animals could be observed even after 24 h. 
The circulation was similar with 5 kDa PEG. Unshielded polyplexes showed a strong 
retention in the liver. Folic acid modified poly(sarcosine) (PSarFolA) was then used for 
targeting the folate receptor (FR) positive cells. An interesting finding was the change 
in size of nanoparticles. For small degrees of particle modification with PSarFolA, the 
size of polyplexes did not significantly change compared to unshielded polyplexes 
(~170 nm). Increasing amounts resulted in aggregates (determined by DLS) and 
further increase to equimolar amounts of PSarFolA and 1073 led to small defined 
particles of ~25 nm. The specific binding of PSarFolA functionalized polyplexes to FR-
positive KB cells could be demonstrated, but no uptake into cells was observed. As a 
consequence and probably because of the redox-sensitive carrier 1073, which is 
unfavorable for KB cells, the targeted system did not mediate any gene silencing. 
   Summary 
   144 
In the fourth part, the lipo-oligomer 991 was extended by a click-reactive azido-function 
to yield oligomer 1106. siRNA polyplexes with non-reducible oligomers showed 
favorable gene silencing activity in folic receptor-positive KB cells. Polyplexes formed 
with 1106 were then modified with a DBCO functionalized PEG shielding agent with 
folic acid as a ligand. For precise optimization of the agents, solid phase synthesis was 
used. Different defined shielding and targeting agents with mono- and bis-DBCO and 
varying PEG length were synthesized and tested. We could show that the bivalent 
DBCO structure with short PEG24 sequence was superior in terms of particle formation, 
serum stability, receptor targeting, cellular uptake and gene silencing ability. 
Biodistribution assays with subcutaneous FR-positive L1210 tumor-bearing mice 
revealed the longest retention at the tumor site. The formulation was then tested for 
gene silencing in vivo and showed ~60 % mRNA knockdown. No significant side 
effects were recognized based on the body weight analysis and clinical chemistry of 
blood samples. 
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6 Appendix 
6.1 Abbreviations 
AB5  Proteinic toxin complex containing 1 subunit A and 5 subunits B  
Ac2O   Acetic anhydride  
bp  Base pair 
bPEIS  Branched bioreducible polyethylenimine sulfide 
Boc   tert-Butoxycarbonyl protecting group  
BODIPY Boron-dipyrromethene 
CholA  5β-Cholanic acid 
DBCO Dibenzocyclooctyne group 
DCM   Dichloromethane  
DCVC  Dry column vacuum chromatography  
DETA  Diethylene triamine 
DIPEA  N,N-Diisopropylethylamine  
DLS  Dynamic light scattering 
DMEM  Dulbecco’s modified Eagle’s medium  
DMF   N,N-Dimethylformamide  
DNA   Desoxyribonucleic acid  
DSP  Dithiodipropionic acid di(N-succinimidyl ester) 
dsRNA  Double-stranded RNA  
EDA  Ethylene diamine 
EDTA  Ethylendiaminetetraacetic acid  
EGFP  Enhanced green fluorescent protein 
EHCO  N-(1-aminoethyl) iminobis[N-(oleoyl- cysteinyl-histidinyl-1-aminoethyl) 
Propionamide] 
ER  Endoplasmatic reticulum 
ERAD  Endoplasmatic reticulum-associated degradation 
EtBr   Ethidium bromide  
FBS   Fetal bovine serum  
FCS  Fluorescence correlation spectroscopy 
Fmoc   Fluorenylmethoxycarbonyl protecting group  
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FolA   Folic acid  
FR   Folate receptor  
GFP  Green fluorescent protein 
GSH   Glutathione 
Gtt  Glutaroyl triethylene tetramine 
HBG   Hepes-buffered glucose  
HBTU  2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium 
hexafluorophosphate  
HDO  Oligoethylenimine with 1,6-hexandiol diacrylate 
HEPES  N-(2-hydroxethyl) piperazine-N‘-(2-ethansulfonic acid)  
HIV-1  Human immunodeficiency virus 1 
HMW   High molecular weight  
HOBt   1-Hydroxybenzotriazole  
INF7  An endosomolytic influenza virus derived peptide  
ivDde  1-(4,4-dimethyl-2,6-dioxocyclohex-1-ylidene)-3-methylbutyl protecting 
group  
kDa  Kilodalton 
LMW   Low molecular weight  
LPEI   Linear polyethylenimine  
MeCN  Acetonitrile  
mM  Millimolar 
mRNA  Messenger RNA 
MTBE  Methyl tert-butyl ether  
MTT  3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide  
mV  Millivolt 
MWCO Molecular weight cut-off  
MyrA   Myristic acid 
N/P   Nitrogen to phosphates ratio  
NEM   N-ethylmaleimide 
NHS   N-Hydroxysuccinimide 
nm  Nanometer 
NMP   N-Methyl-2-pyrrolidone  
NMR   Nuclear magnetic resonance  
OEI   Oligoethylenimine 
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OleA  Oleic acid 
PAA   Polyamino acid  
PAEI  Poly(amido ethylenimine) 
pCMVLuc  Plasmid encoding for firefly luciferase under the control of the 
cytomegalie virus (CMV) promoter  
PDI   Polydispersity index  
pDNA  Plasmid DNA  
PEG   Polyethylene glycol  
PEI   Polyethylenimine 
PEIS   Bioreducible polyethylenimine sulfide 
PIC  Polyion complex 
pKa  -log10 Ka (acid dissociation constant) 
PyBOP  Benzotriazol-1-yloxy-tripyrrolidinophosphonium hexafluorophosphate  
RISC  RNA-induced silencing complex 
RLU   Relative light units  
RNA   Ribonucleic acid  
RP-HPLC  Reversed-phase high-performance liquid chromatography  
RPC  Reducible polycation 
RT   Room temperature  
SEC   Size-exclusion chromatography  
siRNA  Small interfering RNA 
SPAAC  Strain-promoted alkyne-azide cycloaddition  
Sph   Succinoyl-pentaethylene hexamine  
SPS   Solid-phase synthesis  
SteA  Stearic acid 
Stp   Succinoyl-tetraethylene pentamine  
SV40  Simian virus 40 
TAT  Trans-Activator of Transcription 
TBE   Tris-boric acid-EDTA buffer  
TEPA  Tetraethylene pentamine  
TETA   Triethylene tetramine  
TFA   Trifluoroacetic acid  
THF   Tetrahydrofuran  
TIS   Triisopropylsilane 
   Appendix 
   148 
6.2 Summary of SPS derived oligomers 
Table 18 Summary of SPS derived oligomers 
Oligomer 
ID 
Topology Sequence (C→N) 
Proton. 
Amines 
Chapter 
49 T-Shape C-Stp2-K-ε[K-α,ε(OleA)2]αStp2-C 13 3.1 
386 3-arm C-Stp3-K-ε[-Stp3-C]αStp3-C 29 3.1 
413 T-Shape C-Stp2-K-ε[K-α,ε(NH2)2]αStp2-C 13 3.1 
454 T-Shape C-Y3-Stp2-K-ε[K-α,ε(OleA)2]αStp2-Y3-C 13 3.1 
464 T-Shape C-Y3-Stp2-K-ε[K-α,ε(Y3)2]αStp2-Y3-C 13 3.1 
465 T-Shape C-Y3-Stp2-K-ε[K-α,ε(NH2)2]αStp2-Y3-C 13 3.1 
468 T-Shape C-Stp2-K-ε[K-α,ε(Y3)2]αStp2-C 13 3.1 
591 T-Shape CRC-Stp2-K-ε[K-α,ε(NH2)2]αStp2-CRC 15 3.1 
592 T-Shape CRC-Stp2-K-ε[K-α,ε(OleA)2]αStp2-CRC 15 3.1 
593 T-Shape CRC-Stp2-K-ε[K-α,ε(Y3)2]αStp2-CRC 15 3.1 
594 T-Shape CRC-Y3-Stp2-K-ε[K-α,ε(NH2)2]αStp2-Y3-CRC 15 3.1 
595 T-Shape CRC-Y3-Stp2-K-ε[K-α,ε(OleA)2]αStp2-Y3-CRC 15 3.1 
596 T-Shape CRC-Y3-Stp2-K-ε[K-α,ε(Y3)2]αStp2-Y3-CRC 15 3.1 
652 3-arm CRC-Stp3-K-ε[-Stp3-C]αStp3-C 30 3.1 
653 3-arm C-Stp3-K-ε[-Stp3-CRC]αStp3-CRC 31 3.1 
654 3-arm CRC-Stp3-K-ε[-Stp3-CRC]αStp3-CRC 32 3.1 
736 PEG 2-arm K-ε[-PEG24-SucA]α K-ε[-Stp4-C]αStp4-C 26 3.1 
737 PEG 2-arm K-ε[-PEG24-FolA]α K-ε[-Stp4-C]αStp4-C 26 3.1 
738 PEG 2-arm K-ε[-PEG24-SucA]α K-ε[-Stp4-CRC]αStp4-CRC 28 3.1 
739 PEG 2-arm K-ε[-PEG24- FolA]α K-ε[-Stp4-CRC]αStp4-CRC 28 3.1 
740 - W-Stp2-ssbb-L3-W 7 3.2 
782 U-shape K-αK-α,ε[Stp3-ssbb-(CholA)2]2 19 3.2 
783 U-shape K-αK-α,ε[Stp3-(CholA)2]2 19 3.2 
871 i-Shape Stp4-H6-K-α,ε(CholA) 12 3.2 
969 i-Shape Stp4-H6-ssbb-K-α,ε(CholA)2 12 3.2 
989 T-Shape Y3-Stp2-K-ε[G-K-α,ε(SteA)2]αStp2-Y3 13 3.2 
990  T-Shape Y3-Stp2-K-ε[G-ssbb-K-α,ε(SteA)2]αStp2-Y3 13 3.2 
991 T-Shape Y3-Stp2-K-ε[G-K-α,ε(CholA)2]αStp2-Y3 13 3.2 
992 T-Shape Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3 13 3.2, 3.3 
1073 T-Shape Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3-K-ε(N3) 13 3.3 
1081 T-Shape Y3-Stp2-K-ε[G-K-α,ε(MyrA)2]αStp2-Y3 13 3.2 
1082 T-Shape Y3-Stp2-K-ε[G-ssbb-K-α,ε(MyrA)2]αStp2-Y3 13 3.2 
1086 T-Shape K-ε(N3)-Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3-K-ε(N3) 13 3.3 
1106 T-Shape Y3-Stp2-K-ε[G-K-α,ε(CholA)2]αStp2-Y3-K-ε(N3) 13 3.4 
1107 T-Shape Y3-Stp2-K-ε[G-K-α,ε(OleA)2]αStp2-Y3 13 3.2 
1108 T-Shape Y3-Stp2-K-ε[G-ssbb-K-α,ε(OleA)2]αStp2-Y3 13 3.2 
 
6.3 Summary of SPS derived shielding agents 
Table 19 Summary of SPS derived shielding agents 
ID Name Sequence (C→N) Chapter 
1138 DBCO-PEG24 PEG24-DBCO 3.4 
1139 DBCO-PEG24-FolA K-ε(PEG24-DBCO)-FolA 3.4 
1140 DBCO-PEG48-FolA K-ε[(PEG24)2-DBCO]-FolA 3.4 
1141 DBCO-PEG72-FolA K-ε[(PEG24)3-DBCO]-FolA 3.4 
1145 DBCO2-ss2-PEG24-FolA K-ε[PEG24-K-α,ε(ssbb-DBCO)2]-FolA 3.4 
1146 DBCO2-ss2-PEG48-FolA K-ε[(PEG24)2-K-α,ε(ssbb-DBCO)2]-FolA 3.4 
1147 DBCO2-ss2-PEG72-FolA K-ε[(PEG24)3-K-α,ε(ssbb-DBCO)2]-FolA 3.4 
   Appendix 
   149 
6.4 Analytical Data 
6.4.1 1H NMR spectrum of disulfide-linker building block(ssbb) 
 
 
1-(9H-fluoren-9-yl)-3,12-dioxo-2-oxa-7,8-dithia-4,11-diazapentadecan-15-oic acid 
(ssbb)  1H NMR (500 MHz, Methanol-d4) δ (ppm)  7.81 (d, J = 7.5 Hz, Ha, 2H), 7.67 
(d, J = 7.4 Hz, Hb, 2H), 7.41 (t, J = 7.4 Hz, Hc,  2H), 7.33 (t, J = 7.4 Hz, Hd, 2H), 4.38 
(d, J = 6.9 Hz, He, 2H), 4.22 (t, J = 6.8 Hz, Hf, 1H), 3.49 (t, J = 6.7 Hz, Hg, 2H), 3.43 
(t, J = 6.7 Hz, Hh, 2H), 2.76-2.87 (m, Hi, 4H), 2.60 (t, J = 6.6 Hz, Hj, 2H), 2.48 (t, J = 
6.8 Hz, Hk, 2H).  
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6.4.2 1H NMR spectra of oligomers 
 
49: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.7-0.8 (s, 6 H, -CH3 oleic acid), 
1.0-2.25 (m, 68 H, βγδH lysine, -CH2- oleic acid), 2.4-2.6 (m, 16 H, -CO-CH2-CH2-
CO-), 2.8-3.1 (m, 8 H, εH lysine and cysteine), 3.15-3.6 (m, 64 H, -CH2- Tp), 4.0-4.5 
(m, 4 H, αH amino acids), 5.15-5.3 (m, 4 H, -CH- oleic acid). 
386: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.15-2.0 (m, 6 H, βγδH lysine), 
2.35-2.65 (m, 36 H, -CO-CH2-CH2-CO-), 2.8-3.1 (m, 8 H, εH lysine and cysteine), 
3.11-3.3 (m, 36 H, -CH2- Tp), 3.32-3.67 (m, 108 H, -CH2- Tp), 4.09-4.4 (m, 4 H, αH 
amino acids). 
413: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.1-1.9 (m, 12 H, βγδH lysine), 
2.4-2.7 (m, 16 H, -CO-CH2-CH2-CO-), 2.8-3.1 (m, 8 H, εH lysine and cysteine), 3.1-
3.6 (m, 64 H, -CH2- Tp), 3.8-4.4 (m, 4 H, αH amino acids). 
454: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.7-0.8 (s, 6 H, -CH3 oleic acid), 
0.8-2.0 (m, 68 H, βγδH lysine, -CH2- oleic acid), 2.3-2.6 (m, 16 H, -CO-CH2-CH2-CO-
), 2.6-3.1 (m, 20 H, εH lysine, tyrosine and cysteine), 3.1-3.6 (m, 64 H, -CH2- Tp), 4.0-
4.6 (m, 10 H, αH amino acids), 5.15-5.3 (m, 4 H, -CH- oleic acid), 6.65-7.35 (m, 24 H, 
-CH- tyrosine). 
464: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.1-1.9 (m, 12 H, βγδH lysine), 
2.3-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 2.6-3.1 (m, 32 H, εH lysine, cysteine and 
tyrosine), 3.1-3.6 (m, 64 H, -CH2- Tp), 3.8-4.5 (m, 16 H, αH amino acids), 6.65-7.15 
(m, 48 H, -CH- tyrosine). 
465: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.1-1.8 (m, 12 H, βγδH lysine), 
2.3-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 2.6-3.1 (m, 20 H, εH lysine, cysteine and 
tyrosine), 3.1-3.6 (m, 64 H, -CH2- Tp), 3.7-4.5 (m, 10 H, αH amino acids), 6.65-7.15 
(m, 24 H, -CH- tyrosine). 
468: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.9-1.9 (m, 12 H, βγδH lysine), 
2.3-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 2.6-3.1 (m, 20 H, εH lysine, cysteine and 
tyrosine), 3.1-3.6 (m, 64 H, -CH2- Tp), 3.75-4.5 (m, 10 H, αH amino acids), 6.65-7.15 
(m, 24 H, -CH- tyrosine). 
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591: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.2-2.0 (m, 20 H, βγδH lysine 
and βγH arginine), 2.4-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 2.8-3.2 (m, 16 H, εH lysine, 
δH arginine and cysteine), 3.2-3.7 (m, 64 H, -CH2- Tp), 3.8-4.4 (m, 8 H, αH amino 
acids).  
592: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.7-0.9 (s, 6 H, -CH3 oleic acid), 
1.0-2.3 (m, 76 H, βγδH lysine and βγH arginine, -CH2- oleic acid), 2.4-2.6 (m, 16 H, -
CO-CH2-CH2-CO-), 2.8-3.2 (m, 16 H, εH lysine, δH arginine and cysteine), 3.2-3.7 (m, 
64 H, -CH2- Tp), 4.0-4.5 (m, 8 H, αH amino acids), 5.15-5.3 (m, 4 H, -CH- oleic acid).   
593: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.9-1.9 (m, 20 H, βγδH lysine 
and βγH arginine), 2.4-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 2.6-3.2 (m, 28 H, εH lysine, 
δH arginine, cysteine and tyrosine), 3.2-3.7 (m, 64 H, -CH2- Tp), 3.8-4.6 (m, 14 H, αH 
amino acids), 6.6-7.1 (m, 24 H, -CH- tyrosine).  
594: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.1-1.8 (m, 20 H, βγδH lysine 
and βγH arginine), 2.3-2.6 (m, 16 H, -CO-CH2-CH2-CO-), 2.6-3.1 (m, 28 H, εH lysine, 
δH arginine, cysteine and tyrosine), 3.1-3.6 (m, 64 H, -CH2- Tp), 3.8-4.6 (m, 14 H, αH 
amino acids), 6.65-7.15 (m, 24 H, -CH- tyrosine).  
595: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.5-0.7 (s, 6 H, -CH3 oleic acid), 
0.8-1.9 (m, 76 H, βγδH lysine and βγH arginine, -CH2- oleic acid), 2.3-2.6 (m, 16 H, -
CO-CH2-CH2-CO-), 2.6-3.1 (m, 28 H, εH lysine, δH arginine, tyrosine and cysteine), 
3.1-3.6 (m, 64 H, -CH2- Tp), 4.0-4.6 (m, 14 H, αH amino acids), 5.15-5.3 (m, 4 H, -CH- 
oleic acid), 6.65-7.35 (m, 24 H, -CH- tyrosine). 
596: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 0.9-1.9 (m, 20 H, βγδH lysine 
and βγH arginine), 2.3-2.55 (m, 16 H, -CO-CH2-CH2-CO-), 2.6-3.1 (m, 40 H, εH lysine, 
δH arginine, cysteine and tyrosine), 3.1-3.6 (m, 64 H, -CH2- Tp), 3.8-4.6 (m, 20 H, αH 
amino acids), 6.65-7.15 (m, 48 H, -CH- tyrosine). 
652: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.15-2.0 (m, 10 H, βγδH lysine 
and βγH arginine), 2.35-2.65 (m, 36 H, -CO-CH2-CH2-CO-), 2.8-3.1 (m, 12 H, εH 
lysine, δH arginine and cysteine), 3.11-3.3 (m, 36 H, -CH2- Tp), 3.32-3.67 (m, 108 H, 
-CH2- Tp), 4.09-4.4 (m, 6 H, αH amino acids). 
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653: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.15-2.0 (m, 14 H, βγδH lysine 
and βγH arginine), 2.35-2.65 (m, 36 H, -CO-CH2-CH2-CO-), 2.8-3.1 (m, 16 H, εH 
lysine, δH arginine and cysteine), 3.11-3.3 (m, 36 H, -CH2- Tp), 3.32-3.67 (m, 108 H, 
-CH2- Tp), 4.09-4.4 (m, 8 H, αH amino acids). 
654: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.15-2.0 (m, 18 H, βγδH lysine 
and βγH arginine), 2.35-2.65 (m, 36 H, -CO-CH2-CH2-CO-), 2.8-3.1 (m, 20 H, εH 
lysine, δH arginine and cysteine), 3.11-3.3 (m, 36 H, -CH2- Tp), 3.32-3.67 (m, 108 H, 
-CH2- Tp), 4.09-4.4 (m, 10 H, αH amino acids). 
736: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.2-1.9 (m, 12 H, βγδH lysine), 
2.3-2.6 (m, 38 H, -CO-CH2-CH2-CO-,  -CO-CH2- dPEG24), 2.6-3.1 (m, 8 H, εH lysine 
and cysteine), 3.1-3.6 (m, 128 H, -CH2- Tp), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -
CH2-N- dPEG24), 4.0-4.3 (m, 4 H, αH amino acids). 
737: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.2-1.9 (m, 12 H, βγδH lysine), 
2.1-2.4 (m, 4 H, βγH glutamic acid ) 2.3-2.6 (m, 34 H, -CO-CH2-CH2-CO-,  -CO-CH2- 
dPEG24), 2.6-3.1 (m, 8 H, εH lysine and cysteine), 3.1-3.6 (m, 128 H, -CH2- Tp), 3.5-
3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.3 (m, 4 H, αH amino acids), 
4.3-4.7 (m, 3H, -CH2-N-  pteroic acid, αH glutamic acid),  6.7 (d, 2H, aromatic ring H 
pteroic acid), 7.6 (d, 2H, aromatic ring H pteroic acid), 8.7 (s, 1H, aromatic ring H 
pteroic acid). 
738: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.2-1.9 (m, 20 H, βγδH lysine 
and βγH arginine), 2.3-2.6 (m, 38 H, -CO-CH2-CH2-CO-,  -CO-CH2- dPEG24), 2.6-
3.1 (m, 16 H, εH lysine, δH arginine and cysteine), 3.1-3.6 (m, 128 H, -CH2- Tp), 3.5-
3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 4.0-4.3 (m, 4 H, αH amino acids). 
739: 1H NMR (400 MHz, Deuterium oxide) δ (ppm) = 1.2-1.9 (m, 20 H, βγδH lysine 
and βγH arginine), 2.1-2.4 (m, 4 H, βγH glutamic acid ) 2.3-2.6 (m, 34 H, -CO-CH2-
CH2-CO-,  -CO-CH2- dPEG24), 2.6-3.1 (m, 16 H, εH lysine, δH arginine and cysteine), 
3.1-3.6 (m, 128 H, -CH2- Tp), 3.5-3.7 (m, 98 H, -CH2-O- dPEG24, -CH2-N- dPEG24), 
4.0-4.3 (m, 4 H, αH amino acids), 4.3-4.7 (m, 3H, -CH2-N-  pteroic acid, αH glutamic 
acid),  6.7 (d, 2H, aromatic ring H pteroic acid), 7.6 (d, 2H, aromatic ring H pteroic acid), 
8.7 (s, 1H, aromatic ring H pteroic acid). 
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740 (test structure): Sequence (C→N): W-Stp2-ssbb-L3-W 
 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.95 (m, 18 H, δH leucine), 1.10-
1.60 (m, 12 H, βγH leucine), 2.20-2.50 (m, 12 H, -CO-CH2-CH2-CO- Stp and ssbb), 
2.60-2.80 (m, 4 H, -CH2-SS-CH2-), 2.90-3.55 (m, 40 H, -CH2- Tp and ssbb, εH 
tryptophane), 4.10-4.60 (m, 5 H, αH tryptophanes and leucines), 7.00-7.65 (m, 10 H, 
aromatic H tryptophane). 
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782: Sequence (C→N): K-αK-α,ε[Stp3-ssbb-(CholA)2]2 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.45-2.40 m, 88 H, βγδH lysine, 
cholanic acid), 2.40-2.60 (m, 36 H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- 
cholanic acid), 2.65-3.15 (m, 12 H, εH lysine, -CH2- ssbb), 3.15-3.65 (m, 96 H, -CH2- 
Tp), 4.15-4.30 (m, 2 H, αH lysines). 
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783: Sequence (C→N): K-αK-α,ε[Stp3-(CholA)2]2 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.50-2.35 m, 88 H, βγδH lysine, 
cholanic acid), 2.40-2.60 (m, 28 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- cholanic acid), 
2.85-3.15 (m, 4 H, εH lysine), 3.15-3.65 (m, 96 H, -CH2- Tp), 4.15-4.30 (m, 2 H, αH 
lysines). 
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871: Sequence (C→N): Stp4-H6-K-α,ε(CholA)2 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 m, 82 H, βγδH lysine, 
cholanic acid), 2.40-2.55 (m, 20 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- cholanic acid), 
2.55-3.05 (m, 14 H, εH lysine and histidine), 3.05-3.60 (m, 64 H, -CH2- Tp), 3.95-4.65 
(m, 7 H, αH lysines and histidines), 7.10-7.35 (d, 6 H, aromatic H histidine), 8.5-8.65 
(m, 6 H, aromatic H histidine). 
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969: Sequence (C→N): Stp4-H6-ssbb-K-α,ε(CholA)2 
 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 m, 82 H, βγδH lysine, 
cholanic acid), 2.30-2.55 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- 
cholanic acid), 2.55-3.15 (m, 22 H, εH lysine and histidine, -CH2- ssbb), 3.15-3.65 (m, 
64 H, -CH2- Tp), 3.75-4.65 (m, 7 H, αH lysines and histidines), 7.10-7.35 (d, 6 H, 
aromatic H histidine), 8.50-8.70 (m, 6 H, aromatic H histidine). 
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989: Sequence (C→N): Y3-Stp2-K-ε[G-K-α,ε(SteA)2]αStp2-Y3 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.65-0.85 (s, 6 H, -CH3 stearic acid), 
0.85-2.25 (m, 76 H, βγδH lysine, -CH2- stearic acid), 2.3-2.65 (m, 20 H, -CO-CH2-
CH2-CO- Stp, -CO-CH2- stearic acid), 2.65-3.1 (m, 16 H, εH lysine and tyrosine), 3.1-
3.6 (m, 64 H, -CH2- Tp), 3.65-4.65 (m, 10 H, αH amino acids), 6.65-7.25 (m, 24 H, -
CH- tyrosine).  
   Appendix 
   159 
990: Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(SteA)2]αStp2-Y3 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.50-2.25 (m, 82 H, βγδH lysine, -
CH2- and -CH3 stearic acid), 2.3-2.6 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-
CH2- stearic acid), 2.6-3.1 (m, 24 H, εH lysine and tyrosine, -CH2- ssbb), 3.1-3.6 (m, 
64 H, -CH2- Tp), 3.65-4.55 (m, 10 H, αH amino acids), 6.6-7.3 (m, 24 H, -CH- tyrosine).  
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991: Sequence (C→N): Y3-Stp2-K-ε[G-K-α,ε(CholA)2]αStp2-Y3 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.35-2.20 (m, 88 H, βγδH lysine, 
cholanic acid), 2.2-2.6 (m, 20 H, -CO-CH2-CH2-CO- Stp, -CO-CH2- cholanic acid), 
2.6-3.05 (m, 16 H, εH lysine and tyrosine), 3.05-3.60 (m, 64 H, -CH2- Tp), 3.60-4.60 
(m, 10 H, αH amino acids), 6.50-7.25 (m, 24 H, -CH- tyrosine).  
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992: Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 (m, 88 H, βγδH lysine, 
cholanic acid), 2.3-2.7 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, -CO-CH2- cholanic 
acid), 2.70-3.15 (m, 24 H, εH lysine and tyrosine, -CH2- ssbb), 3.15-3.80 (m, 64 H, -
CH2- Tp), 3.65-4.65 (m, 10 H, αH amino acids), 6.60-7.35 (m, 24 H, -CH- tyrosine).
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1073: Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3-K-ε(N3) 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 (m, 96 H, βγδH lysine, 
βγδεH azidolysine, cholanic acid), 2.3-2.7 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, 
-CO-CH2- cholanic acid), 2.70-3.15 (m, 24 H, εH lysine and tyrosine, -CH2- ssbb), 
3.15-3.80 (m, 64 H, -CH2- Tp), 3.65-4.65 (m, 11 H, αH amino acids), 6.60-7.35 (m, 24 
H, -CH- tyrosine).  
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1081: Sequence (C→N): Y3-Stp2-K-ε[G-K-α,ε(MyrA)2]αStp2-Y3 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 myristic acid), 
0.85-2.30 (m, 56 H, βγδH lysine, myristic acid), 2.3-2.6 (m, 20 H, -CO-CH2-CH2-CO- 
Stp, -CO-CH2- myristic acid), 2.6-3.10 (m, 16 H, εH lysine and tyrosine), 3.10-3.65 (m, 
64 H, -CH2- Tp), 3.65-4.55 (m, 10 H, αH amino acids), 6.60-7.10 (m, 24 H, -CH- 
tyrosine).  
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1082: Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(MyrA)2]αStp2-Y3 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.80 (s, 6 H, -CH3 myristic acid), 
0.80-2.25 (m, 56 H, βγδH lysine, myristic acid), 2.3-2.6 (m, 24 H, -CO-CH2-CH2-CO- 
Stp and ssbb, -CO-CH2- myristic acid), 2.60-3.05 (m, 24 H, εH lysine and tyrosine, -
CH2- ssbb), 3.05-3.60 (m, 64 H, -CH2- Tp), 3.65-4.55 (m, 10 H, αH amino acids), 6.60-
7.15 (m, 24 H, -CH- tyrosine).  
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1086: Sequence (C→N): K-ε(N3)-Y3-Stp2-K-ε[G-ssbb-K-α,ε(CholA)2]αStp2-Y3-K-ε(N3) 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.40-2.30 (m, 104 H, βγδH lysine, 
βγδεH azidolysine, cholanic acid), 2.3-2.7 (m, 24 H, -CO-CH2-CH2-CO- Stp and ssbb, 
-CO-CH2- cholanic acid), 2.70-3.15 (m, 24 H, εH lysine and tyrosine, -CH2- ssbb), 
3.15-3.80 (m, 64 H, -CH2- Tp), 3.65-4.65 (m, 12 H, αH amino acids), 6.60-7.35 (m, 24 
H, -CH- tyrosine).  
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1106: Sequence (C→N): Y3-Stp2-K-ε[G-K-α,ε(CholA)2]αStp2-Y3-K-ε(N3) 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.35-2.20 (m, 96 H, βγδH lysine, 
βγδεH azidolysine, cholanic acid), 2.2-2.6 (m, 20 H, -CO-CH2-CH2-CO- Stp, -CO-
CH2- cholanic acid), 2.6-3.05 (m, 16 H, εH lysine and tyrosine), 3.05-3.60 (m, 64 H, -
CH2- Tp), 3.60-4.60 (m, 11 H, αH amino acids), 6.50-7.25 (m, 24 H, -CH- tyrosine). 
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1107: Sequence (C→N): Y3-Stp2-K-ε[G-K-α,ε(OleA)2]αStp2-Y3 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.85 (s, 6 H, -CH3 oleic acid), 
0.85-2.25 (m, 72 H, βγδH lysine, -CH2- oleic acid), 2.25-2.60 (m, 20 H, -CO-CH2-CH2-
CO- Stp, -CO-CH2- oleic acid), 2.65-3.1 (m, 16 H, εH lysine and tyrosine), 3.1-3.65 (m, 
64 H, -CH2- Tp), 3.70-4.55 (m, 10 H, αH amino acids), 5.05 – 5.25  (s, 4 H,  
-CH=CH- oleic acid), 6.60 -7.15 (m, 24 H, -CH- tyrosine).  
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1108: Sequence (C→N): Y3-Stp2-K-ε[G-ssbb-K-α,ε(OleA)2]αStp2-Y3 
 
 
 
 
 
 
 
 
1H NMR (500 MHz, Deuterium oxide) δ (ppm) = 0.60-0.80 (s, 6 H, -CH3 oleic acid), 
0.85-2.10 (m, 72 H, βγδH lysine, -CH2- oleic acid), 2.25-2.60 (m, 22 H, -CO-CH2-CH2-
CO- Stp, -CO-CH2- oleic acid), 2.60-3.0 (m, 22 H, εH lysine and tyrosine), 3.05-3.65 
(m, 64 H, -CH2- Tp), 3.70-4.60 (m, 10 H, αH amino acids), 5.00 – 5.25  (s, 4 H, -
CH=CH- oleic acid), 6.55 -7.15 (m, 24 H, -CH- tyrosine).  
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6.4.3 Mass spectra of oligomers 
Table 20 Summarizing table oligomers. Mass data recorded with a Bruker MALDI-TOF instrument 
Oligomer Molecular formula [M+H]+ calc. [M+H]+ found 
740 (Test structure) C72H119N19O12S2 1506.9 1506.1 
782 (CholA-ss-u) C148H280N38O21S4 3055.0 3056.1 
783 (CholA-u) C132H252N34O17 2587.0 2587.2 
871 (CholA-i) C138H232N40O18 2738.9 2739.2 
969 (CholA-ss-i) C146H246N42O20S2 2972.9 2973.2 
989 (SteA-t) C152H251N31O26 2927.9 2929.3 
990 (SteA-ss-t) C160H265N33O28S2 3162.0 3163.6 
991 (CholA-t) C164H259N31O26 3080.0 3079.0 
992 (CholA-ss-t) C172H273N33O28S2 3314.0 3314.2 
1073 (CholA-ss-t-N3) C178H283N37O29S2 3468.1 3466.2 
1081 (MyrA-t) C144H235N31O26 2815.8 2813.6 
1082 (MyrA-ss-t) C152H249N33O28S2 3049.9 3048.2 
1086 (CholA-ss-t-2N3) C184H293N41O30S2 3622.2 3621.3 
1106 (CholA-t-N3) C170H269N35O27 3234.1 3233.0 
1107 (OleA-t) C152H247N31O26 2923.9 2922.9 
1108 (OleA-ss-t) C160H261N33O28S2 3158.0 3156.3 
 
 
6.4.3.1 Full mass spectra of oligomers 
 
740 (Test structure) 
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782 (CholA-ss-u) 
 
783 (CholA-u) 
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871 (CholA-i) 
 
969 (CholA-ss-i) 
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989 (SteA-t) 
 
990 (SteA-ss-t) 
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991 (CholA-t) 
 
992 (CholA-ss-t) 
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1073 (CholA-ss-t-N3) 
 
1081 (MyrA-t) 
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1082 (MyrA-ss-t) 
 
1086 (CholA-ss-t-2N3) 
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1106 (CholA-t-N3) 
 
1107 (OleA-t) 
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1108 (OleA-ss-t) 
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6.4.4 Mass spectra of shielding agents 
Table 21 Summarizing table shielding agents. Mass data recorded with a Bruker MALDI-TOF instrument 
Shielding agent ID Molecular formula [M+X]+ calc. [M+X]+ found 
DBCO-PEG24 1138 C72H120N2O28 1482.8 [Na] 1481.3 [Na] 
DBCO-PEG24-FolA 1139 C97H149N11O34 2033.0 [Na] 2035.5 [Na] 
DBCO-PEG48-FolA 1140 C148H250N12O59 3161.7 [Na] 3158.1 [Na] 
DBCO-PEG72-FolA 1141 C199H351N13O84 4289.4 [Na] 4284.2 [Na] 
DBCO2-ss2-PEG24-FolA 1145 C140H206N18O41S4 2923.4 [H] 2922.9 [H] 
DBCO2-ss2-PEG48-FolA 1146 C191H307N19O66S4 4073. [Na] 4073.1 [Na] 
DBCO2-ss2-PEG72-FolA 1147 C242H408N20O91S4 5200. [Na] 5196.2 [Na] 
 
 
 
6.4.4.1 Full mass spectra of shielding agents 
 
1138 (DBCO-PEG24) 
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1139 (DBCO-PEG24-FolA) 
 
1140 (DBCO-PEG48-FolA) 
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1141 (DBCO-PEG72-FolA) 
 
1145 (DBCO2-ss2-PEG24-FolA) 
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1146 (DBCO2-ss2-PEG24-FolA) 
 
1147 (DBCO2-ss2-PEG24-FolA) 
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